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Resumo 
 
Há frequentemente uma discrepância entre os dados clínicos, incluindo análises 
laboratoriais, e a experiência de se estar doente. O objetivo deste trabalho foi procurar 
indicadores-chave de desempenho de doença para além dos dados numéricos habituais. 
Como modelo de investigação, utilizamos a Doença Renal Crónica (DRC). Esses 
indicadores devem traduzir a experiência de viver com a doença e serem sensíveis às 
decisões médicas, para que possam ser alvo de intervenção. No capítulo 2, é feita uma 
contextualização da DRC, apresentando-se uma extensa lista dos indicadores que 
actualmente orientam as decisões dos médicos. No capítulo 3, faz-se uma abordagem geral 
das doenças crónicas, destacando modelos de gestão da doença crónica. Alguns indicadores 
actualmente usados também são referidos. 
O trabalho experimental é apresentado no capítulo 4. A nossa hipótese baseou-se 
num modelo conceptual que postulava que uma determinada medida de resultados auto-
relatados pelos doentes (PROM: Patient Reported Outcome Measures) seria adequada para 
uso diário em contexto clínico se tivesse uma correlação estatisticamente significativa entre 
os preditores (variáveis demográficas, índices de comorbilidade, estimativas de Taxa de 
Filtração Glomerular - TFGe - e eventos adversos do ano anterior) e os resultados (morte, 
diálise, hospitalizações e idas ao serviço de urgência), servindo assim como indicador de 
bem-estar. Realizámos um estudo observacional, tendo recrutado 60 doentes renais 
crónicos que responderam a vários questionários de PROM: “Short Physical Performance 
Battery” (SPPB), “World Health Organization Disability Assessment Schedule” 
(WHODAS), “Satisfaction With Life Scale” (SWLS) e “Kidney Disease Quality of Life” 
(KDQoL). O período de acompanhamento foi de 24 meses. Finalmente, estudámos a 
relevância dos resultados para os doentes. Para isso, foi-lhes pedido que classificassem seis 
desfechos, de acordo com o que acham que deveria ser a prioridade do seu médico (“evitar 
a morte”, “evitar a diálise”, “evitar o agravamento dos exames laboratoriais”, “evitar a 
deterioração do seu estado geral”, “evitar internamentos hospitalares” e “evitar idas ao 
serviço de urgência”). 
Os resultados permitiram concluir que: 1) O SPPB previu morte, diálise e 
hospitalizações. 2) O WHODAS previu morte e diálise. 3) O domínio Função Física do 
KDQoL previu morte e hospitalizações. 4) O domínio Saúde Mental do KDQoL previu 
morte. 5) O domínio Energia/vitalidade do KDQoL previu hospitalizações. 6) O domínio 
físico do KDQoL previu diálise. 7) Domínio de Saúde Mental do KDQoL previu 
hospitalizações e idas ao serviço de urgência. 8) Os domínios Dor, Função Social e Saúde 
Geral do KDQoL, bem como o SWLS não foram úteis na previsão de nenhum dos 
resultados propostos. 9) A fórmula de Cockcroft-Gault (CG) para calcular a TFGe é a única 
que previu a morte. 10) Todas as fórmulas de cálculo da TFGe previram o início da diálise. 
11) Apenas a fórmula de CG pôde prever a pontuação de algumas escalas do PROM: SPPB, 
domínio da Função Física do KDQoL e WHODAS. 12) Ambas as escalas de comorbilidade 
de Charlson (de 1987 e 2011) são úteis para a predição dos resultados estudados: a primeira 
prevê mortes e internamentos hospitalares, enquanto a segunda prediz morte, diálise, 
hospitalizações e idas ao serviço de urgência. 13) A principal prioridade dos doentes é que 
a principal preocupação do seu médico seja “evitar a morte”, enquanto as opções “evitar 
diálise” e “evitar o agravamento dos exames laboratoriais” vêm a seguir, empatadas. 14) 
Os doentes classificaram as opções “evitar hospitalização” e “evitar episódios de urgência” 
nos últimos lugares, depois de todas as demais.  
Finalmente, 15) O modelo conceptual proposto permitiu identificar oito 
possibilidades diferentes de relação entre preditores, PROM e resultados. Quatro deles 
mostraram ter utilidade clínica. São necessários estudos longitudinais com PROM para 
reforçar o seu papel no consultório e na enfermaria, e também na gestão da doença. 
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Abstract There is often a discrepancy between clinical data, including laboratory tests, 
and the patients’ experience of being ill. The goal of this work was to search for Key 
Performance Indicators (KPI) of disease other than the usual numeric data.  As research 
model, we have used Chronic Kidney Disease (CKD). Those indicators should express 
the experience of living with the disease and be sensible to medical decisions so that 
they can be targeted for intervention. In chapter 2, a contextualization of CKD is made, 
presenting an extensive list of the standard indicators that currently drive physicians’ 
decisions. A general approach to chronic diseases is presented in chapter 3, highlighting 
models of interventions. Some existing indicators are also covered. 
The experimental work is presented in chapter 4. Our hypothesis was based on 
a conceptual model which postulated that a given Patient Reported Outcome Measure 
(PROM) would be suitable for daily use in the clinical context provided that it would 
link predictors (demographic variables, comorbidity indices, estimates of Glomerular 
Filtration Rate – eGFR - and untoward events of the previous year) to Endpoints (death, 
dialysis, hospitalizations and emergency episodes) with statistically significant 
relationships and serve as indicator as surrogate of well-being. We conducted an 
observational study and recruited 60 patients with CKD to whom several questionnaires 
of PROM were administered: Short Physical Performance Battery (SPPB), World 
Health Organization Disability Assessment Schedule (WHODAS), Satisfaction With 
Life Scale (SWLS) and Kidney Disease Quality of Life (KDQoL). Follow-up period 
was 24 months. Lastly, we wanted to know the relevancy of the endpoints to the 
patients. For that, they were asked to rank six endpoints according to what they think 
their physician’s priority should be (avoid death, avoid dialysis, avoid worsening of lab 
tests, prevent further deterioration of medical condition, avoid hospital admissions and 
avoid emergency episodes).  
We conclude that: 1) SPPB could predict death, dialysis and hospital 
admissions. 2) WHODAS could predict death and dialysis. 3) Physical Functioning 
domain of KDQoL could predict death and hospital admissions. 4) Role Emotional 
domain of KDQoL could predict death. 5) Energy/Vitality domain of KDQoL could 
predict hospital admissions. 6) Role Physical domain of KDQoL could predict dialysis. 
7) Mental Health domain of KDQoL could predict hospital admissions and emergency 
episodes. 8) Pain, Social Function and General Health domains of KDQoL, and SWLS 
were not useful in predicting any of the proposed endpoints. 9) The Cockcroft-Gault 
(CG) formula to compute eGFR is the only that could predict mortality. 10) All eGFR 
formulae predicted beginning of dialysis. 11) Only the CG formula could predict the 
scores of some PROM scales: SPPB, Physical Function domain of KDQoL and 
WHODAS. 12) Both the Charlson comorbidity scales (1987 and 2011) are useful for 
the prediction of studied endpoints: the first predicts death and hospital admissions 
while the second predicted mortality, dialysis, hospitalizations and emergency episodes. 
13) The highest priority of patients is that their physician’s main concern should be to 
“Avoid death” whereas options “Avoid dialysis” and “Avoid worsening of laboratory 
tests” came next, in a tie. 14) Patients ranked “Avoid hospitalization” and “Avoid 
emergency episodes” in the last places, after all the others.  
Finally, 15) Eight possible schemes were drawn from the analysis of the 
conceptual model. Four of them have shown to have clinical utility. Longitudinal 
exploration of these PROM is needed in order to reinforce their clear place at office and 
bedside and in disease management. 
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“Ignoranti, quem portum petat, nullus suus ventus est.” 
(For someone who doesn’t know where he’s sailing to, no wind is favourable) 
Lucius Annaeus Seneca (Séc I d.C.) 
 
 
 
“If you can't measure it, you can't improve it.” 
Peter Drucker (1909-2005) 
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1 Introduction 
 
1.1  Scope of the Problem 
 
Nephrology earned its independence as a medical speciality with the introduction of 
dialysis to chronic kidney patients in March 1960, in Seattle, USA 1. Since then, millions of 
patients have had their lives artificially extended thanks to machines that replace their lost 
kidney function. In spite of being a very severe disease, many of them have been able to 
lead an almost normal, productive existence with personal achievements both on the 
personal and at the social level, working, building a family, creating artistic work and 
enjoying life. 
Nevertheless, living with dialysis poses a significant burden on a person’s life, 
impacting considerably on well-being. This is a paradox, because of the extensive 
rehabilitation that patients get, which makes them feel well enough to dream a life without 
the need of this imprisoning therapy, creating negative feelings of indignation, frustration 
and, ultimately, depression 2 3. Moreover, the patients rarely live long enough to complete 
the mourning cycle of resignation and often die in anger or depression. 
The initiation of dialysis is a dramatic moment in patients’ lives 4 5. If they still in 
employment or not, their existence will subsequently be conditioned by the obligation of 
going to a dialysis clinic three times a week and stay there for four hours in the same 
position. The alternative, peritoneal dialysis, is not burden-free: three or four pauses in daily 
routine for a 30 to 40-minute operation which is not risk free either. Alternatively, sleeping 
every night connected to a machine that performs the exchanges. Some symptoms that they 
will experience will be due to dialysis, but most emerge from the simultaneous and 
continuous loss of residual kidney function, expressed as worsening of their health status, 
or are due to comorbidities, namely cardiovascular complications, which are particularly 
health limiting and the principal cause of death. Even so, all the blame will go to the 
treatment. Patients often get depressed, other concomitant diseases become evident and 
the general well-being suffers. in spite of a high standard quality care and support, it is far 
from being a comfortable experience for the patient. Some have compared it to living with 
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a cancer, as far as symptom burden and impairment of quality of life are related 6. 
Unfortunately, it is the only chance they have to stay alive.  
 On the other hand, in developed countries, there is almost free access to dialysis, 
which is currently offered to many patients who would not have been considered suitable 
during the early decades of outpatient dialysis practice. Furthermore, patients are older, 
have more comorbidities and it is pertinent to challenge the option of proposing a Renal 
Replacement Therapy (RRT) to every patient that presents end stage renal failure 7. 
 Conservative treatment has emerged as an alternative option to RRT 8. Some 
extreme cases offer little doubt about candidacy to RRT: absence of relationship with the 
world, advanced metastatic disease, very elderly frailty and advanced incurable diseases 
that lead to great functional limitations. These are some examples of situations in which 
little doubt rests on how the patient will benefit from RRT. However, there are other cases 
that, being less obvious, pose serious problems for decision making, especially when there 
is resistance of the patient or when patients present other comorbid conditions 9. 
 The role of the physician is to give counselling, which is based on a prediction of how 
the patient will cope and lead a life with an acceptable well-being. The key decision of 
proceeding or not to chronic dialysis therapy is a topic for which there will never be a 
randomized controlled trial to compare the outcomes of those who did with the ones who 
didn’t. Scientific data regarding this theme will ever be composed of retrospective studies, 
weakening available evidence. Even for those who are to begin therapy, the choice of the 
right moment for treatment is not discussion free. The only published randomized 
controlled trial on this issue was not free of controversy 10.  
 Furthermore, in this context, the experience of living with a chronic, potentially 
mortal disease, is not yet accountable, in a sense that there isn’t a target to aim for 
improvement, other than postponing the beginning of dialysis or death. Many decisions are 
often based on existing laboratory data and others, like blood pressure, which, although very 
important to drive medications, are seen by the patients as mere numbers. When a patient 
is informed that creatinine is rising, meaning that probably kidney failure is worsening, he 
often answers back that he feels well and has no limitations to his usual life, so he sees no 
need to worry. The disease is often asymptomatic until late stages. Meanwhile, organs and 
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systems are continuously worsening and becoming irreversibly damaged. The invoice will 
come later, in the form of morbidity and mortality. On the other hand, these numeric 
landmarks of disease are the gold standard references to clinical practice because clinical 
research has been guided by them 11.   
 
 
1.2  Epistemological Pathway 
 
The need to combine clinical data and the real life of the patient, lead us to set a 
search for other ways of measuring well-being and try to include its several dimensions in a 
broader framework that could allow a better evaluation and management of each patient, 
pursuing a better life, as far as health is concerned. As taking care of chronic patients is like 
managing a part of their health, the first idea that came to our mind was to make an analogy 
with management tools, namely the Balanced Scorecard (BSC), idealized by Kaplan and 
Norton in 1992 12. A BSC with clinical data would be perfect to guide the management of a 
patient with chronic disease. 
The concept of BSC is very interesting: it is a management tool created to classify 
organizations, not only by their financial results, but also taking care of customer 
satisfaction, seeking excellence in the internal process and caring about learning and 
improving.  It can be brought down from the organization perspective to a person one, in a 
process called cascading, allowing individual evaluation. 
In the clinical setting, an analogy could be tried at this individual level. If we consider 
the global treatment of a patient as a major strategic goal, it can be categorised and 
structured into several aspects to which a physician must pay attention. As in the original 
Balanced Scorecard, a Clinical Balanced Scorecard (CBS) could be developed, also with four 
strategic dimensions, each one expressed by measurable endpoints:  
- firstly, the core angle, represented by financial results of the management model 
would have its counterpart in the clinical and analytic results;  
- secondly, costumers’ satisfaction, which would correspond to the feedback given 
by the patients when they report their well-being and rehabilitation;  
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- thirdly, the pursuit of excellence of the internal process, that could be associated 
with concerns on doing things right (i.e. making decisions with a good cost-
effectiveness ratio so the maximum number of patients could be treated with 
available resources);  
- finally, the organizations’ ability to investigate and develop could be translated 
to the teaching capacity of the physicians to patients, so that the patients can 
also participate in their own rehabilitation efforts, and the indicators would be 
the accomplishment of healthier lifestyle driven attitudes. 
 
In the clinical setting, the “client” is the patient. From a deontological perspective, 
this should always be the priority. For this reason, this section of the BSC was chosen to be 
the first to be addressed within the scope of the present research work. 
On the other hand, measuring outcomes reported by patients is becoming the gold 
standard of evaluating quality of care 13  and many tools are being developed and studied. 
Each one addresses a particular aspect of patients’ lives. As far as we know, most of Patient 
Reported Outcome Measures (PROM) are studying patients when they were already on 
dialysis or transplanted, but less work has been done with pre-dialysis patients 14. There is 
increasing awareness for a new paradigm in the management of these patients: the upgrade 
from the survival point of view to an increased quality of life and the need for its 
accountability 15. In this context, well-being is, thus, a fundamental concept for the research 
being reported. 
The validation of a set of patient-related outcomes is of seminal value to the 
construction of a reliable Clinical Balanced Scorecard.  
 
 
1.3  Motivation and Objectives 
 
We face this work as a contribution to a better understanding of life with kidney 
disease. This exploratory work aimed at looking for a better measure of what is in stake, 
when it is time to decide to move to a new phase of the patients’ lives, and contributing to 
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a more complete evaluation of a patient who is at the other side of the desk, waiting for 
medical decision or guidance. That measure must be based on well-being and decisions must 
be based on when and how dialysis can be supplemental to the continuous loss of well-being 
that the disease brings. 
The way to the ideal patient-reported measure, demands a strong connection 
between patients’ characteristics and important life events in their lives. It is, thus, of 
primary importance: 
- to disclosure connections between patients’ attributes (demographics, 
comorbidities, level of kidney function) and life events, such as beginning of 
dialysis, hospitalizations, usage of emergency services or death; 
- to evaluate the representativeness of the available indicators, as far as this 
specific disease is concerned; 
- to assess their predictive value, in relation to important life events, surrogates of 
illness. 
Secondarily, as we are dealing with renal patients, it was also considered important 
to reach a better understanding of which is the best way to estimate kidney function on a 
well-being perspective. 
Thirdly, given the importance and the impact that comorbidities have on outcomes, 
it is of central importance to understand what the best marker of those conditions is so that 
their influence can be best assessed.  
Finally, among the several endpoints classically considered in literature (the ones 
that usually guide medical decisions, as well as research), we felt it would also be important 
to check which one(s) would be the patients’ favourite(s), in line with the search of giving 
voice to the patients and hierarchize their expectation and contribute to a better life 
experience. 
 
 
1.4  Structure of the Document 
 
The present work is composed by six chapters, including this introduction: 
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In Chapter 2, Chronic Kidney Disease, a brief review about Chronic Kidney Disease is 
made, focused on methods to measure results and criteria to drive decisions. At the end of 
the chapter, the clinical indicators that currently drive medical decisions are highlighted. 
Chapter 3, Managing Chronic Disease and Measuring Quality of Care, covers aspects 
of chronic diseases, how they have been addressed in terms of care organization and 
thoughts on how it can be accountable for continuous improvement, including a review of 
key performance indicators of healthcare, under diverse points of view. 
Chapter 4, Experimental Work, describes the research done in search for indicators 
of performance, simultaneously reliable and easy to use on everyday life. 
In Chapter 5, Discussion, results of experimental work are reviewed, looking for 
benchmark and trying to find clues to its validation. 
Finally, Chapter 6, Conclusions and Future Work presents some conclusions about 
this work and envisages relevant topics that might be explored in the future. 
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2 Chronic Kidney Disease 
 
2.1 What is Chronic Kidney Disease? 
 
Chronic Kidney Disease (CKD), formerly called Chronic Renal Failure, is defined as the 
progressive and irreversible loss of kidney function for longer than three months, 
irrespective of the cause 16 17. It is due to structural or functional abnormalities that lead to 
a decreasing number of working nephrons, the functional units of the kidneys. Although the 
remaining nephrons, trying to compensate for the loss of renal mass, by dilation and 
hyperfiltration, ultimately, they become fibrotic and lose their function. This  is a vicious 
cycle that ends up in a total loss of function which is incompatible with a normal life and 
ultimately requires Renal Replacement Therapy (RRT) by dialysis or kidney transplantation 
for survival 18.  
Some discussion has taken place about the parameters and thresholds that could be 
considered as the limiting definitions of CKD. These came to be albuminuria above 
30mg/day, Glomerular Filtration Rate (GFR) below 60 mL/min/1.73m2  and the presence of 
anatomic abnormalities of kidneys and urinary tracts 19.  
Recent trends have widened the definition of CKD, leading to the inclusion of 
patients, who, in spite of having normal renal function, present markers of kidney damage, 
such as abnormalities of blood or urine composition as well as abnormalities detected by 
imaging examinations. It ended up including people at increased risk of developing CKD who 
could benefit from an integrated effort to improve outcomes, although they may not yet 
have renal failure stricto sensu. 
 
 
2.2 Clinical Guidelines 
 
The Kidney Disease Outcomes Quality Initiative (KDOQI) was launched by the 
National Kidney Foundation (NKF) in 2002 16. It was the successor of an earlier set of 
guidelines published in 1997 (Dialysis Outcomes Quality Initiative - DOQI) specifically 
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directed at problems of dialysis patients 20. The assumed goal of the 2002 KDOQI initiative 
was to broaden the scope of this task to all stages of kidney disease. Later, in 2012, the 
mission was renamed “Kidney Disease Improving Global Outcomes” (KDIGO) 21, after a 
sequence of updates. 
 These were two sets of guidelines that, among several others, were intended to 
increase global awareness of CKD and gather the available evidence of the best medical 
options to diagnosis, investigate and treat this disease. Three important results of these 
initiatives have been the new name for the disease (CKD), a new classification and the 
settlement of a new conceptual model for the natural history of CKD. 
 The first important result of this initiative was the change of the name of the disease. 
The concept CKD replaced the old designation of this condition (Renal Failure), which is now 
reserved for the most advanced stages of the disease, when GFR decreases significantly. The 
concept of End-Stage Renal Disease (ESRD) is now left for those patients who are on RRT 
(dialysis or transplantation). Moreover, Terminal Renal Failure was definitively abandoned, 
enhancing the new paradigm of a chronic, rather than a terminal disease. And an interesting 
aspect about this shift of name is related to the replacement of the word “renal”, of Latin 
origin, by the word “kidney”, of Anglo-Saxon root. It must be noted that this decision was 
taken in the USA context, in order to increase the general American population awareness 
of this problem. 
 A remarkable achievement of this initiative was the establishment of a grading 
system. The aim of this system was to guide stratification of risk for complications and 
progression of CKD, as well as to guide the disease management. Furthermore, this grading 
system has been very useful to help decisions on treatments and define prognosis, intensity 
of monitoring and patient education (Table 1). 
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Table 1 - CKD Stages 16 
 
 
 
 
 
 
 
Also, KDOQI presented a new conceptual model that represents a continuum of 
development, progression and complications of CKD, each phase requiring a different 
approach and management (Figure 1). Complications of CKD are diverse and include 
consequences of impaired clearance of toxins, of cardiovascular disease, of albuminuria, of 
deficient regulation of the internal milieu, of deficient production of hormones and  of drug 
accumulation 22. 
 
 
Figure 1 - Conceptual model for CKD (adapted from 16 22) 
 
In the original 2002 KDOQI, estimated Glomerular Filtration Rate (eGFR) was the only 
variable considered for stratification. The upgrade of the KDIGO framework brought a new 
discriminator in Stage 3, which was divided into two sub-categories, designated 3a (eGFR 
between 45 and 59 mL/min) and 3b (eGFR between 30 and 44 mL/min). Albuminuria was 
also included as a prognostic marker. The reason for albumin staging addition was the 
independent risk for death and morbidity events that albuminuria has shown to be 23. 
CKD Stage eGFR (mL/min) Description 
1 > 90 Kidney damage with normal or increased GFR 
2 60 – 89 Kidney damage with mild decrease in GFR 
3 30 – 59 Moderate decrease in GFR 
4 15 – 29 Severe decrease in GFR 
5 < 15 or dialysis Kidney failure 
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Albuminuria has become a marker, not only of kidney damage, but also of overall 
cardiovascular risk. 
Figure 2 shows the KDIGO prognostic framework. The conjunction of the values of 
GFR and albuminuria gives an estimated risk for all-cause mortality, cardiovascular mortality, 
ESRD, CKD progression and Acute Kidney Injury (AKI). These were expressed in the original 
model within the context of a traffic light staging system. Four colours were defined, 
representing the increasing likelihood of developing future kidney and cardiovascular 
complications (green, yellow, orange and red). Although this staging system was useful to 
determine which patients need more intense monitoring, more therapy management tools 
are needed for risk prediction at the individual level. 
 
 
Figure 2 - Prognosis of CKD by GFR and albuminuria category (adapted from 21) 
 
 
2.3 Epidemiology 
 
CKD is a public health problem with worldwide implications 24. It is a major economic 
burden with significant costs in health care 25 26. RRT is very expensive and accounts for 
substantial costs to national health systems. In the USA, for example, in 2015, there were 
703,243 patients on RRT, spending more than 33 billion USD of the Medicare budget. 
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However, in spite of outstanding technological evolution and developments, outcomes 
remain poor 27. Simultaneously, many countries in the world do not have  conditions to 
maintain a comprehensive program of chronic dialysis, and patients die without an 
opportunity to be treated 28. 
The above-mentioned data refers to those patients who actually started RRT. 
However, CKD begins long before that moment and all epidemiological studies have the 
important problem of the non-existence of solid criteria to start measuring the progression 
of CKD. It is also true that most people with CKD are not aware of it, so this disease can be 
pictured as the classical image of an iceberg of which only the top (the most advanced cases) 
is seen, while most cases (the milder ones) are asymptomatic and, because of that, hidden 
29. Therefore, CKD is, thus, underdiagnosed and underreported, leading to a silent 
progression, often escaping health systems surveillance and preventive programmes. This 
fact also has obvious implications on outcomes. 
The Third National Health and Nutrition Examination Survey (NHANES III) study 30 has 
reported a prevalence of CKD of 16.93% in the 2013-2014 cohort after several previous 
cohorts with prevalence between 13 and 15%, demonstrating that it is increasing. A 
worldwide estimation of the population in RRT reached a number larger than 3,600 million 
people 31. Geographic and racial differences apply 32. The growth of cardiovascular disease 
as well as diabetes and hypertension continuously lead to an increased incidence and 
prevalence of CKD 33-35. 
According to the yearly report of the Portuguese Society of Nephrology 36, during the 
year of 2017, there were 2,372 new patients on RRT, corresponding to an incidence of 230 
new cases p.m.p., and by the end of 2017 the prevalence of CKD patients on RRT was 1,965 
cases p.m.p., corresponding to 20,259 patients, 12,741 of which were on dialysis (both 
peritoneal and haemodialysis), and 7,518 carried a kidney transplant. Although the 
incidence has stabilized in the last 10 years, Portugal still ranks as number 1 in Europe for 
prevalence and number 9 in the world for incidence of CKD and number 5 in prevalence, 
only behind Taiwan, Japan, USA and Singapore. 
On the other hand, another source of controversy it the fact that some patients may 
just be ageing, not getting sicker, as it is also well known that GFR decreases with age 37 38.  
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2.4 Aetiology 
 
The current main causes of CKD are diabetes and arterial hypertension 39. Other 
important causes are Primary Glomerulonephritis, Adult Polycystic Autosomal Disease, 
urinary tract malformations, chronic pyelonephritis, obstructive tract disease, and systemic 
diseases of immunologic origin, like Systemic Lupus Erythematosus (SLE) or vasculitis. In 
addition, haematological malignancies, like multiple myeloma, and viral infections, as well 
as amyloidosis, can lead to CKD. Sometimes, pathological conditions that cause AKI episodes 
that don’t recover, progress to CKD. Chronic diseases, like malignancies or hepatic viral 
infections, can also present as both AKI and CKD 40. 
 Nephrotoxins may also play a role in development of CKD. Drugs such as nonsteroidal 
anti-inflammatories, aminoglycosides and lithium are examples of medicines where 
continuous use increases the risk of CKD, and the list is long 41. Finally, there are diseases 
that involve the kidney, at the  genetic level 42, and by indirect mechanisms that can lead to 
kidney injury, for example, sickle cell anaemia 43. Familial nephropathy is an ill-defined group 
of diseases that can also be in the origin of CKD. Components of this group tend to be 
identified with exploration of the human genome 44. 
 There is also a strong link between cardiac and kidney disease 45-50. It was found that 
patients with cardiac disease and dyslipidaemia, particularly high Low-Density Lipoproteins 
(LDL) levels 51 are in greater risk for kidney disease. Concerning obesity 52 and smoking 53 54, 
although epidemiologically related 55, no direct cause-effect relationship has been found 
with CKD, suggesting that concomitant conditions are responsible for both risk factors and 
kidney disease. In many cases there is a "chicken and egg" situation, making it difficult to tell 
which came first.  
 Patterns of aetiologies of CKD have a significant geographic variability 56. These 
conditions are dependent on racial/genetic differences but are also related to habits and 
lifestyle (with salt ingestion, smoking and cholesterol levels at the top), and socio-
demographic factors. 
 Nevertheless, there is still an important number of patients that reach end-stage 
renal disease without knowledge of their condition and the cause of those patients’ CKD is 
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still classified as unknown. This also depends on the nephrological coverage of a given region 
or country 57. 
 
 
2.5 Physiopathology 
 
 CKD is a heterogeneous group of disorders characterized by modifications of kidney 
function and structure. It is the common final pathway of many diseases that injure the 
kidneys, both primarily and systemically. Partial loss of renal mass leads to adaptive 
physiological change. As nephron loss progresses, there is a combination of hypertrophy and 
hyperfunction of the remaining nephrons 18 58 59. This is why body water and concentrations 
of sodium, potassium, calcium, phosphorus and uremic toxins, like urea and creatinine 
remain within the normal range in mild and moderate renal failure. 
 This adaptive hyperfiltration has a limit beyond which different symptoms may be 
observed, such as volume overload due to deficient water excretion or increased serum 
levels of toxins due to decreased urinary excretion, namely ammonia compounds, 
hyperuricaemia, hyperkalaemia or hyperphosphatemia, to mention the most common. 
There can also be anaemia and mineral bone disease due to lack of synthesis of hormones 
(Erythropoietin and 1,25-Dihidroxi-cholecalciferol, respectively). Arterial hypertension is a 
common finding of CKD and is due to a variety of mechanisms, both related to retention of 
water and salt, and to hyperactivity of the renin-angiotensin-aldosterone axis and processes 
of oxidative stress and insulin resistance 60.  
Some of these homeostatic responses are responsible for abnormalities of 
laboratory test results or symptoms and signs that appear throughout the course of the 
disease and often constitute the main focus of physicians when they follow patients with 
this disease. 
Metabolism of drugs can also be disturbed, due to several reasons: oedema can lead 
to altered volume of distribution and decreased gastrointestinal absorption. Protein binding 
may also be altered thus leading to reduced renal excretion and drug retention.  There is 
often the need to either adapt the dosage of a drug or the interval between drug 
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administrations. All patients therefore with renal disease must be monitored closely, 
particularly for signs of unexpected drug toxicity 61. 
 
 
2.6 Natural History  
 
 CKD is asymptomatic until late stages. Clinical manifestations are very 
heterogeneous and depend mostly on the underlying cause and severity of the disease. 
Symptoms that appear in more advanced stages are related to complications, such as 
volume overload, arterial hypertension, anaemia, hyperkalaemia, hypocalcaemia, 
hyperphosphatemia, hyperparathyroidism, susceptibility to infections, increased risk to 
cardiovascular disease, decreased physical capacity, cognitive impairment and increased 
drug toxicity.  
 These complications can be due to accumulation of toxins or drugs, can be direct 
consequences of albuminuria or cardiovascular disease, of a deficient regulation of the 
internal milieu or can be caused by deficient production of hormones. Some of these 
complications, if not controlled, can be a cause of death. 
 The full picture (so-called “uremic syndrome”) may include asthenia, anorexia, 
nausea, vomiting, weight loss, pericarditis, peripheral neuropathy, volume overload, 
hyperkalaemia, metabolic acidosis, hypertension, anaemia, bone disease and central 
nervous system abnormalities, including headache, sleeping disorders or cognitive changes, 
ranging from loss of concentration to seizures and coma. This constellation of symptoms 
appears irregularly over the course of the disease. It is variable from patient to patient and 
its intensity may prompt the patient to seek urgent therapy advice. Many times, this has a 
correlation with the speed of progression and presentation of the disease and with 
comorbidities, rather than the grade of kidney dysfunction. 
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2.7 Diagnosis 
 
 Either by the classical definition and according to KDOQI and KDIGO definitions, the 
decreased GFR must be persistent over the last three months so that the diagnosis of CKD 
can be considered. It is fundamental to check clinical files in search for past measurements 
such as creatinine, urine dipstick, urinalysis and sediment examinations. In addition, imaging 
exams and especially ultrasonography may show small kidneys with reduction of cortical 
thickness. Demonstration of the progression of renal function over time is also mandatory, 
since one single measurement is not enough to classify the patient as having CKD. Ruling out 
AKI is of paramount importance, as the strategy to each one of these groups of patients is 
completely different. 
 It is also important to identify the cause of CKD, if possible, because it allows specific 
therapies, when available, to be directed at preventing further progression and injury. The 
rate of progression, risk of complications and possibility of transplantation are not the same 
for all CKD causes. Unfortunately, very often there is no specific therapy to the underlying 
disease that is causing kidney injury, and in those cases kidney protective measures are all 
we have to offer to the patient, aiming at delaying disease progression. 
 
 
2.8 The Difficulties of Measuring Kidney Function 
 
Although kidney function usually denotes the blood purification processes, kidneys 
have several other important tasks. Beyond clearing toxins from the blood, kidneys are 
fundamental players not only in the regulation on the internal milieu components, namely 
water, ions, pH, blood pressure, but also as endocrine glands that produce hormones such 
as erythropoietin, renin or activated vitamin D. All these factors can be the cause of 
impairments or complications, and many of them have been correlated to symptoms and 
signs of the clinical picture of uraemia 62.  
The EUTox Work Group 63 is a working group of the European Society of Artificial 
Organs and an endorsed working group of the European Renal Association (ERA-EDTA) that 
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is committed to discovering new toxins and disclosing their importance. There are more than 
one hundred identified uremic toxins and many of them have no clinical importance. 
Therefore, it is not surprising that some aspects of kidney disease have not evolved in 
parallel with laboratory test abnormalities. 
Some of the kidney functions are performed by the glomerulus, other by the renal 
tubules. There may be disease in both components of the nephron, but also in the renal 
vasculature 64 and interstitium 65 66. Nevertheless, GFR has been considered to be the best 
index of the purification processes of the kidney and its decline is the gold standard 
measurement of kidney disease progression. As the disease is clinically silent until late 
stages, there has been a great deal of effort to find a marker which correlates between its 
blood concentration and the percentage of functioning kidney. The importance of 
measuring GFR transcends its use in the clinical setting. It serves as both predictor and 
outcome in the research environment and results of investigations are interpreted taking 
this into consideration. The need for a rigorous index of kidney function is unquestionable. 
The molecule to explore as representative of GFR would be one that has three 
features: it is freely filtered by the glomeruli; it is neither secreted nor reabsorbed in renal 
tubules; it is not metabolized inside the kidney.  
Several substances and techniques have been studied to meet these criteria 67 68: 
inulin, cystatin, some radiographic contrast agents (for example, Iohexol or Iotalamate), 
radioactive isotopes (for example, 125-iodine marked-Iotalamate) and creatinine. Most are 
exogenous; they must be administered to the patient. Inulin is generally used in research 
and the laboratory context. Radioactive isotopes are used in nuclear imaging. Other 
techniques such as Magnetic Resonance Imaging have been tried in the research context 69. 
Cystatin and creatinine are both used in the clinical context, the latter being more popular 
because there is more experience with it and it is less expensive. So, the choice has mostly 
focused on the measurement of serum creatinine 70. 
 The concept of “creatinine clearance” is defined as “the virtual volume of plasma 
that is cleared of its creatinine in each unit of time” 71, and it is used interchangeably with 
GFR. The usual operational unit is mL/min, although it can also be µmol/L, according to the 
International System of Units. Normal values depend, among others, on age, gender and 
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race, but they are often around 100 mL/min, which allows us to roughly associate the value 
to a percentage of normality. 
 The classic method to estimate creatinine clearance requires a 24-hour urine sample, 
however, this is difficult for the patient and introduces a potential source of error, as the 
collection of urine is often incomplete. Another cause for loss of accuracy in more advanced 
cases is the small quantity of tubular secretion of creatinine, whose percentage becomes 
significant when GFR is very low, changing the final result. Therefore, formulae have been 
developed to estimate GFR and, each one with its imperfections, has performed its task both 
in clinical and research settings (figure 3). 72 
 
Cockcroft-Gault formula 73 ("#$%&'()∗+(,'-./0∗12(&.,3,3(  * 0.85 (if female) 
 
MDRD formula (6 variables) 74 
170 * creatinine-0.999 * age-0,176 * 0,762 (if female) * 1,18 (if black) * urea-017 * albumin0,318 
 
MDRD formula (4 variables) 75 
175 x creatinine-1.154 * age-0.203 * 1.212 (if black) * 0.742 (if female) 
 
CKD-EPI formula 76 
If female and creatinine < 0.7 mg/dL:   144 * 452(&.,3,3($./ 7	$.90:   * 0.993&'( * 1.159 (if black)  
If female and creatinine > 0.7 mg/dL:   144 * 452(&.,3,3($./ 7	".0$:	  * 0.993&'( * 1.159 (if black)  
If male   and creatinine < 0.9 mg/dL:   141 * 452(&.,3,3($.: 7	$.#""   * 0.993&'( * 1.159 (if black)  
If male   and creatinine > 0.9 mg/dL:    141 *	452(&.,3,3($.: 7	".0$:   * 0.993&'( * 1.159 (if black) 
 
Figure 3 - Formulae used to estimate GFR 
[Units: age (years); serum creatinine and urea (mg/dL); weight (Kg)] 
 
  The oldest and still most used formula to estimate GFR is the Cockcroft-Gault (CG) 
formula, first published in 1976, which uses serum creatinine values, age, weight and has a 
correction factor for gender 73. It is not corrected for race, being very sensitive to variations 
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of muscle mass. 
  Another important formula is the Modification of Diet in Renal Disease Study (MDRD) 
equation 74. This formula was first published in 1999 and has 6 variables: serum creatinine, 
urea and albumin, age, gender and race. Later, in 2006 75, another formula was developed, 
using only four variables (creatinine, age, gender and race), demanding a standardized 
measurement of serum creatinine and claiming to provide reasonably accurate GFR 
estimates in patients with chronic kidney disease and a measured GFR of lower than 90 
mL/min per 1.73 m2. This 4-variable equation is increasingly being used, both in clinical and 
in research context. However, some claim that, in subjects with GFR over 60 mL/min/1.73 
m2, it may underestimate renal function 77, as well as in elderly and women 78.  
  Nevertheless, MDRD formulae were never universally accepted as the ones to be 
used routine and controversies still go on 79. Furthermore, CG is the easiest to use. Hundreds 
of studies have been performed to address this controversy. A direct comparison is difficult 
because many studies don’t use standardized measurements of creatinine 80. That’s why 
other approaches were tried. A reanalysis of NHANES database has led to the outset of the 
most recent formula, the CKD-EPI equation 76, which considers age, gender, race and 
clusters of creatinine values, separating lower and higher ones. In fact, this is not a single 
formula, but a combination of eight, and estimation of GFR through this set of equations has 
supposedly allowed estimation of CKD prevalence closer to what is thought to be the real 
value. 
  All of these formulae have the problem of not being validated for children or elderly, 
for whom special formulae were developed  81-83. Some other formulae have been proposed. 
One of them is Lund-Malmo formula 84 85, which claims to be more accurate in the presence 
of established CKD, opposed to CKD-EPI formula which, according to these authors, would 
be preferable for screening tests. Another one is the Haematocrit Urea and Gender (HUGE) 
formula 86 87, which brings a different approach, being useful for diagnosis and prognosis of 
CKD. One other formulae is the Mayo Quadratic formula, which claims to address the 
measurement, not only of diseased people, but also healthy ones.88 
  In fact, the exact value of glomerular filtration rate is not the essential. The final use 
of these formulae is to frame the current kidney function of a particular patient in one of 
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the KDOQI framework’s stages, previously mentioned. Moreover, these formulae are only 
useful in stable, "steady-state" patients. They are also not supposed to address, for example, 
hospitalized, febrile or catabolic patients, or the ones with AKI. They only give estimations 
of GFR. 
  An isolated estimation of GFR must not be analysed alone. It must always be 
interpreted in context with the patient’s disease. An abnormal GFR value in an otherwise 
healthy person can be a false positive test and laboratory error should be considered. The 
same applies to a value which does not fit in the usual disease progressions of the patient.  
  Besides, creatinine, being a metabolic product of a muscular component (creatine), 
it is dependent on muscular mass, varying according to gender, race, weight and age. All 
these are potential factors of error, requiring standardization so that they can be safely used 
as surrogates of GFR 89. The same happens with proteinuria, which only appears when 
lesions are already established and may not be present in early phases, when there could be 
opportunity for preventive intervention. Some argue that more important than an isolated 
measurement is the rate of decline of kidney function 90. 
  The association between AKI and CKD is also a matter of intense study, as there is 
increasing evidence that the former often leads to the latter. In this context there have been 
developments regarding biomarkers of kidney injury before kidney glomerular function 
begins to fall. Some of them have been correlated to the subsequent development of CKD. 
Among them are Neutrophil Gelatinase-Associated Lipocalin (NGAL), related to renal 
ischaemia or infection, Kidney Injury Molecule-1 (KIM-1), also detectable following 
ischaemic kidney injury, and Liver-type Fatty Acid Binding Protein (L-FABP) and Asymmetric 
dimethylarginine (ADMA), which have shown to be upregulated, as well as increased urine 
levels, in AKI and CKD, involving complex pathways of nitric oxide metabolism 67. Also, in 
paediatrics, some of these biomarkers are being investigated and making their way to 
recognition 91. Yet, there is still a long way to go until they become gold standards of kidney 
lesions of kidney functions in clinical context or research targets. 
  Meanwhile, we must rely on GFR as the main marker of kidney function, so that it 
can guide us to effective interventions that slow down or halt the progression of CKD. This 
is particularly a hard job because, although GFR declines very quickly on later stages of the 
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disease, it decreases slowly at the beginning, hampering the detection of evolution during 
that time, which is very long.  
  However, even in more advanced phases, in which creatinine clearance is already 
recognized as being indicative of how kidneys clear toxins, it is still just a number that often 
fails to link to the real capacities of the patients’ lives with the fewer disabilities they can live 
with. It is very important to get a strong correlation between estimated GFR and life events, 
such as hospitalization or death, the milestones that really matter to patients. 
 
 
2.9 Strategies for Management and Performance Indicators 
 
 Recommendations for specific therapies are beyond the scope of this text. However, 
as a summary, it may be said that there is a consensus for the five broad strategies that 
should be followed 92 93: 
a) treatment of reversible causes of renal failure 
b) prevention or slowing kidney disease progression 
c) prevention and treatment of the complications 
d) adjustment of drug doses to the level of estimated GFR, when appropriate 
e) adequate preparation of the patients in whom RRT will be required. 
 
Table 2 lists some of the CKD complications that are usually addressed in patients 
with progressive CKD and the performance indicators used to address them. Some of them 
are still controversial because even if they are recognized to occur during disease 
progression, their overall impact on quality of life, morbidity and mortality is not known.  
The usual approach to CKD management includes addressing each one of these 
problems 94. Some of them have implications on others. Therefore, acting on one of these 
issues often leads to changes in others, both beneficial and deleterious. The usual office 
practice is to check each one of the various clinical parameters and prescribe medicines or 
give advice towards antagonizing the factors responsible for their cause. 
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Table 2 - Performance indicators for the clinical problems of CKD 
 
 
 
Clinical problems to be addressed Performance Indicators 
 Volume overload/oedema Weight; Presence of Godet’s sign; Pulmonary Sounds; turgor of 
jugular veins; hepatomegaly. 
 Losing weight (for obese patients) BMI variation 
 Hyperkalaemia Serum Potassium 
 Metabolic acidosis Serum Bicarbonate; Serum CO2 
 Arterial Hypertension Arterial Pressure (systolic and diastolic) 
 Cardiac dysfunction Echocardiogram data 
 Anaemia Haemoglobin, Haematocrit 
 Iron kinetics Ferritin, Transferrin Saturation, Hypochromic erythrocytes 
 Mineral Bone Disease Serum Calcium and Phosphorus; Serum Intact Parathyroid hormone 
(PTH); Alkaline Phosphatase 
 Dyslipidaemia Total Cholesterol; HDL and LDL Cholesterol; Triglycerides 
 Hyperuricemia Serum Uric Acid 
 Sexual dysfunction Yes/No: data from history 
 Malnutrition Weight; Serum Albumin; Physical Examination 
 Inflammation Leukocytes, C-reactive Protein (and also pro-inflammatory 
cytokines: IL-6, IL-10, TNF-a, complement components, 
prostaglandins, leukotrienes, not currently used in clinical practice)  
 Glycaemic control (for diabetic patients) Glycated Haemoglobin 
 Thyroid dysfunction Thyroid-stimulating hormone 
 Pericarditis Echocardiogram; Cardiac Murmur on physical examination 
 Uremic neuropathy Yes/No: data from history 
 Uremic Bleeding Yes/No: data from history 
   
General patient education Performance Indicators 
 Salt restriction Yes/No: data from history  
(also: urinary sodium may be of use) 
 Moderate protein restriction Yes/No: data from history 
 Smoking cessation Yes/No: data from history  
(also: Serum Cotinine) 
 Nephrotoxic drug eviction Yes/No: data from history 
 Lifestyle modifications (diet, exercise, etc.) Yes/No: data from history 
 Vaccination Yes/No: data from history; specific serology 
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At the beginning of the follow-up, there is a time in which any physician can lead the 
treatment because goals are general, broadly related to cardiovascular prevention, there 
being no specific demands, as they are similar and sometimes concurrent with other 
diseases. Many times, specialists, other than nephrologists, also come across CKD while 
treating other organ diseases: family physicians, internists, cardiologists, endocrinologists, 
vascular surgeons or neurologists, to mention but a few. It is important to stress that up to 
a point, these general strategies are available to any physician.  
Referral to a nephrologist generally depends on national and local practice habits, 
guidelines and protocols, and on the availability of medical services 95. There is though one 
indication for a nephrologist appointment that meets a consensus: GFR below 30 mL/min 96. 
This indication for referral to the nephrologist is based on treatment of specific 
complications that usually appear more often from this milestone on. This early referral, as 
opposed to later, has demonstrated to be associated with lower mortality after initiation of 
dialysis 97. Another study 98 reinforces this idea and emphasizes that it is true irrespective of 
the aetiology of CKD and enhances the benefits of a very early” (more than 12 months) 
preparation for RRT. 
 Preparation for RRT is also an important reason to refer a CKD patient to a 
nephrologist. This includes choice of modality, construction of adequate vascular access or 
peritoneal catheter, vaccination, preparation for transplantation when appropriate, and 
specific treatment of complications such as anaemia, mineral bone disease and metabolic 
acidosis with drugs that, at least in Portugal, are only available at the nephrologist’s office. 
 Currently the nephrologist doesn’t work in isolation. Dealing with CKD implies being 
part of a broader framework that some have called Disease Management 99. The continuous 
monitoring of the patient status and circumstances is mandatory for the success. Beyond 
clinical and physiological indicators, other key performance indicators must be followed for 
success. Among them are health promoting behaviours, well-being and quality of life, health 
care utilization and, because resources are not infinite, health care costs. These are, in 
general, the components of the proposed Clinical Balanced Scorecard that we are aiming 
for. 
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3 Managing Chronic Disease and Measuring Quality of Care 
 
A chronic disease is a disease that lasts for a long time, very often a lifetime. It cannot 
be cured neither it just disappears. Although its symptoms are sometimes less severe than 
those of the acute phase of the disease, chronic disease demands permanent care and 
brings long lasting suffering to the patient. Chronic diseases may be progressive or can 
evolve by bursts, often resulting in incomplete recovery, in partial or complete disability and 
ultimately leading to death. 
A survey published in 2014 100 refers that 117 million Americans had at least one 
chronic condition and at least 25.5% of the people had at least two. Arterial hypertension, 
obesity, coronary heart disease, stroke, diabetes, cancer, arthritis, hepatitis, weak or failing 
kidneys, asthma, and Chronic Obstructive Pulmonary Disease (COPD) are among the top 
causes of death, 70% of which are chronic conditions 101. Two of these chronic diseases 
(heart disease and cancer) together account for nearly 46% of all deaths. Arthritis is the most 
common cause of disability. In Europe numbers are not significantly different 102. 
A detailed definition of Chronic Disease is beyond the scope of this text, as all 
definitions available agree that Chronic Kidney Disease (CKD) fulfils criteria for being 
considered chronic 103. 
 
 
3.1  The Individual Level 
 
The primary need of a patient when he seeks the physician with some kind of 
complaint may not necessarily be the cure. Although this may be absolutely true for acute 
diseases, it may not be so when we deal with incurable diseases, which become long lasting. 
In these cases, the patients will only aim to live as long as possible with the best possible 
quality of life: that is translated into less suffering, less disease burden, less consumption of 
medical care and the most complete rehabilitation they can get. In other words, the chronic 
patient aims to maintain his autonomy and self-helping skills, his communication capabilities 
and his social interaction. In the evidence-based medicine era, the scientific community is 
Managing Chronic Disease and Measuring Quality of Care 
 
 36 
looking for the standard of care that can best pursuit that goal. This is what should be 
considered Quality of Care. This where the concept of disease management arises, meaning 
a broader sense than simply “treating” the diseased person. 
The classical approach to chronic disease has been mechanistic, hospital and 
physician-centric, considering that the cause has either an anatomical or a chemical 
foundation. Following this paradigm, the physician addresses each one of the potential 
clinical problems of a given pathologic condition and how they express, both clinical and 
analytically, and the main focus of attention is given to those symptoms, signs and very often 
(too often) laboratory tests as outcomes. The problem is that all of them, especially the 
latter, have little impact on patients’ perception of improvement. When these diseases don’t 
bring progressive disability, they are silent until late stages, when clinical untoward events, 
some of them catastrophic, happen. In fact, laboratory tests are just numbers that often 
mean nothing to patients’ everyday life. Not rarely, the toll that they have to face to keep 
some lab test within the right limits is greater that the perceived benefit against degradation 
of health status and, therefore they don’t comply with the physician’s recommendations.  
Furthermore, there is a selection bias. Depending on when vigilance starts, time to 
hard endpoints that really impact people’s life (for example, a catastrophic event like 
hospitalization or death) is not uniform, making it difficult to explain the need of a treatment 
or a change of lifestyle. Every patient knows another one with the same disease, for whom 
the result of a medical decision has been different. The same happens with endpoints in 
research context: rather than considering a defined number to demonstrate a given 
intervention, it might be proposed an interval between two stages as the standard measure 
for progression, both upwards or downwards (improvement or worsening) of a certain 
medical condition. Another problem is that patients have multiple comorbidities and it is 
also important to analyse the mutual interference of all variables. 
This calls for a dynamic view of the problem. The concept of disease trajectory is, 
thus, most appropriate in this context, as it reflects the evolution and, by that way, 
reproduces the way the patient (and his support) is coping with the disease. The difficulty is 
to find a variable that can easily express that progression. There is a need to evaluate 
concepts like well-being, quality of life, depression, rehabilitation, functionality, 
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comorbidity, happiness, and many others. These should, in fact, be the goals to pursue 104. 
This is why we have chosen the designation “Management of Chronic Patient”, to include a 
broader dimension than simply “Treatment of the diseased person”, as usually used 
currently. 
 
 
3.2 The Organizational Level 
 
 Chronic diseases represent a heavy burden, not only to the patient, but also to his 
family and the society, both considering personal suffering and economic issues. The 
growing aging of populations in modern societies led to an increase of the number of chronic 
patients, and no country is truly prepared for that. The problem is not new: in 1996, 75% of 
health expenditure was on chronic care 105. Since then it didn’t improve: according to US 
Center for Disease Control and Prevention (CDC), that number rose to 86% in 2010 106, 48% 
of the people having at least one chronic pathologic condition. This is important, not only 
due to direct medical costs, such as medication and increased utilization of health services, 
but also to indirect ones, as for example, decreased work productivity and premature 
retirement.  
 At a governmental level, chronic diseases tend to be seen as being, neither urgent, 
nor the eventual improvements easy to advertise, falling in politicians’ priorities rankings, as 
compared to competing calls for budgetary attention. However, it has become evident that 
the traditional model of acute care, based on episodic contacts between the patient and 
health institutions is no longer capable of meeting the long-term needs of an aging, chronic 
diseased population. 
 Consequently, there have been important efforts to deal with this problem. 
Ambulatory care is increasingly becoming recognized as the right way to do it, where 
preventive actions are the core activity and, because of that, they are potentially more 
effective since they are monitored more closely to families’ and people’s lives. Even when 
patients need differentiated care, some new solutions are being designed, such as home-
hospitalization 107 108 and palliative end-of-life care 109.  
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 So far, several models of care created to deal with chronic disease have been 
proposed, mostly in the US, and their detailed discussion is made elsewhere 110. As a 
summary, it can be said that all of them are multidisciplinary, involving nurses, social 
workers, psychologists and other health care professionals. This is why single-standing 
private practice medical offices are no longer adequate to deal with these conditions. In 
general, it can be said that the ideal environment to treat chronic diseases is a health 
delivery system or health organization, as long as they promote a proactive, patient centred, 
evidence-based delivery of care, patient safety, as well as community linkage and health 
education programmes for patients and families to promote self-management as far as 
possible. Some claim that each system should be directed to one type of disease, to 
homogenize beneficiaries and increase efficiency, but this is not consensual, because many 
patients have multiple conditions and separation of care of several pathologies makes more 
difficult to integrate problems of each patient 102. Another essential requisite is the existence 
of a good omniscient information system where everything is recorded for future memory 
and as a part of a learning structure 111.  
An expert panel meeting on older adults with multiple chronic conditions, held by 
the National Institute on Aging in 2012 112 recommended that any organized program of 
care of older persons with multiple chronic conditions should always complete a brief initial 
composite measure including symptom burden, measures of depression and anxiety, 
information on daily activities, assessment of physical and cognitive functions and evaluation 
of caregiver burden. These are broadly the components of Patients Reported Outcome 
Measures (PROM) generally used in this context, which are going to be addressed further 
on. 
A shared essential aspect to all is the need to be accountable, trying to find the right 
outcomes, as one cannot improve what can’t be measured. Performance indicators are 
endless, each one directed to a detail that can be addressed, ranging from global to 
individual issues. The search for such quality outcome indicators is clearly a priority. 
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3.3 The Importance of Assessing the Success of Healthcare Interventions 
 
 Success, in general, is understood as making progress towards strategic goals or 
periodically achieving some level considered to be adequate or desirable. In clinical context, 
this notion is often intangible, because it is subjective and context dependent. In some cases, 
it is very difficult to define clearly what the main purpose of medical action is, as far as clinical 
outcomes are concerned. Nevertheless, regardless of the situation, one can summarize 
success of medical care as “delivering value to the patient” 113. This delivered value can be 
translated in a life with quality, free from limitations due to health problems. 
 In acute diseases, these definitions are clearer: the patients want to be cured of the 
disease they are suffering from and they long to return to their previous healthy state as 
soon as possible. In this context, being sick or healthy are two mutually exclusive conditions 
in which a person can be. 
 In chronic conditions, as already said, patients are going to face their disease for a 
long period of time (if not forever) and patients and their families want to live as long as 
possible, with the less possible distress. This can be expressed by different outcomes. For 
example, patients may want to return to work especially if the disease made them stop 
working. In addition, they will want to recover from the disease where possible or when a 
flare has occurred. Most importantly, they look to regain independence, if some of it was 
lost and to avoid a bad outcome, such as a myocardial infarction, stroke or dialysis.  
 Measuring quality of care is, thus, essential. It will allow: quality assessment of the 
care itself, after creation of standards for comparison; interpretation of epidemiological data 
so that it can have relevant impact on future decisions; validation of clinical trials results and 
endorsement to practice guidelines; cost-effectiveness analysis, encouragement of patients 
for compliance; other scientific and economic purposes, namely payment for performance 
and continuous improvement. 
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3.4 The Point of View of Quality Management 
 
Donabedian, back in 1966 114 in his seminal paper, outlined the main aspects of the 
evaluation of quality of care. This opened doors to new ways of facing this issue. He pointed 
out that evaluation of the medical activity, as the result of patient-physician interaction, was 
dependant on three interdependent vectors: structure, process and results.  
The first one, structure, is related to the settings in which the process takes place. It 
refers to adequacy of facilities, equipment, administrative support, number and 
qualifications of professionals, existence of information and institutional issues. In a sense, 
baseline characteristics of a sample of patients being intervened can also be considered a 
structural feature of the system, because they are the departure point and have impact on 
outcomes. 
Process is the second dimension of quality and it is related to appropriateness, 
completeness and redundancy of the interaction of the patient with the health professional 
or institution: medical history, physical examination, accurate diagnostic tests or preventive 
management. 
Finally, there is a criterion that more accurately estimates quality than the 
measurement or verification of pre-requisites of structure and process. According to 
Donabedian 114, it’s the measurement of outcomes (results) that can best lead to a degree 
of quality evaluation which can be reflected in good results to the patient, contextualized 
with the other two criteria (structure and process). In common language efficacy and 
efficiency are designations often used. The first tells how a goal is being or has been 
achieved, the second relates it to the consumption of resources.  
 A good method to improve quality is to periodically check outcomes and evaluate 
the influence of process and structure on them and how changes in the latter can improve 
the former. This is the classical “plan-do-check-act” cycle, or Kaizen, which is the gold 
standard of quality improvement programmes 115 116. 
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3.5 Health-Related Quality of Life 
 
The definition of Health formulated in 1948 by the World Health Organization (WHO) 
Constitution 117 ("Health is a state of complete physical, mental, and social well-being and 
not merely the absence of disease or infirmity”) has evolved to a multidimensional level, 
including physical function, emotional and cognitive functions. This also includes 
perceptions about present and future health, morbidity, premature mortality and life 
expectancy, as well as various symptoms and physiologic states 118. This goes along with 
concerns regarding the coping with the disability in chronic diseases. Even when a chronic 
disease is reasonably controlled, it is the way it is experienced by the patient that endorses 
the success of medical decisions. 
Morbidity is, therefore, the relevant concept in this context. The need for 
hospitalization or usage of medical services are indirect markers of well-being and, 
therefore, of Health-Related Quality of Life (HRQoL). These measures give information about 
the lowest levels of health but give little information about smaller disabilities. Pursuing 
improvements in these indicators will provide only a minimal assessment of patient 
improvement. If, however, differences between perfect health and smaller disabilities were 
measured and improvement was pursued, the level of health enhancement would be 
greater. 
This apparent disparity of concurrent concepts has led to the search of a composite 
index of overall health by combining data about the presence or absence of various diseases 
and conditions. Quality of life (QoL) is a comprehensive popular term that encompasses the 
sense of well-being, and includes aspects of happiness and satisfaction with life as a whole. 
Being subjective, it may have a different meaning for each person in a given society and is 
necessarily different across cultures and geographies. It is a balance of several dimensions, 
both positive and negative: physical performance, vitality, social inclusion, religious beliefs, 
education, employment, life satisfaction, wealth, family issues, finance and environment. 
Another definition of QoL, is “good quality of human life” 119. It has several 
dimensions, ranging from the individual up to the society level. These lead to diverging 
focuses and very different definitions. On the community level, these dimensions together 
Managing Chronic Disease and Measuring Quality of Care 
 
 42 
build the complete picture of a society’s well-being: ecology, economics, politics, education, 
safety, security, health, are some of the areas of interest. Many of them are related to 
cultural issues and expectations. Nonetheless, QoL is always recognized and presented as a 
target to achieve. 
In this process, the WHO proposed a definition of individual QoL: “the individual’s 
perception of his position in life and in relation to his goals, expectations, standards and 
concerns” 120. 
An important determinant of individual QoL is health. Without health, a person can’t 
enjoy life to the fullest. In other words, his/her QoL becomes diminished. The WHO 
addressed this matter, by creating instruments to measure HRQoL 120. HRQoL has been 
defined as the “impact of disease and treatment across the physical, psychological, social 
and somatic domains of functioning and well-being” 121. Consequently, every disease or 
condition can be assessed by the impact it has on QoL and many attempts have been made 
with this goal in mind. Moreover, the importance of the health component of QoL is justified 
because it is a very important variable in one’s life. Measuring HRQoL gives a standardized 
idea of the patients’ experience of the disease and its toll in several dimensions on human 
life.  
According to some authors, given this subjective feature, QoL is not being correctly 
measured, as it can only be suitably measured by determining the opinions of patients and 
by using validated instruments 122 123. 
 
 
3.6 The Point of View of Utility 
 
Quality Adjusted Life Year (QALY) is a measure of estimated quality of life. It was 
developed as a measure of effectiveness and utility for decision-making in several contexts, 
mostly managerial, budgetary and resource assigning. The basic concept is that individuals 
move through health states over time and that each health state has a value attached to it. 
Any situation of a disease or disability would represent a lower value, taking into account a 
Managing Chronic Disease and Measuring Quality of Care 
 
 43 
discount of an amount of time correspondent to the imparity brought about by that relative 
inability 124.   
There is a derived concept, the Disability Adjusted Life Years (DALY) that intends to 
measure the impact of health loss by the quality of life. On the contrary, QALY considers 
both quality and quantity of living, considering health gain. The difference between them is 
rather technical and its explanation is outside the scope of this text 125. 
Both are methods of evaluation of the impact of health interventions as a result of a 
resource allocation. They assume that a year of life in perfect health is worth 1.0 QALY and 
death corresponds to 0.0 QALY. It combines duration of life with a level of utility of a given 
intervention, and the utility is the improvement of health brought by a given treatment or 
decision. Variation of utility and survival are then compared to help steer medical and 
political decisions. For example, a 3-year survival after a surgery with a utility improvement 
of 0.7 corresponds to 2.1 QALY; another competing treatment that brings a 9-year survival 
with utility of 0.4 corresponds to 3.6 QALY. The latter would be the favoured measure for 
medical decisions or budget assignment. 
Utility is calculated by asking the patient about their options regarding their valuation 
of health benefits of a given decision in a pertinent time frame. Value is measured in terms 
of preference between two options. An earlier benefit is valued over a later one, like when 
applying a discount interest rate to the value foreseen. If a group is considered, benefits 
across the individuals are considered and used for the group. 
Another technique to compute utility is the Time Trade-off (TTO). TTO is used to 
measure the QoL that a person or group is experiencing. An individual would be presented 
with the following question: “Imagine that you have 10 years left to live. You have two 
options: either live those 10 years in your current health status or give up some of those years 
in exchange for the rest of the time in perfect health.” 126 127. The answer given by the 
individuals show how many years in the current health state they would be willing to trade-
off, in order to regain full health. This answer can be used to calculate the individuals' quality 
of life in the present health state. If a person answers, for example, three years, it means 
that he/she compares seven years of perfect health with 10 years in the current status 
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assigning the same value to both situations. His/her TTO value is 0.7. This result is often used 
to compute QALYs, combining mortality and morbidity in the same scale. 
An important limitation of this kind of measures is the subjectivity that they carry, 
both to the evaluation and to the perception of urgency by each person. Moreover, as its 
calculation is very complex, it is of limited use in the clinical setting 128.  
Therefore, this concept is mostly used for cost-effectiveness analyses, rather than 
the follow-up of individual cases. It is the most important unit used by National Institute of 
Clinical Excellence (NICE), in the UK, to assess cost-effectiveness of new treatments 129. 
Nevertheless, necessary data for its calculation comes from sets of patients and is influenced 
by their everyday life. In a way, it can be considered, at least, a worth-mentioning PROM-
derived index and it may be useful in ecological studies. 
 
 
3.7 Surrogate Outcomes 
 
In chronic care, a specific endpoint (good or bad) is often inappropriate to use 
because it is too far in time or too catastrophic to be useful for a model of continuous 
improvement that uses the “plan-do-check-act” cycle 115.  
Therefore, mortality, probably the most used endpoints in research, has relevance 
only if we are dealing with a life-threatening disease within the span of the observation 
period. Chronic diseases often have a long period before mortality occurs, lessening the 
significance of this endpoint in a short-term analysis. In these cases, it is more relevant to 
know how patients are coping with such a disease and how it is preventing them leading 
normal lives or to check if they can still work and earn, or to count hospital admissions or 
visits to the physician or the emergency department, and aim for their reduction, than to 
wait for their deaths. Time to an event can also, in this context, be an intermediate endpoint 
of interest, especially if it refers to a relevant endpoint to achieve or avoid.  
These are the so-called surrogate endpoints that are frequently used as 
replacements of clinical endpoints, as research guides  or to adjust decisions and processes. 
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Going back to the Donabedian’s framework 115, it corresponds to adding an intermediate 
outcome between the process and the final outcome. 
It is important that these intermediate outcomes have three qualities: firstly, that 
they are relevant to patients, showing improvement of their disease status, rehabilitation,  
quality of life improvement, the reduction of adverse events or avoidable suffering; secondly 
that there is a rationale between the disease process and the measured outcome; thirdly 
that physicians’ actions have some impact on those endpoints, so that they may be 
correlated to the improvement of the specific indicator.  
In other words, the link between the surrogate endpoint and the clinically relevant 
outcome must be validated, either with a logical explanation by aetiopathogenic or 
pathophysiologic mechanisms or by a proven causal epidemiological link. There must be the 
possibility of predicting the effect of the intervention, such as a pharmacologic or non-
pharmacologic treatment, on the clinical outcome. There should also be as fewer 
confounding factors as possible. 
These surrogate endpoints should also be indicative of what the impact of the 
disease is on patients’ lives. Good examples of this are: absences from work, visits or 
referrals to the emergency department; hospital admissions and number of inpatient days 
(this correlates with severity of complications, but it is also dependent on organization of 
hospitals, together with the medical action itself). Sometimes it may be necessary to build 
composite endpoints, gathering occurrences of similar meaning, to assure that they happen 
in a frequency big enough to allow statistical analysis 130. 
 
 
3.8 Comorbidity Indices 
 
Comorbidity is defined as the presence of more than one distinct disease in the same 
individual 131. It is widely recognized as an important contributor to outcomes both because 
it has impact on morbidity and also because it introduces bias in selection in the research 
context. In 1987, Charlson created the first tool 132 aimed at prospectively attempting to 
reach a method for classifying comorbid conditions which might change the risk of mortality 
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for use in longitudinal studies. An important drive for this research was the finding that many 
trials excluded patients with comorbidities to prevent their interference in the results, but 
this led to sample analyses that were less representative of clinical reality, decreasing 
reproducibility of results. The original Charlson comorbidity scale included 17 conditions, 
each one scored according to the risk of mortality.  
Later on, in 2011 133, a work of revalidation took place, adapting the scale to newer 
realities in an international context. This update followed the recognition that some diseases 
that formerly were considered to be life limiting could have improved prognoses. 
Components of both scales are presented in table 3. 
 
Table 3 - Charlson Comorbidity Indices (1987 and 2011 versions) 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comorbidities Original 1987 scale 132 2011 update 133 
Myocardial Infarct 1 point - 
Congestive Heart Failure 1 point 2 points 
Peripheral Vascular Disease 1 point - 
Cerebrovascular Disease 1 point - 
Dementia 1 point 2 points 
Chronic Pulmonary Disease 1 point 1 point 
Connective Tissue Disorders 1 point 1 point 
Ulcer disease 1 point - 
Mild Liver Disease 1 point 2 points 
Diabetes 1 point - 
Hemiplegia 2 points 2 points 
Paraplegia - 2 points 
Moderate or severe renal disease 2 points 1 point 
Diabetes with end-organ damage 2 points 1 point 
Any tumour 2 points 2 points 
Leukaemia   2 points 2 points 
Lymphoma 2 points 2 points 
Any solid tumour 6 points 6 points 
Moderate or severe liver disease 3 points 4 points 
AIDS 6 points 4 points 
Age (each decade above 40) 1 point   
Highest Score (most diseased) 35 points 
(plus points due to age) 
34 points 
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  The Charlson comorbidity index has been widely accepted as a standard for 
evaluation of comorbidities, both at clinical and research level. A search of PubMed with 
keywords such as “Charlson” or “Charlson Comorbidity Index” returned more than 10,000 
references, from all specialities, ranging from clinical to managerial subject areas. It has been 
very important to allow patients with comorbidities to participate in clinical trials and widen 
the span of its results. It is interesting to verify that most articles still use the original version 
even though it has been challenged as outdated. 
  Another comorbidity scale was published in 2002 by Davies 134, specially directed to 
CKD patients on peritoneal dialysis. It is a very simple score that considers seven conditions: 
malignancy, ischaemic heart disease, peripheral vascular disease, left ventricular 
dysfunction, diabetes mellitus, auto-immune disease and any other significant disease. It 
also adds points according to age and number of comorbidities. The gradation ranges from 
zero to two points and it correlates to mortality risk.  A comparison with the original (1987) 
Charlson comorbidity index 135, found that both Davies and Charlson comorbidity scores 
were significant predictors of outcomes, with the Charlson Comorbidity Index being a 
stronger predictor for mortality and the Davies score a stronger predictor of hospitalizations. 
 Three other scales have been presented as alternatives to quantify the impact of 
comorbidities: one is the Index of Coexistent Diseases (ICED), another is the Disease Burden 
Morbidity Assessment (DBMA) and the third is the Sickness Impact Profile (SIP).  
The first one, ICED, is a questionnaire that aggregates the presence and severity of 
19 medical conditions and 11 physical impairments, gathering data into two scales (one 
related to disease severity, the other showing physical impairment). In the nephrological 
context, this was used in the Haemodialysis (HEMO) study 136 137. It has also been used in 
orthopaedic context 138. It. A problem with this test is its size, which means it is impractical 
to use in a clinical daily context.  
The other comorbidity index, DBMA, was originally published in 2005 139. It is an 
extensive questionnaire that covers 21 health conditions, not only asking for their existence, 
but also inquiring about the disability that each one of them causes to the individual.  
Compared to others, it can be easily completed, including older people, without the 
limitation of having to be administered by professionals with medical background. This is, 
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usually a limitation to using these instruments in large samples of patients either in primary 
care settings or the general population. 
Finally, SIP, which was originally published in 1975 140, more than a comorbidity index, 
is a generic health status measure of change in behaviour as a consequence of HRQoL. It 
claims to be a measure of sickness related to dysfunction based on activities of daily living. 
It has a 136-item questionnaire divided in 12 categories: sleep and rest, work, eating, home 
management, recreation and hobbies, ambulation, mobility, body care and movement, 
social interaction, alertness behaviour, emotional behaviour, and communication. There is 
a shorter version with 68 questions 141 142. Both versions are very long, are difficult to use in 
the clinical setting and as a result are not being widely used. 
 
 
3.9 Patient Reported Outcome Measures 
 
Treating chronic patients with success depends on a strong bond between the 
physician and the patient. The former is supposed to look for a complete understanding of 
most dimensions of their patients’ experience of the disease. Not only are symptom status 
and physical functions important, but also mental health, social function and general well-
being are relevant issues to be perceived by someone who has the responsibility to prescribe 
drugs, give important advice that changes patients’ lives, and perform invasive techniques. 
All these interventions must be programmed and executed with the exact needs of the 
patients in mind and look to solve their health needs. No one can assess those needs better 
than the patients themselves. 
Rehabilitation, well-being and HRQoL are only some of the examples of important 
goals of medical treatment with subjective implications which are completely dependent on 
how the patient feels and complains, and on many characteristics of his personality, familial 
environment or social status. 
PROM are tests that intend to get a standardized answer from the patients as a reply 
to questions or statements which represent several themes of interest and whose 
codification leads to knowledge of their opinions, feelings, experiences, capabilities and 
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perceptions. There are hundreds of PROM scales, which include health status assessments, 
functional status, symptoms and symptom burden reporting measures, health behaviours, 
experience with care, treatment satisfaction measures, economic impact measures, and 
instruments for assessing specific dimensions of the patient experience such as physical and 
mental performance, depression and anxiety 13.  
It is also important to mention that, for most environments, in this acronym, patient 
refers, not only to the diseased person, but also to all related people of the micro-system 
around him/her: family, formal and informal caregivers and any related person. However, 
some institutions and authorities confine this designation to information that comes directly 
from the patient about the status of their health condition without an interpretation or 
amendment of his answer by a physician. The FDA  has  specific guidance for use on Medical 
Product Development to Support Labelling Claims 143, in which the definition demands the 
absence of an intermediate between the patient and the recorded data.  
There is a similar concept that includes all patient care experiences, values, 
preferences, satisfaction, expectations and this is designated the Patient Reported 
Experience Measures (PREM). It is also used to assess quality of health systems, beyond 
individual patient status. In some contexts, PROM and PREM can be linked 144.  
Limitations of PROM include aspects related to populations, namely very young, 
elderly and most fragile ones, low literacy, language and other problems of communication, 
culture and functional inabilities, both physical and cognitive. Cultural barriers also 
constitute a hurdle to overpass. 
PROM can help decisions in several fields: in the clinical environment, to help 
diagnosis, stage diseases or monitor results of treatments; in research, it can be used as 
outcomes for testing medicines, devices or techniques; in management, to assess 
performance or serve as quality indicators of benchmarking; in society, to give information 
to patients in order to help choices of providers. 
The proliferation of PROM has led to questions of validity. The National Quality 
Forum addressed this issue creating a framework for validation of the newly created PROM 
145. According to it, it is mandatory to document the conceptual and measurement model, 
the reliability (through internal consistency and reproducibility), the validity (content, 
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construct and criteria and responsiveness validity), the facility of the interpretation of 
scores, the feasibility the alternative modes and methods of administration, cultural and 
language adaptations and the capability of electronic health records. 
Moreover, since 2004 a National Institute of Health (NIH) funded initiative named 
Patient Reported Outcome Measures Information System (PROMISÓ) 146 147 has also been 
trying to summarize many aspects of patients’ information that only they can provide. The 
publicly expressed goal of PROMIS is to develop a "psychometrically validated, dynamic 
system to measure these patient-reported outcomes efficiently in study participants with a 
wide range of chronic diseases and demographic characteristics." 148 
Using a computer adaptive test with simple questions, it provides an instant report 
of health status reaching several different domains and returning results that may be 
compared to the general public and to people who belong to the same age and gender. Data 
has been being collected in a central databank and has led to the creation of hundreds of 
scales which intend to comprehensively score these subjective dimensions of the patient 
status. PROMISÓ claims to be “a set of person-centred measures that evaluates and 
monitors physical, mental, and social health in adults and children. It can be used with the 
general population and with individuals living with chronic conditions” 149.   
Some PROM are generic, others are disease targeted. Many of them address each one 
of these aspects and some try to handle them all. Generic tests are validated for the general 
population and aim at representing non-specific aspects of being ill. They are, in general, 
less sensitive to certain features of each disease. Their advantage is the ability to compare a 
more heterogeneous group of patients. On the other hand, disease-targeted questionnaires 
were validated for a particular condition, they are normally very specific, avoid ceiling or 
floor effect and intend to portrait the behaviour of a defined disease. 
 Figure 4 presents the global framework of PROMISÓ. 
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Figure 4 - PROMISÓ Adult Self-Reported Health framework (adapted from 149) 
 
In a broader sense, several kinds of information can originate a PROM: HRQoL; activity 
limitations (disability); symptoms and burden of disease; experience with care; health 
behaviours; QoL and patient satisfaction. Its scope can range from disease into other 
domains of patients’ lives (Figure 5).   
 
 
Figure 5  - Scope of PROM (adapted from 144) 
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Another issue is the cumulative difficulty and statistical noise by increasing the 
comprehensiveness of a given scale. On the other side of the spectrum are the simpler scales 
which induce loss of precision and information. The more we want to extract from a scale, 
the more complex the process of its validation becomes.  
Table 4 summarizes some generic tools.  
 
Table 4 - Selected generic PROM and domains they measure 
 
 
 
 
 
 
Acronym Full Name Domains covered 
MOS SF-36 150 
(also, SF-20, SF-12, 
SF-6D) 
Medical Outcomes Study Short Form Bodily pain, physical functioning, vitality, mental health, social 
functioning, role limitations due to emotional or physical problems, 
general health perception 
QWB-SA 151 Quality of Well Being   – Scale Assessment Depression 
SIP 141 Sickness Impact Profile Physical composite, psychosocial composite, general health. 
PROMIS-57 146 
(also, 43 and 29) 
Patient-Reported Outcome Measurement 
Information System 
Pain, physical function, fatigue, sleep disturbance, anxiety, 
depression, ability to participate in social roles. 
WHOQOL-BREF 152 World Health Organization Quality of Life 
Scale 
Physical health, psychological, social relationships, environment 
IIRS 153 Illness Intrusiveness Rating Scale Physical well-being, diet, work, finance, marital, sexual, family 
relationships, social relations and other aspects of life 
PHQ 154 Patient Health Questionnaire Depression 
SDI 155 Social Difficulties Inventory Everyday living, social distress, self and other money subjects 
GAD-7 156 Generalized Anxiety Disorder 7-item Scale Anxiety 
ESASr 157 Edmonton Symptom Assessment System 
revised 
Pain, tiredness, drowsiness, nausea, appetite shortness of breath, 
anxiety, depression, well-being 
ESS 158 Epworth Sleepiness Scale Insomnia 
CH-RLSq 159 Cambridge-Hopkins diagnostic 
questionnaire for Restless Leg Syndrome 
Restless leg syndrome 
HUI2 160 Health Utility Index Pain, mobility, self-care, sensation fertility, emotion, cognition 
EQ-5D 161 162 Euro-Qol 5 dimensions Pain, mobility, self-care, anxiety, depression, general health 
LASA 163 Linear Analog Self-Assessment Scale Physical, emotional and social dimensions, summarizing 29 areas 
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Table 5 describes a CKD-specific PROM. Most of them have been studied in CKD 
patients already on dialysis or transplanted. 
 
 
Table 5 - CKD disease-targeted PROM and domains they measure 
 
Acronym Full Name Domains covered 
QLI-D 164 Quality of Life Index – Dialysis Health and functioning, psychosocial/spiritual, social, economic, family, general 
health 
KDQOL-LF, 
KDQOL-SF 165 
Kidney Disease Quality of Life 
(Long Form and Short Form) 
Physical functioning, role physical, pain, general health, social function, emotional 
well-being, role emotional, energy/vitality  
KDQ 166 Kidney Disease Questionnaire Physical symptoms, fatigue, depression, relationship with others, frustration 
KTQ 167 Kidney Transplant Questionnaire Physical symptoms, fatigue, uncertainty, appearance, emotional 
RQOLP 168 Renal Quality of Life Profile Physical activity, impact of treatment, eating and drinking, psychosocial activities, 
leisure time 
CHEQ 169 CHOICE Health Experience 
Questionnaire 
Physical functioning, sexual functioning, sleep, diet, vitality, body image, bodily 
pain, cognitive functioning, mental health, social functioning, role emotional, role 
physical, work, recreation, travel, finances, dialysis access, freedom, general QoL 
RDI-QLQ 170 Renal Dependent Individualized 
Quality of Life Questionnaire 
Physical functioning, sex life, enjoyment of food, restriction of fluid, physical 
appearance, family life, worries about the future, motivation, spiritual/religious, 
social life, friendships, work, leisure, activities dependency, freedom, social, 
prejudice 
 
 
3.10 Objective Performance Status versus Perceived Performance Scales 
 
PROM can provide data on the patients as seen from themselves or they can give an 
exact picture of how they perform certain tasks. They are not exactly the same thing, 
although both dimensions are important because each one shows one side of the coin. Each 
person stands at a level of Maslow pyramid at a given moment and that relative position 
also determines his vision and influences his expectations 171. 
In fact, these objective indicators have different meanings to different people. The 
same level of performance in two persons is not perceived as equal by each one of them, 
and thus, the success of a given intervention is not recognized in the same way. In this case, 
although the objective threshold is achieved, medical care may not be recognized as useful.  
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During the course of a chronic disease, there must be a definition and undertaking 
of an unbiased treatment goal. Good examples of measures are the performance of the 
patient in relation to his daily activities: can he feed, dress and wash himself? Can he walk 
alone? Is he able to live independently? How much can he walk or run? Can he create and 
enjoy the more or less sophisticated pleasures of life? How is his social life? How much time 
does he spend of medical care? How many daily medications does he take to remain in 
equilibrium?  
Thus, both in the research and clinical environments, as well as in managerial 
context, the most objective measures should be looked for so that results can be 
comparable. On the other hand, It has been demonstrated that performance and self-report 
measures may complement each other in providing useful information about functional 
status 172.  
The ideal scale should be strong enough to support adequate medical decisions by 
reducing subjectivity and increasing objectivity, namely to be able to distinguish impairment 
due to dysfunction related to the studied disease or condition, or due to normal aging, and 
being able to eliminate bias caused by misplaced expectations. 
 
 
3.11 Some Examples of PROM Scales  
 
The medical speciality that makes the most use of these kind of scales is, by far, 
oncology. The reason is easy to understand: cancer is becoming a chronic, rather than a 
rapidly lethal disease and metrics are needed to assess prognosis and evolution, as well as 
providing indication and support to decision making when escalating those expensive and 
burdensome therapies. Another reason is that oncology is a leading speciality in 
pharmaceutical investigation 173 and these scales are very useful as instruments of research. 
 Gerontology, as well, is increasing its use: elder people get sick of many diseases that 
become chronic, emphasizing the need for measures of status that summarize all the effects 
of competing diseases. Moreover, dealing with proximity of death increases the relative 
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importance of indicators of success or failure, as far as health care is related, other than the 
prolongation of life itself. 
 Also, primary care is increasingly using PROM to help medical decisions and monitor 
patient valued outcomes. Recently, PROM based guidance showed improved health 
outcomes and fitted moderately with goals, specifically pain improvement, and opened 
ways for routine use of PROM as outcome measurements 174. In this context, attempts for 
the development of a generic PROM questionnaire for primary care have been tested  175. 
In the nephrology field, PROM scales are also being used, both in research and in the 
clinical environment, at the decision rather than at office level. A report of the PROM 
Measurement Group,  at Oxford University, addressed this question with a focus on kidney 
disease 176.  A total of 29 different tests were reviewed and divided in four broad categories: 
generic measures, health utility measures, renal specific multidimensional questionnaires 
and symptom-focused questionnaires. Some were considered overlapping, other 
complementary. The report recommends that PROM should have a greater role in the 
National Health Service (NHS), namely through a combination of these tests. 
In fact, the NHS has already implemented the National PROM programme whose 
intention is to monitor the effect of NHS interventions on QoL and well-being. The first 
programmes  have been carried out   with patients undergoing orthopaedic surgical 
procedures 177.  
 
3.11.1 Karnofsky Performance Scale 
 
Although Karnofsky Performance scale (KPS) is not a PROM in strictu senso, as data 
is obtained from external observation, rather than from the patients’ own reports or 
answers, it is mentioned in this section because it uses data directly extracted from their 
daily lives, considering their performance, behaviours and activities. 
KPS is a performance status scale that assesses the patients’ actual level of function 
and capability of self-care, classifying them by their functional impairment. It summarizes 
their ability to perform daily activities, and the level of assistance that is required to do so. 
It was first described in 1949, in an article originally published as a chapter of a proceedings 
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book of an oncology symposium 178, establishing a gradation of 11 levels of autonomy, 
ranging from a complete autonomy to a dying status. This classification would help to 
evaluate the usefulness of using aggressive chemotherapeutic agents in the control or cure 
of neoplastic disease. 
Since then it has been used thousands of times, as a numerical guide to patients' 
general health, in many environments, both clinical and in research, in a wide range of 
situations, from evaluation of patients to decision for therapy escalation, determination of 
appropriateness for nursing homes referral, stratification of patient samples, the evaluation 
of individual patients’ response to treatment, alone or together with other objective 
measures. It is, by far, the most used PROM, in several areas of medicine. 
The Eastern Cooperative Oncology Group (ECOG), working since the sixties, created 
a new scale 179, derived from the first, but is much simpler. It considers five levels: normal 
activity; symptomatic but nearly fully ambulatory; bed time less than 50%; bed time more 
than 50%; and unable to get out of bed. There was a good agreement between the ECOG 
and KPS with no statistical difference being found between them 180. Later, in 2005, an 
Australian group tried to adapt it to a palliative care environment 181.   
Despite the widespread usage of KPS, most of the research used to understand and 
systematize it was done in the eighties 182. KPS is  often used as a surrogate of dependence 
in activities of daily living (ADL) and an algorithm conciliating KPS and ECOG scales addressed 
this subject 182: a KPS of 70 corresponds to ADL independence and a KPS of lower than 50 is 
equivalent to full ADL dependency.  
In a longitudinal cohort study with stage 5 CKD patients managed conservatively it 
was found that functional status remained stable during the last year of life but declined 
steeply in the last months and weeks of life 183. This concept of trajectory of disease is very 
important because disease is a dynamic process and it is essential to know the prognosis for 
a better treatment of these patients 184.  
Table 6 presents KPS and ECOG scales in parallel, showing the equivalences between 
both. 
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Table 6 - Karnofsky Performance Scale and ECOG scale in parallel 
 
Karnofsky Performance Scale 
ECOG Scale 
Interpretation Score Description 
Able to carry on normal 
activity and to work; no 
special care needed. 
100 
Normal, no complaints; no 
evidence of disease. 
0 — Fully active, able to carry 
on all pre-disease performance 
without restriction. 
90 
Able to carry on normal 
activity; minor signs or 
symptoms of disease. 
1 — Restricted in physically 
strenuous activity but 
ambulatory and able to carry 
out work of a light or sedentary 
nature, e.g., light house work, 
office work. 
Unable to work; able to live 
at home and care for most 
personal needs; varying 
amount of assistance 
needed. 
 
80 
Normal activity with effort; 
some signs or symptoms of 
disease. 
70 
Cares for self; unable to carry 
on normal activity or to do 
active work. 
2 — Ambulatory and capable 
of all selfcare but unable to 
carry out any work activities; 
up and about more than 50% 
of waking hours. 
60 
Requires occasional assistance 
but is able to care for most of 
his personal needs. 
Unable to care for self; 
requires equivalent of 
institutional of hospital 
care; disease may be 
progressing rapidly. 
 
50 
Requires considerable 
assistance and frequent 
medical care. 
3 — Capable of only limited 
selfcare; confined to bed or 
chair more than 50% of waking 
hours. 40 
Disabled; requires special care 
and assistance. 
30 
Severely disabled; hospital 
admission is indicated although 
death not imminent. 
4 — Completely disabled; 
cannot carry on any selfcare; 
totally confined to bed or chair. 
20 
Very sick; hospital admission 
necessary; active supportive 
treatment necessary. 
10 
Moribund; fatal processes 
progressing rapidly. 
 0 Dead 5 – Dead 
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3.11.2 Short Form 36 and Kidney Disease Quality of Life 
 
 The Medical Outcomes Study (MOS) was a health survey designed to investigate if 
variations in patient outcomes were explained by differences of care or specialty, as well as 
to develop practical tools for the routine monitoring of patient outcomes in medical practice 
185. Following that study, one of the tests that emerged as a marker of overall health status 
was the MOS Short Form 36 (SF-36)  150 186. This initially had questions covering 40 health 
related concepts. Of these, eight areas were selected in a search for a generic standard 
instrument that would be easier to use and would add useful information to a more 
complete understanding of results. The final format of the questionnaire contains questions 
to provide measures in eight domains of HRQoL: physical function; role limitations due to 
physical health or emotional problems; bodily pain; energy/vitality; social interaction; 
mental health; and general health perceptions. The scale was constructed for self-
administration by persons 14 years of age and older, and for administration by a trained 
interviewer in person or by telephone 186. There are thousands of publications in many areas 
of medicine and many languages and cultural adaptations, namely in Portuguese 187 188.  
 The shift to the use of SF-36 in the nephrological context began in an attempt to 
validate this tool for end-stage renal patients 165 189 and the evolution of this scale came to 
be the most widely used one in the nephrological context, the Kidney Disease Quality of Life 
(KDQoL) test. This is a tool that includes generic questions plus some related to the burden 
of kidney disease. This part presents specific questions aimed at kidney disease symptoms. 
It allows an understanding of both physical and mental dimensions of the disease, expressed 
in eight domains:  
- Physical Function;  
- Physical Performance (“Role Physical”);  
- Pain,  
- General Health Status (“General Health”);  
- Emotional Well-Being (“Mental Health”);  
- Emotional Performance (“Role Emotional”);  
- Vitality/Energy; 
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- Quality of Social Interaction (“Social Function”).  
 
These eight domains are often grouped in two synthetic variables, the Physical 
Summary, including the first four, and the Mental Summary, gathering the last four. One last 
question covers the patients’ perception of change in health status. A whole summary score 
is not advised because it is not validated and also because it would lose the ability to 
discriminate between the several dimensions of HRQoL which supposedly would be the 
targets to follow for improvement. 
KDQoL has become the preferred measure of HRQoL for CKD patients on dialysis. 
The test correlates with number of hospitalizations and mortalities in patients on chronic 
dialysis 190 191, and with number of medications being taken (pill burden) 192. There are also 
publications comparing therapeutic options 193, and the study of anaemia in CKD is the most 
studied subject as far as HRQoL is concerned 194. Unfortunately, most studies were made in 
patients already experiencing renal replacement therapy (RRT) i.e. haemodialysis, peritoneal 
dialysis, as well as transplanted patients. Little is known about CKD patients prior to receiving 
RRT 195 196. A study on pre-dialysis CKD patients has shown significant differences between 
two groups of patients, one “well nourished” and another “mal nourished” 197. 
There is another HRQoL test (EuroQoL-5D), which is often used, due to its simplicity. 
It covers 5 dimensions of QoL: pain; mobility; self-care; anxiety; depression; and general 
health. It was created by a European working group with the intention of complementing 
other quality-of-life measures and to facilitate the collection of a common data set for 
reference purposes 161 162. It is also validated in Portuguese 198.  
 
3.11.3 World Health Organization Disability Assessment Schedule 
 
The World Health Organization Disability Assessment Schedule (WHODAS) is an 
instrument for the generic assessment of health and disability. It was developed by the 
WHO, making it globally relevant and adaptable to all cultures and environments. Rather 
than being directed to any particular disease, it is intended to be used across all diseases, 
both physical and mental. It is the operationalization of the International Classification of 
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Functioning, Disability and Health 199. The framework adopted by the WHO for measuring 
health and disability is set to be used both at the clinical office and epidemiological settings. 
It covers six domains of functioning: cognition (understanding and communicating); mobility 
(moving and getting around); self-care (attending to one’s hygiene, dressing, eating and 
staying alone); inter-personal relationship (getting along, interacting with other people); 
daily life activities (domestic responsibilities, leisure, work and school); and participation in 
community activities (joining in community activities, participating in society) 200. One of its 
objectives was to develop a simple, short and easy to administer health assessment tool. 
The result is expressed in standardized levels of disability. It has three versions, ranging from 
the most detailed 36-item, that takes about 20 minutes to complete, to the 12-item, lasting 
five minutes. It can be administered by an interviewer (both personal and computer 
assisted), a proxy or by the subject himself. The current release is 2.0 201. The Portuguese 
version validation was published in 2015 202. 
There are two ways to compute the scores of the WHODAS 2.0. The simpler short 
version assigns points to each of the answers i.e. from one point for “none” to 4 points for 
“extreme”. At the end, all these points are summed up without any other operation, 
assuming an equal range of each category that can be answered. This simpler way can be 
best used in a clinical context. The most complex method, according to information provided 
by the WHO 203, takes into account different weights and severity. First it sums up the scores 
within each domain, then it sums all six domains and finally converts summary scores into a 
percentage. It is a reverse scale: the maximum score (100%) would correspond to the full 
disability.  
A recent paper compared WHODAS 2.0 with another index of disability, the Modified 
Barthel Index. It concluded that the Modified Barthel Index doesn’t consider the patients’ 
perspective, although it could predict length of stay in a cohort of patients admitted into 
inpatient rehabilitation units after elective hip or knee arthroplasty, opposite to WHODAS 
which did. It suggests that both scales could be used as complementary in order to provide 
integration of clinical information with a PROM 204. 
Another interesting paper found out that WHODAS 2.0 was associated with 
disabilities of upper and lower extremities HRQoL and suggested that WHODAS 2.0, as it 
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isn’t targeted to a specific disease, it can be used to compare different diseases, as far as 
disability is concerned 205. To our knowledge, WHODAS has never been used in CKD patients. 
 
3.11.4 Short Physical Performance Battery  
 
The Short Physical Performance Battery is a simple standardized test designed to 
assess physical performance and disability 172, after the Timed Up & Go test, previously used 
in nursing homes with elderly people 206. It covers three areas: muscle strength (also called 
“sit-to-stand” performance), standing balance and walking speed. Most of the work done 
with this scale has been used in a physical rehabilitation context, not only in clinical 207, but 
also in a research context as an endpoint 208, or to assess patient compliance with allocated 
treatments in clinical trials 209. 
It consists of three tests of lower-extremity function: assessment of balance by 
standing in three different positions, chair stand and walking (gait) speed, by walking four 
meters. Each of these challenges is scored on a scale from zero to four. The total ranges 
from zero (the worst performer) to 12 (the best performer). It has been shown that dialysis 
patients have worse scores than the ones with heart failure, COPD or a group classified as 
high cardiovascular risk 210. These patients were selected from sample of dialysis patients 
but, as only candidates to kidney transplant were selected, it is indicative of how worse a 
general population of dialysis patients may perform. It has shown to have a correlation with 
QoL, measured by EuroQoL-5D 211, as well as disability, decline in health, increased hospital 
length of stay and death 212. It was also used in elderly hospitalized CKD patients being 
predictive of incapacity and death in elderly patients after hospital discharge from an acute 
episode. It also correlated with CKD stage 213. 
 
3.11.5 Satisfaction With Life Scale 
 
Satisfaction with life is a subjective concept that includes several dimensions. It is the 
result of the interaction of physical, mental and social components. In addition, it includes 
the capacity of coping with adversities, resilience, disease resistance and capacity of 
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recovery, among others. At the individual level, it has been correlated with decreased risk 
of disease, illness, and injury, better immune functioning, better coping and faster recovery, 
more success at work, higher incomes, more fulfilling relationships, greater contribution to 
communities and longer life expectancy. At a nationwide level, it correlated with more 
political engagement and stability, lower divorce rates, more equality, and better records of 
civil liberty 214. 
The attempt to quantify life satisfaction as a whole, led to the creation of Satisfaction 
With Life Scale (SWLS) in 1985 215. The scale does not assess satisfaction with life domains 
such as health or finances but allows subjects to integrate and weight these domains the 
way they choose.  
It is an easy test to answer. Participants say how they classify five sentences in a 7-
point scale, ranging from strong disagreement to strong agreement. These points are 
summed up and give a result that measures cognitive judgement of one’s satisfaction to life. 
Overall the result amplitude ranges from five to 35 points, rating satisfaction with life in six 
grades.  
Given the fact that satisfaction with one’s life is dependent not only on physical and 
mental conditions, but also on personal expectations, it is interesting to note that the five 
sentences that compose this test cover broad themes of what one’s life may be: it has 
questions about ideals; life conditions; success in achieving what is important in life; being 
satisfied with life; and regrets with past options. It intends to give a global assessment of a 
person’s QoL according to his/her own criteria 216. The authors argue that it is a suitable 
summary measure of well-being as it can adapt to the quality of life relative to one’s 
priorities, being eligible as a single common metric of overall life satisfaction. 
Moreover, there is a feature that authors value most in this concept: satisfaction with 
life is a cognitive/judgmental aspect of well-being, rather than with emotions. It is a global 
assessment of a person’s QoL according to his own chosen criteria which are based on a 
comparison that the person sets for one’s self, rather than externally imposed or judged 
important by the researcher. The subjectivity of the concept submitted is one’s 
circumstances and hence valuable by itself. If it influences other outcomes, it will become a 
valid surrogate endpoint to pursue. 
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Therefore, SWLS is one of the most extensively used and validated instruments in well-
being research. However, to our knowledge, it has never been published in CKD patients.  
 
 
3.12 State of Progress and Rising Questions  
 
Gathering all variables that compose the circumstance of a chronic patient, one can 
postulate a chain of events and conditions that may be faced as targets for medical 
attention. All of them can be addressed as far as CKD is concerned. Current guidelines are 
mainly focused in reducing the risk of cardiovascular morbidity and mortality, and in treating 
complications. They enhance risk factors which are targetable by pharmacological or 
technological device treatments. The drive for this priority is often a commercial one, as not 
every patient dies of cardiovascular disease and there is certainly something to be achieved, 
even for those who ultimately do. There must be other possibilities. 
Therefore, physicians’ interventions are generally guided by clinical and analytical 
variables that reflect changes believed to be in the origin of the disease but, although 
related, often fail to focus on a better life experience of the patient while waiting for the 
final event, as all chronic diseases will eventually lead to death. 
Some intermediate important concepts arise at this stage, including Disability, QoL 
and satisfaction with life. Most studies on this area were carried out in dialysis or 
transplanted patients, where the control of statistic technicalities is easier. However, the 
relationship between these different concepts has never been studied in CKD patients 
before reaching the point when they need RRT. 
This work aims to investigate these intermediate goals of treatment, with the view 
to replace the current ones as the targets to tackle when physicians treat and follow-up 
patients with CKD. They could serve as KPIs of the experience of being sick with this disease. 
Kidney function measurement and comorbidity valuation from a well-being 
perspective were also two concerns during this research work. 
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Additionally, it was also an objective to find out what the preferences of the patients 
are, as far as medical care is concerned, and use them as the outcomes to follow, in order 
to approach a definition of success of a therapeutic treatment or strategy. 
Meanwhile it is necessary to establish the relationship between these concepts 
(Disability, Quality of Life and Satisfaction with Life) and “hard” outcomes (beginning of 
dialysis, hospital admissions, visits to emergency room, worsening of lab results and death), 
with special emphasis on the ones that patients will consider priorities. 
Some initial question areas came to our attention. These evolved into the research 
questions:  
- Which eGFR formula is more useful at predicting of outcomes and correlating 
with well-being? 
- How does a population of CKD perform as far as PROM are concerned? 
- What are the most important predictors of PROM in a CKD population?  
- How can PROM predict future endpoints? 
- What are patients’ priorities concerning their treatment? What are their 
preferences regarding what their physicians first concerns should be? 
 
If an answer to these questions is found, the comprehensive tool for managing the 
chronic patient will be better understood and the path to its discovery will have begun. 
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4 Experimental Work 
 
4.1 General Plan of the Work and Research Questions 
 
The choice for reliable measures of well-being should be meaningful for the patients’ 
demands.  In addition, they should be related to the baseline characteristics of the patients 
they are supposed to be representing. It should also be mandatory that they can predict 
future endpoints, so that they can come to be used routinely in the clinical context. This 
experimental work intends to test published well-being tools to check if they fulfil those 
conditions. Chronic Kidney Disease (CKD) is a good model of chronic disease because it goes 
through different phases across a patient’s life and it has several stages, each one with its 
ups and downs, but providing a suitable model for analysing targets of accountability and 
intervention for improvement. 
 This chapter addresses 5 topics, each one attempting to answer an investigation 
question: 
1. After description of the methodology used for work (section 4.2.), we present a 
baseline characterization of a Chronic Kidney Disease (CKD) Population in an 
outpatient clinic of a hospital of the Portuguese National Health Service: e.g. 
demographic data, comorbidity indices, kidney function and last year’s events, 
such as hospitalizations and usage of emergency services. This section is mainly 
descriptive but it is important to the contextualization of the results to follow in 
other sections. (section 4.3.) 
2. Regarding kidney function measurement, the question being asked was which 
estimated Glomerular Filtration Rate (eGFR) formula was more useful at 
predicting outcomes and correlating with well-being? Available evidence has 
been focused on finding what is the best formula to assess creatinine clearance, 
as representative of GFR. The focus of this research was to correlate the results 
with outcomes and markers of well-being. (section 4.4.) 
3. How do PROM represent a CKD population? How does a CKD population perform 
as far as Patient Reported Outcome Measures (PROM) are concerned?  As a 
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chronic disease, some impairments of life may have an impact of how patients 
describe their experience. We wanted to evaluate the performance of the 
sample of patients under review, and compare the results with other chronic 
diseases and with other series of CKD patients. In addition, it was important to 
look for baseline variables that could predict PROM scores. Among them, as 
literature presents two indices of comorbidities, it was important to evaluate 
which one was better in predicting both PROM scores and the defined endpoints. 
(sections 4.5. and 4.6.) 
4. What is the impact of baseline variables on future endpoints? And how can 
PROM predict the defined endpoints at 24 months (mortality, beginning of 
dialysis, hospitalizations and utilization of emergency services? Achieving a good 
or avoiding a bad outcome is a goal of health care. A given PROM will only be 
useful if, beyond describing the well-being of the patient, and representing the 
context and conditions of patients, it is capable of predicting future outcomes 
known to be significant for the individual patient. This section we are looking for 
the PROM that fulfil these conditions. (section 4.7.) 
5. What are patients’ priorities concerning their treatment? What are their 
preferences regarding what their physicians’ first concerns should be? Generally, 
some standard endpoints are assumed to represent patient and disease 
management goals. We asked patients for their opinion concerning these issues. 
We took six endpoints commonly described in the literature as the ones to follow 
to create scientific evidence for medical decisions and research (death, dialysis, 
hospitalization, emergency services usage, worsening of general health, and 
worsening of laboratory tests) and asked CKD patients for their opinion about 
what their physician’s priority should be.  (section 4.8.) 
 
The integration of this information may allow the confirmation of our proposed 
conceptual model of relationships between baseline variables (demographic data, 
comorbidities, kidney function and previous year’s events), PROM and defined endpoints 
(Figure 6). 
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Figure 6 - Conceptual model/general plan of the investigation 
 
Disclosing the influence of both baseline variables and PROM on “hard” endpoints at 
24 months will lead to the identification of the ideal PROM, this will transfer the influence 
of the first ones on the latter. PROM fulfilling these two conditions of being both 
representative of baseline characteristics and predictive of the same endpoints as those 
baseline variables will be suitable for daily usage in the clinical context. They can then be 
considered as surrogates for those endpoints and the collection of the necessary data to 
compute that PROM should earn the right to be claimed as part of the medical appointment. 
As demographic data, we have considered gender, age, employment situation, 
schooling and income. For comorbidities, we have chosen the Charlson Comorbidities 
Indices, both the original (1987) and the 2011 revised version. Regarding estimation of GFR, 
we have checked the performance of the four most published formulae (CG, MDRD 4, MDRD 
6 and CKD-EPI). Finally, the last year’s events recorded were hospitalizations and episodes 
of emergency room utilization. 
As examples of PROM, we have selected Short Physical Performance Battery (SPPB), 
the World Health Organization Disability Assessment Schedule version 2.0 (WHODAS), the 
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Satisfaction With Life Scale (SWLS) and the Kidney Disease Quality of Life version 1.3 
(KDQoL). 
Finally, as “hard” endpoints we chose Death, Beginning of Dialysis within 24 months, 
Hospitalization and Emergency episodes during 24 months. 
 
4.2 Patients and Methods 
 
4.2.1 Preparation of Work, Regulatory and Legal Issues 
 
In compliance with applicable legislation and guidelines 217, authorizations from local 
Ethics Committee, hospital’s Administration Board and National Commission for Data 
Protection (CNPD) were obtained prior to all study-related activities. 
All patients accepting to participate signed an Informed Consent form before all 
study-related activities. During all stages of the work, patients were anonymised and 
identified by a study number (ID01-ID60), making impossible to identify individuals. 
Copies of these documents are presented in the appendix. 
 
4.2.2 Recruitment, Deliverance of Questionnaires and Collection of Medical Data 
 
We recruited 60 patients from an adult outpatient clinic of Nephrology in a public 
hospital of the Portuguese National Health Service, on the day of a regular visit to the 
nephrologist, in 19 different days, from December 2014 to April 2015.  
At the end of a normal medical appointment, they were invited to participate in this 
study, the goal of the investigation being orally explained by the author. The criteria of 
inclusion were having the diagnosis of CKD and being able to understand the questions. After 
the Informed Consent was signed, the patients were introduced to the assistants who 
delivered the questionnaires in an adjacent room, without the presence of the author.  
To ensure uniformity of deliverance, two trained university designated assistants 
delivered all the questionnaires. All interviews were conducted in Portuguese. Each 
interview was performed in private and lasted between 30 and 40 minutes. Some older 
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patients, who asked for it, were allowed to have a family member or informal caregiver in 
the room, but attention was made neither to let them answer, nor to let them help to 
perform the tasks. There was no payment or other benefit for patients and their families, 
and no change of the regular treatment was made to the participating patients.  
Clinical data from the patients was extracted from the digital files of the hospital 
(Software “SClínico HospitalarÒ”, Portuguese Ministry of Health). For some older data, 
paper files were also consulted. 
 
4.2.3 Demographics, Comorbidities, Estimated Glomerular Filtration Rate and 
Medical Events in the 12 Months Before Baseline 
 
Demographic data collected was: gender, date of birth (to compute age), formal 
education (“schooling”), family income and employment situation (active/retired). 
Categories studied were:  
- For age, three categories were considered: below 65, between 65 and 75 and 
above 75 years old.  
- For schooling, 4 groups were considered: less than primary education, 
completed primary education, completed secondary education and university 
degree.  
- For income, 3 levels of annual revenue were considered: below 7,000€ (National 
Minimum Wage), between 7,000 and 20,000€ and above 20,000€. 
- For employment situation, 2 conditions were considered: active and retired. 
 
Coexisting comorbid conditions were assessed by the Charlson Comorbidities Index 
scales, both 1987 132 and 2011 133  versions. Data was extracted from patient files by a unique 
independent physician, to ensure uniformity. 
Four formulas were used to compute the estimated Glomerular Filtration Rate 
(eGFR), which was used as an evaluation of kidney function, in order to classify patients 
according the CKD stages. The formulas were: Cockcroft-Gault (CG) 73, MDRD with 6 
variables (MDRD6) 74, MDRD with 4 variables (MDRD4) 75 and Chronic Kidney Disease 
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Epidemiology Collaboration (CKD-EPI) 76. This calculation was made at three time points: 
baseline, at 12 months and at 24 months after answering the questionnaires. Data was 
inserted manually in an Excel spreadsheet and results were recorded in mL/min.  
Retrospective data was also collected, regarding number of hospital admissions, 
inpatient days, episodes of ER, time since last hospital discharge and time since last episode 
of ER in the previous 12 months before baseline. 
 
4.2.4 Instruments Used to Evaluate Patient Reported Outcome Measures 
 
Among the many available questionnaires, four were chosen to represent several 
dimensions of personal well-being on the patient point of view: WHODAS 2.0 (Portuguese 
version with 12-items) for assessment of disability 202, SPPB for physical performance 172, 
SWLS for general satisfaction with life 215 and the generic part of KDQoL (Portuguese version 
1.3) 187 , for Health Related Quality of Life (HRQoL). The first three were chosen because of 
their simplicity and ease of use, being good candidates for utilization at the bedside, and the 
last one because it is more widely accepted and already validated for kidney disease 
patients.  
The short version of WHODAS 2.0 explains 81% of the variance of the long version 
questionnaire 200. We used the simple scoring system, which is more practical to use in a 
hand-score approach and may come to be chosen as the method of choice in the busy 
clinical context with pencil-paper interview situations, the setting used for the collection of 
data. As the WHO website 218 says, “the simple sum of the scores of the items across all 
domains constitutes a statistic that is sufficient to describe the degree of functional 
limitations”.   
SPPB and SWLS were used in its standard form, so that it could be applicable for 
clinical use in a medical office environment, should it fulfil the demanded conditions. 
Regarding KDQoL-SF, eight HRQoL domains were discriminated: Physical Functioning 
(KDQoL_PF), Role Physical (KDQoL_RP), Pain (KDQoL_Pain), General Health (KDQoL_GH), 
Vitality/Energy/Fatigue (KDQoL_VT), Social Function (KDQoL_SF), Role Emotional 
Experimental Work 
 
 71 
(KDQoL_RE), and Emotional Well-Being/Mental Health (KDQoL_MH). These variables are 
shown in table 7. 
 
Table 7 - KDQoL evaluation tool (adapted from 165) 
 
 
There are Physical and Mental Health summary scores, plus the burden of kidney 
disease score. However, these as well as a total score have not been validated against 
predictors or outcomes and as it would be unclear as to what they would represent,  their 
inclusion is not recommended 219. Therefore, we didn’t use them and, in the scope of this 
work, each of the domains is meant to be analysed separately as a variable with its intrinsic 
meaning.  
In relation to the other 43 questions of KDQoL-Long Form questionnaire, about 
symptoms/problems of kidney disease and effects of kidney disease, they are intended to 
evaluate specific CKD symptoms that may be present in the late phases of the disease, just 
when they are about to reach the need for dialysis. In early phases, the disease is mostly 
asymptomatic. This section of the questionnaire has consistently been used to assess 
rehabilitation in dialysis patients 220. In other words, after reaching the full picture of CKD 
and beginning RRT, the improvement of these scores would prove the success of therapy. 
As this was not the focus of this work, this data was not analysed. 
Besides, there is evidence of a good correlation between the eight HRQoL domains 
analysed and all but three areas of that extended scale. These are quality of social 
interaction, social support and patient satisfaction 221. Consequently, the expression of most 
Variable name Dimension name Questions related Number of questions 
KDQoL_PF Physical Function 
3a, 3b, 3c, 3d, 3e, 3f, 
3g, 3h, 3i, 3j 
10 
KDQoL _RP Role Physical 4a, 4b, 4c, 4d 4 
KDQoL _Pain Pain 7, 8 2 
KDQoL _GH General Health 1, 11a, 11b, 11c, 11d 5 
KDQoL _VT Vitality/Energy/Fatigue 9a, 9e, 9g, 9i 4 
KDQoL _SF Social Function 6, 10 2 
KDQoL _RE Role Emotional 5a, 5b, 5c 3 
KDQoL _MH Mental Health 9b, 9c, 9d, 9f, 9h 5 
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of those problems is safeguarded. Moreover, they add a lot of work and turn it harder to 
use in office context, thus not adequate as good simple sentinel tests for the right moment 
to start dialysis, before symptoms arise.  
 
4.2.5 Endpoints 
 
Five endpoints were considered: “Death”, “Beginning of dialysis”, “Hospital 
admissions” and “Emergency Room (ER) utilization”. The first two for being dramatic events 
in a patient’s life, the third and fourth as surrogates of worsening health problems and the 
last because it is considered the gold standard of CKD staging 21. 
Follow-up time was 24 months. Endpoints “Death” and “Beginning of dialysis” were 
studied both as binaries (yes/no) within that period and as time to event. Endpoint “Hospital 
admission” was investigated under more than one perspective: counts of episodes, time to 
event and number of inpatient days (as a surrogate of severity) during observation period. 
For endpoint “ER usage”, count of episodes during the same period and time to event were 
considered. All these four “hard” endpoints were considered as outcome events for survival 
analysis. Only the patients who survived and had not begun dialysis at 24 months were 
considered for statistical analysis regarding hospital admissions and emergency services 
usage. 
 
4.2.6 Patients’ Priorities and Preferences 
 
Patients’ priorities were an important concern in this study in order to rank 
endpoints. Participants were asked about their opinion regarding what their physician’s 
priority should be, the question being formulated the following way: “My physician’s priority 
should be… “, and choosing among six different options; “…that I don’t dye”; “…that I don’t 
need dialysis”; “…that my lab tests don’t get worse”; “…that I don’t need hospital 
admission”; “…that I don’t need to go to ER”; “… that my general health doesn’t get worse”.  
As it was very difficult for the patients to rank these 6 options using a Likert scale 222, 
questions were made asking each one against another in a championship-like grid (fig 7). 
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Figure 7 - Options for patients’ priorities 
 
Every alternative was opposed against all the others. (For example, patients were 
asked if they preferred that their physician’s priority should be avoiding the beginning of 
dialysis, or avoiding hospitalizations; another question was if they preferred that their 
physician’s priority should be to avoid their death or avoid the beginning of dialysis.) Fifteen 
choices were put to each participant, combining all possibilities among those six alternatives. 
Each alternative was challenged 5 times against different options. Each “victory” was 
awarded 1 point. If one choice won to all, it would score 5 points. On the other end, if an 
option lost against all others, it would have zero (0) points. Two variables were used for 
statistical analysis: firstly, the total number of points of each option computed for each 
patient, decoding the ranking assigned by him/her, as well as the intensity of the 
preferences; secondly, the percentage of patients that assigned each of the six alternatives 
as a rank (1st, 2nd, 3rd options, and so on, down to 6th and last option). 
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The alternative “avoid worsening of health condition” was deliberately left on this 
list although it has different characteristics. It is a multidimensional endpoint, a surrogate of 
Quality of Life (QoL), functionality and well-being, and may be useful as a calibrator for this 
scale, giving some insight into knowing the real meaning of each option to the patients. It 
was not considered as an endpoint for not having a definite variable that could represent it. 
One patient refused to answer to this set of questions and this is why total number 
of answers to this item will be 59. 
 
4.2.7 Statistical Analysis  
 
Summary (descriptive) statistics were reported as mean and standard deviations, 
median and quartiles, where relevant for continuous variables and as counts and 
percentages for categorical variables.  
Correlations (Spearman rank test) between the renal function estimations (CG, EPI, 
MDRD4 and MDRD6 formulae) were performed at baseline, 12 and at 24 months. The 
correlation between baseline and 24 months were also tested for prediction purposes.   
 To evaluate internal consistency of PROM, Cronbach’s alpha 223 of PROMs scales: 
WHODAS, SWLS, SPPB and each one of the 8 domains of KDQoL was calculated. Also, 
correlation results between PROM scales and other numerical scales: Charlson_1987, 
Charlson_2011, eGFR scale, with binary category variables (gender, categorized age: ≤65 
versus >65; labour situation: active versus retired, yearly income: ≤7000 € versus >7000 €, 
and schooling: less than primary school versus at least primary school) were established. 
Spearman rank test was used between two quantitative variables, while correlation point-
bi-serial was used between one continuous variable and one binary category variable.  
Linear regression models for the PROM prediction were also performed (linear 
coefficients, LC, and 95% Confidence Intervals, CI). Residuals analysis and testing for model 
significance were conducted. The multivariable analysis was performed only for the 
variables presenting p≤0.05. 
For each time-to-event endpoint (“Death within 24 months”, “Dialysis within 24 
months”, “Hospital Admissions within 24 months” and “ER episodes within 24 months”), 
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potential relationships (Hazard Ratios, HR, and 95% Confidence Intervals, CI) associated to 
the remaining different scales and demographic variables were explored in univariable 
analysis, using a Cox regression model.  The multivariable analysis was performed only for 
the variables presenting at least p≤0.05 in the univariate model. 
For the patients’ priorities analysis, a one-way repeated measure was used to test 
mean score differences between patients’ preferences (“that I don’t die”; “that I don’t need 
dialysis”; “that my lab tests don’t get worse”; “that I don’t need hospital admission”; “that I 
don’t need to go to ER”;” that my general health doesn’t get worse”). The sphericity 
assumption was verified by Huynh-Feldt epsilon. Normality residuals were verified by visual 
QQ plot inspection. Comparison between independent groups was performed using the 
Mann-Whitney test.   
All statistical analyses were performed using SPSS® Software, version 22.0 (SPSS, Inc., 
Chicago, IL) and p-values under 0.05 were considered significant. 
 
 
4.3 Baseline Characterization of a CKD Population 
 
4.3.1 Demographics 
 
Baseline characteristics of participants (at the moment they answered to 
questionnaires and tests) are summarized in table 8. Average (mean) age was 67.43±14.19 
years, with a median of 68.5, the first quartile 56.8 and the third quartile 79. Almost three 
quarters of the patients (71.7%) were retired. Due to the reduced size of the sample, other 
demographic variables were collapsed to two categories. For Education, 21,7% had less than 
Primary School and for Income, 28,3% had a yearly income of less than 7000 €. 
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Table 8 - Sample characterization at baseline (n=60) 
 
 n (%)   n (%) 
Gender   Schooling  
   Male 31 (51.7)     Less than Primary School 13 (21.7) 
   Female 29 (48.3)     Complete Primary School 23 (38.3) 
      Secondary School  12 (20.0) 
Age      University degree 12 (20.0) 
   ≤65 24 (40.0)    
   ]65;75] 15 (25.0)  Yearly Income (€)  
   >75 21 (35.0)     ≤7000 17 (28.3) 
      ]7000-20000] 37 (61.7) 
Labour situation      >20000 6 (10.0) 
   Active 17 (28.3)    
   Retired 43 (71.7)    
 
 
4.3.2 Comorbidities 
  
Other health problems of participants were assessed by the Charlson Comorbidity 
Index (versions of both 1987 and 2011) and are summarized in table 9. This sample of CKD 
patients had a moderately low average score, well below 50% of the maximum, computed 
by both scales, suggesting that this may not be an important problem in these patients. The 
2011 scale returned lower values, as compared with the 1987 value. There was, however, a 
high correlation between the two scales (Spearman rank coefficient was 0.692, p<0.001). 
 
Table 9  - Charlson Comorbidity Index at baseline (n=60) 
 
 
 
 
 
 
 Range avg±sd 1st quartile median 3rd quartile 
Charlson Comorbidity Index (1987) 
(scale: 0-35 points + age) 
(2-12) 7.03±2.42 5 7 9 
Charlson Comorbidity Index (2011) 
(scale: 0-34 points) 
(0-10) 2.35±2.90 0 1 3 
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4.3.3 Kidney Function 
 
Table 10 shows absolute counts and percentages of patients in each CKD stage at 
baseline, as calculated by each one of the formulae. There are important differences of the 
CKD stages distribution according to eGFR of each formula. Stage 4 is the mode for CG, 
MDRD4 and MDRD6 formulae with respectively 50.0%, 58.3% and 60.0% of the patients, 
while CKD-EPI formula assigns more patients to stage 3 (53.3%). There are no stage 2 
patients with both MDRD formulae, and MDRD4 is the one that returns the lowest values, 
allocating almost one third of the patients to stage 5, opposed to CKD-EPI, that only 
considers 5 patients (8.3%) as stage 5 patients. The distribution of patients by CKD stages, 
according to MDRD formulae, gives the “worse” picture of the sample, as far as CKD stages 
are concerned. 
Considering values of eGFR, mean eGFR was 27.1±12.9, 31.2±12.8, 19.6±7.4 and 
22.4±8.5, as computed, respectively, by CG, CKD-EPI, MDRD4 and MDRD6 formulae. Again, 
MDRD formulae yielded the lowest values, and CKD-EPI the highest. 
 
Table 10 - Staging of renal function at baseline, according to the four formulae. 
 
 
 
 
 
 
 
 
 
Considering value of eGFR, mean eGFR was 27.1±12.9, 31.2±12.8, 19.6±7.4 and 
22.4±8.5, as computed, respectively, by CG, CKD-EPI, MDRD4 and MDRD6 formulae. Again, 
MDRD formulae yield the lowest values, and CKD-EPI the highest. 
 n (%)   n (%) 
CG stages   MDRD4 stages  
   Stage 2 2 (3.3)     Stage 2 0 (0.0) 
   Stage 3 18 (30.0)     Stage 3 6 (10.0) 
   Stage 4 30 (50.0)     Stage 4 35 (58.3) 
   Stage 5 10 (16.7)     Stage 5 19 (31.7) 
     
CKD-EPI stages   MDRD6 stages  
   Stage 2 1 (1.7)     Stage 2 0 (0.0) 
   Stage 3 32 (53.3)     Stage 3 12(20.0) 
   Stage 4 22 (36.7)     Stage 4 36(60.0) 
   Stage 5 5 (8.3)     Stage 5 12(20.0) 
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4.3.4 Health Untoward Events in the Previous 12 Months 
 
As shown in Figure 7, In the previous 12 months, 49 patients (81.67%) had no 
hospital admissions whereas 9 patients (15%) had at least one hospital admission episode 
(average 1.44± 0.73, range 1-3, median 1). During that period, a total of 13 hospital 
admission episodes were computed. Each episode lasted 12.56±14.04 days (range 2-41, 
median 4). The last discharge from hospital admission had been 121.00±97.23 days, before 
(range 20-323, median 122). 
 
 
Figure 8 - Distribution of hospital admissions among patients in the previous year 
 
For episodes of ER, 38 patients (63.33%) had no ER episodes in the previous year and 
20 patients (33.33%) needed to go, at least once, to the ER, accounting for a total of 45 ER 
episodes (average 2.25±1.25, range 1-5, median 2) (Figure 8). Average time since last ER 
episode was 152.90±117.46 days (range 24-355, median 102).  
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Figure 9 - Distribution of ER episodes among patients in the previous year 
 
Two patients had a health plan that allowed them to be admitted to hospitals outside 
the NHS, so information about their hospital admissions and ER usage was unavailable. 
 
 
4.4 Regarding Kidney Function Measurement, which eGFR Formula is more 
Useful at Predicting of Outcomes and Correlating with Well-Being?  
 
4.4.1 Correlation Matrices Between eGFR Formulae 
 
All eGFR formulae correlated with each other in all time points they were used. 
Spearman coefficients were all above 0.792 at Baseline, 0.603 at 12 months and 0.522 at 24 
months. At baseline, all formulae presented high correlations between them. However, in 
other time points, correlation coefficients decreased, as shown in tables 11, 12 and 13.  
 
Table 11 - Correlation matrix between eGFR at baseline 
 
 
CG CKD-EPI 
(n=60) 
MDRD4 
(n=60) 
MDRD6 
(n=60) 
CG 1 0.769*** 0.792*** 0.835*** 
CKD-EPI  1 0.884*** 0.912*** 
MDRD4   1 0.966*** 
MDRD6    1 
38
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3 3
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Spearman rank correlation; *p<0.05; **p<0.01; ***p<0.001 
 
 
Table 12 - Correlation matrix between eGFR at 12 months 
 
 
 
 
 
 
 
 
Spearman rank correlation; *p<0.05; **p<0.01; ***p<0.001 
 
 
Table 13 - Correlation matrix between eGFR at 24 months 
 
 CG CKD-EPI 
(n=42) 
MDRD4 
(n=42) 
MDRD6 
(n=29) 
CG 1 0.606*** 0.552*** 0.522** 
EPI  1 0.925*** 0.869*** 
MDRD4   1 0.884*** 
MDRD6    1 
Spearman rank correlation; *p<0.05; **p<0.01; ***p<0.001 
 
4.4.2 Evolution of kidney Function Through Time 
 
It is interesting to look at the proportions of each CKD stage at three different time 
points according to different formulae: at baseline, at 12 months and at 24 months, depicted 
in Figure 9.  
 
 CG CKD-EPI 
(n=49) 
MDRD4 
(n=49) 
MDRD6 
(n=46) 
CG 1 0.704*** 0.612*** 0.603*** 
CKD-EPI  1 0.881*** 0.840*** 
MDRD4   1 0.856*** 
MDRD6    1 
Experimental Work 
 
 81 
 
Figure 10 - Distribution of patients through CKD stages in three different time points   
(Baseline (n=60); at 12 months (n=49); at 24 months (n=42)) 
 
Regardless the time point, MDRD formulae returned lower values of eGFR and 
increased the proportion of patients in CKD stages 4 and 5, and considerations made for 
baseline data remained valid. Regardless of the time point, there was clearly a different 
picture of the sample, depending of the used formula, as far as CKD stages were concerned. 
The same happened when raw values of eGFR were evaluated. At 12 months after 
baseline, mean eGFR was 27.2±12.3, 31.5±11.6, 19.8±6.8 and 23.0±8.2, when computed, 
respectively, by CG, CKD-EPI, MDRD4 and MDRD6 formulae. At 24 months, mean eGFR was 
25.5±9.4, 31.2±13.1, 19.3±7.8 and 19.5±5.8, when computed, respectively, by CG, CKD-EPI, 
MDRD4 and MDRD6 formulae. 
Another remarkable finding was that, regardless of the formula used to stage 
patients, more than half of the patients who survived or did not begin dialysis after 24 
months, remained at the same CKD stage (Table 14).  
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Table 14 - Evolution of CKD stages from baseline to 24 months (n=42) 
 
CG 
n (%) 
CKD-EPI 
n (%) 
MDRD 4 
n (%) 
MDRD 6 
n (%) 
Improved CKD stage 4 (9.5) 3 (7.1) 5 (11.9) 0 (0) 
Did not change CKD stage 21 (50.0) 22 (52.4) 27 (64.3) 24 (57.1) 
Worsened CKD stage 17 (40.5) 17 (40.5) 10 (23.8) 5 (11.9) 
Missing data 
  
 13 (31.0) * 
 
(* missing data refers to serum albumin result which was not available for these 13 patients at 24 months) 
 
4.4.3 Prediction of CKD Stage Evolution Through Time 
 
Table 15 shows the correlation between baseline and 24 months eGFR, highlighting 
the correlation of the values of the same formula and showing the higher level of correlation 
for CG.   
 
Table 15 - Correlation results between eGFR at Baseline and 24 months 
 24 months 
 CG 
(n=42) 
CKD-EPI 
(n=42) 
MDRD4 
(n=42) 
MDRD6 
(n=29) 
Baseline CG 0.507*** -0.007 -0.040 -0.031 
Baseline CKD-EPI 0.333* 0.398** 0.425** 0.459* 
Baseline MDRD4 0.282 0.379* 0.417** 0.423* 
Baseline MDRD6 0.345* 0.385* 0.389* 0.471* 
Spearman rank correlation; *p<0.05; **p<0.01; ***p<0.001 
 
Correlations between kidney function measurements at baseline and at 24 months, 
was weak to moderate, the highest being the one given by CG formula. On the other hand, 
there is no predictive value of eGFR as calculated by CG formula to others. Data suggested 
a higher proximity between CKD-EPI, MDRD 4 and MDRD6, and a weaker correlation to CG 
and to each other through time. 
As presented in section 4.6. (table 20), only CG formula was able to demonstrate a 
significant relationship for PROM, namely SPPB, WHODAS and KDQoL_PF, with a linear 
coefficient of 0.083 for SPPB, -0.224 for WHODAS, and 0.008 for KDQoL_PF (p<0.05 for all). 
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It didn’t show any significant relationship with the other tests. Also, all the other formulae 
showed no significant relationships for all PROM tests. 
As presented in section 4.7.1. (table 24), it was found that CG formula could predict 
mortality within 24 months with HR of 0.904) and all formulae could predict the beginning 
of dialysis within 24 months with HR of 0,715; 0.726; 0.789 and 0.849 respectively for 
MDRD4, MDRD 6, CG and CKD-EPI.  
 
 
4.5 How do PROM Represent a CKD Population? How does a CKD population 
Perform as far as PROM are Concerned?  
 
4.5.1 Patient Reported Outcome Measures (PROM) 
 
Scores (average, standard deviation, median, first and third quartile) of all 
dimensions of questionnaires are displayed in table 16.  
 
Table 16 - Raw results of PROM (n=60) 
 
 
 units avg±sd (%) range 1st quartile (%) Median (%) 3rd quartile (%) 
SPPB 0-12 7.4±3.4 (62) 0-12 4 (33) 8 (67) 10 (83) 
SWLS 5-35 25.6±7.5 (69) 6-35 21 (53) 27 (73) 32 (90) 
WHODAS 12-60 20.0±9.8 (17) 12-47 13 (2) 15.5 (7) 23.25 (23) 
KDQoL_PF 0-1 0.64±0.32 0-1 0.35 0.75 0.95 
KDQoL_RP 0-1 0.78±0.30 0-1 0.5 1 1 
KDQoL_Pain 0-1 0.69±0.35 0-1 0.42 0.78 1 
KDQoL_GH 0-1 0.47±0.19 0-1 0.30 0.50 0.60 
KDQoL_VT 0-1 0.50±0.25 0-0.94 0.31 0.50 0,70 
KDQoL_SF 0-1 0.84±0.20 0-1 0.72 1 1 
KDQoL_RE 0-1 0.84±0.27 0-1 0.75 1 1 
KDQoL_MH 0-1 0.65±0.26 0-1 0.45 0.70 0.90 
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Figure 10 shows a comparison in all PROM scales in a normalized way. It is clear that 
KDQoL_RP, Pain, KDQoL_RE and KDQoL_MH show a ceiling effect, as half of the patients had 
maximum scores. For the other variables, the median was high (or very low, in the case of 
WHODAS, as this scale is inverted).  
 
 
Figure 11 - Boxplots of the PROMS scales 
(scale is standardized between 0 and 1 and WHODAS is in reverse scale) 
 
This is suggestive that the general status of this sample of patients was good and it 
also shows that the several PROM did not progress simultaneously, understandably so, 
because they measure different constructs. 
 
4.5.2 Score of PROM in the several to CKD Stages 
Table 17 shows the scores of PROM for each CKD stage, according to several eGFR 
formulae. No statistical inference was drawn, due to the small size of some groups. However, 
in some cases, highlighted in grey, these seems to be a continuous tendency of variation 
downwards (or upwards in the case of WHODAS) in line with advancing kidney function. 
Curiously, the groups of data highlighted in dark grey were the ones for which a univariate 
linear regression model was found, as shown in Table 20.  
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Table 17 - Scores of PROM through CKD stages 
 
formula stage n SPPB SWLS WHODAS KDQoL_PF KDQoL_RP KDQoL_Pain KDQoL_GH KDQoL_VT KDQoL_SF KDQoL_RE KDQoL_MH 
CG 
Stage 2 2 11.0±1.4 24.0±8.5 13.5±2.1 0.98±0.04 0.59±0.22 0.72±0.00 0.73±0.04 0.59±0.31 0.88±0.18 1.00±0.00 0.83±0.18 
Stage 3 18 8.3±3.6 26.6±7.3 16.3±8.4 0.78±0.29 0.87±0.27 0.67±0.32 0.43±0.20 0.56±0.25 0.82±0.23 0.85±0.29 0.70±0.31 
Stage 4 30 7.3±3.1 25.2±8.4 20.9±9.3 0.57±0.30 0.77±0.30 0.66±0.39 0.47±0.19 0.48±0.26 0.84±0.19 0.86±0.19 0.64±0.23 
Stage 5 10 5.6±3.6 25.4±5.9 25.2±11.9 0.54±0.37 0.69±0.34 0.77±0.32 0.50±0.20 0.46±0.25 0.90±0.18 0.73±0.42 0.55±0.26 
CKD-EPI 
Stage 2 1 10.0 18.0 15.0 0.95 0.75 0.72 0.70 0.38 0.75 1.00 0.70 
Stage 3 32 7.8±3.4 26.3±8.9 18.3±8.0 0.65±0.30 0.83±0.26 0.67±0.38 0.45±0.19 0.53±0.26 0.82±0.21 0.86±0.25 0.67±0.27 
Stage 4 22 6.8±3.4 25.5±6.1 22.0±11.7 0.61±0.37 0.74±0.35 0.73±0.31 0.50±0.21 0.49±0.26 0.85±0.19 0.83±0.26 0.64±0.26 
Stage 5 5 7.2±4.5 22.8±1.6 22.8±11.8 0.63±0.36 0.66±0.33 0.62±0.39 0.46±0.16 0.41±0.24 0.98±0.06 0.72±0.44 0.56±0.20 
MDRD4 
Stage 2 0 - - - - - - - - - - - 
Stage 3 6 7.8±5.1 22.5±7.3 20.5±12.6 0.65±0.43 0.82±0.20 0.73±0.24 0.58±0.13 0.41±0.26 0.71±0.26 0.83±0.30 0.55±0.22 
Stage 4 35 8.2±3.0 25.9±8.4 17.8±7.7 0.69±0.43 0.83±0.27 0.66±0.37 0.44±0.19 0.54±0.26 0.85±0.19 0.87±0.22 0.68±0.27 
Stage 5 19 5.9±3.3 26.0±5.9 23.8±11.5 0.54±0.33 0.69±0.33 0.72±0.34 0.50±0.21 0.46±0.24 0.88±0.18 0.79±0.34 0.62±0.26 
MDRD6 
Stage 2 0 - - - - - - - - - - - 
Stage 3 12 7.2±4.3 26.5±6.7 19.0±9.7 0.65±0.34 0.70±0.31 0.78±0.26 0.48±0.22 0.45±0.26 0.76±0.21 0.83±0.34 0.64±0.27 
Stage 4 36 8.1±3.0 25.3±8.4 18.4±8.2 0.68±0.31 0.87±0.22 0.63±0.38 0.47±0.19 0.54±0.25 0.85±0.19 0.87±0.18 0.68±0.26 
Stage 5 12 5.6±3.3 25.4±5.7 25.7±12.6 0.53±0.35 0.59±0.38 0.75±0.33 0.47±0.21 0.43±0.25 0.90±0.18 0.77±0.39 0.57±0.25 
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4.5.3 Evaluation of Internal Consistency of the Questionnaires 
 
Table 18 shows Cronbach’s alpha for the questionnaires, both for this study and 
other studies used for comparison. In this study, all scales demonstrated reliability, 
according to this criterium (Cronbach’s alpha >= 0.6) 224, with the exception of KDQoL_SF, 
which showed little consistency, presenting a Cronbach alpha of 0.315. This may have been 
due to the small size of the sample or to the fact that it is only composed of two questions. 
It may also have been due to a problem in the Portuguese version of the questionnaire: this 
domain is the one that presents the lower indices of internal consistency in more than one 
validation tests we could find for the Portuguese language. On the contrary, it didn’t happen 
in the validation of the original test in English. Due to this fact, all results related to this 
variable must be read with caution, as this may not be representative of the construct for 
which it was created. Also, KDQoL_GH has shown borderline consistency according to this 
criterium (0.605), which is acceptable, provided that results are interpreted with caution 
and taken into consideration in the context of the calculation. 
 
Table 18 - Cronbach’s Alpha of the questionnaires 
 Cronbach’s Alpha 
 Our study 
(CKD) 
Portuguese validation 
 (HD) 
Ferreira, 2000 188 
Brazilian  
(HD) 
Moreira, 2009 225 
Brazilian  
(CKD and HD) 
Duarte, 2005 226 
Original version 
(HD) 
Hays, 1994 165 
WHODAS 12 items 0.895 - - - - 
SPPB 0.783 - - - - 
SWLS 0.863 - - - - 
KDQoL      
     KDQoL_PF 0.944 0.873 0.9 0.895 0.92 
     KDQoL_RP 0.963 0.751 0.9 0.641 0.87 
     KDQoL_Pain 0.908 0.844 0.9 0.666 0.87 
     KDQoL_GH 0.605 0.875 0.7 0.717 0.78 
     KDQoL_VT 0.873 0.826 0.7 0.714 0.90 
     KDQoL_SF 0.314 0.603 0.7 0.598 0.87 
     KDQoL_RE 0.972 0.710 0.9 0.616 0.86 
     KDQoL_MH 0.864 0.645 0.8 0.765 0.80 
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4.5.4 Correlation Matrix Between PROM 
 
Table 19 shows the correlation matrix between all PROM studied (SPPB, SWLS, 
WHODAS and KDQoL). 
Among the 11 PROM tested, we found 12 highly significant correlations (p<0.001), 
the highest Spearman correlation coefficient being presented between KDQoL_PF and both 
WHODAS and SPPB (-0.850 and 0.850, respectively). We found a slightly lower value 
between WHODAS and SPPB (-0.799). The domain with the largest number of correlations 
with high significance is KDQoL_VT: KDQoL_MH (0.719), WHODAS (-0.605), KDQoL_PF 
(0.580). SPPB (0.557) and KDQoL_RE (0.516). The other highly significant correlations were 
found between KDQoL_MH and KDQoL_RE (0.599); between WHODAS and KDQoL_MH (-
0.534) and between WHODAS and KDQoL_RP (-0.466). There were 17 other significant 
relationships with weaker correlations.  
Although we could find a significant negative correlation between KDQoL_SF and 
KDQoL_Pain (-0.559), this must be looked at with extreme caution because tests of internal 
consistency didn’t support that KDQoL_SF expresses the construct of good social function 
strongly enough. Moreover, it makes no sense that the less pain (better score) would harm 
social function, or the other way around. 
On the other hand, KDQoL_GH had no significant correlation with any other PROM. 
The near-limit value of internal consistency for this variable may explain this result.  
SWLS also had few (and weaker) correlations with other PROM. 
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Table 19 - Correlation matrix between all PROM studied 
 
Spearman rank correlation; *p<0.05; **p<0.01; ***p<0.001; highly significant correlations highlighted in bold 
 
 
 SPPB SWLS WHODAS 
KDQoL 
PF RP Pain GH VT SF RE MH 
SPPB 1 0.008 -0.799*** 0.850*** 0.384** -0.324* 0.131 0.557*** 0.346** 0.266* 0.326* 
SWLS  1 -0.095 0.011 0.137 -0.154 -0.055 0.276* 0.181 0.223 0.385** 
WHODAS   1 -0.850*** -0.466*** 0.195 -0.086 -0.605*** -0.296* -0.291* -0.534*** 
KDQoL_PF    1 0.390** 0.271* 0.166 0.580*** 0.394** 0.252 0.407** 
KDQoL_DP     1 0.176 0.010 0.452** 0.073 0.432** 0.425** 
KDQoL_Pain      1 0.015 0.295* -0.559*** -0.121 -0.224 
KDQoL_GH       1 0.006 0.235 -0.014 -0.084 
KDQoL_VT        1 0.250 0.516*** 0.719*** 
KDQoL_SF         1 -0.044 0.130 
KDQoL_RE          1 0.599*** 
KDQoL_MH           1 
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4.6 What are the Most Important Predictors of PROM in a CKD Population? 
  
Table 20 shows linear regression models for SPPB, WHODAS, KDQoL_PF, KDQoL_RP, 
KDQoL_VT and KDQoL_RE. For SPPB, significant positive variables were labour situation 
(active), schooling (more educated), age (younger), less comorbidities (by both formulae) 
and higher eGFR (only when calculated by CG formula). For WHODAS, significant negative 
variables (less disabled) were gender (men), labour situation (active), age (younger), less 
comorbidities (by Charlson_1987) and higher eGFR (only when calculated by CG formula). 
For KDQoL_PF, significant positive variables were gender (men), labour situation (active), 
schooling (more educated), age (younger), less comorbidities (by both formulae) and higher 
eGFR (calculated by CG formula). For KDQoL_RP and KDQoL_VT, the only significant positive 
variable was less comorbidities (by Charslon_1987). For KDQoL_RE, significant positive 
variables were labour situation (active) and age (younger). 
 
Table 20 - Univariate linear regression models for the several PROM 
 
Units: Linear coefficient and 95% CI (p<0.05 for all values presented; ns: non-significant) 
 SPPB WHODAS KDQOL_PF KDQOL_RP KDQOL_VT KDQOL_RE 
Gender       
Male ns 
-6.039 
[-10.884; -1.194] 
0.213 
[0.053;0.372] 
ns ns ns 
Labour situation       
Retired 
-3.828 
[-5.542; -2.113] 
7.774 
[2.503;13.046] 
-0.302 
[-0.472; -0.133] 
ns ns 
-0.157 
[-0.307; -0.008] 
Schooling       
> Primary 
2.812 
[0.767;4.856] 
 
0.300 
[0.111;0.489] 
ns ns ns 
Age (years) 
-0.154 
[-0.203; -0.105] 
0.361 
[0.207;0.515] 
-0.015 
[-0.019; -0.010] 
ns ns 
-0.005 
[-0.010; -0.001] 
Comorbidities       
Charlson_1987 
-0.826 
[-1.130; -0.523] 
1.980 
[1.056;2.905] 
-0.081 
[-0.109; -0.053] 
-0.032 
[-0.063; -0.001] 
-0.034 
[-0.060; -0.008] 
ns 
Charlson_2011 
-0.342 
[-0.640; -0.040] 
ns 
-0.032 
[-0.060; -0.004] 
ns ns ns 
eGFR       
CG  
0.083 
[0.017;0.150] 
-0.224 
[-0.413; -0.034] 
0.008 
[0.002;0.015] 
ns ns ns 
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For the remaining PROM (SWLS, KDQoL_Pain, KDQoL_GH, KDQoL_SF and 
KDQoL_MH), no regression model could be found. Income, eGFR (computed by CKD-EPI, 
MDRD4 and MDRD6 formulae), as well as the number of hospital admissions and ER 
episodes in the last year didn’t show any significant linear regression models to predict 
PROM.  Also, for last year’s health untoward events, no regression model could be found. 
In multivariate analysis, age was a significant determinant for SPPB, WHODAS and 
KDQoL_PF (linear coefficients and CI 95%: -0.137 [-0.197; -0.078], 0.330 [0.161; 0.499] and 
-0.013 [-0.018; -0.007]) and male gender was significant for WHODAS and KDQoL_PF (HR 
and CI 95% respectively -4.553 [-8.935; -0.172] and 0.151 [0.021;0.282]). In other words, 
older patients performed worse in KDQoL_PF, SPPB, WHODAS, and men performed better 
in WHODAS and KDQoL_PF. 
 
 
4.7 What is the Impact of Baseline Variables on Future Endpoints and How 
PROM can Predict Those Endpoints?  
 
Tables 21 and 22 show data related to endpoint variables during 24 months of 
follow-up: 
 
Table 21 - Time to first event (n=59) 
 
 Number of patients 
n 
Time to first event 
(months) 
avg±sd 
Median 
(months) 
Range 
(months) 
Death 8 13.13±7.97 11.42 2-22 
Dialysis 10 10.34±7.62 7.07 1-23 
Hospital Admission 16 10.92±4.96 10.78 2-21 
ER episode 30 9.49±7.10 9.56 1-22 
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During the follow-up period, 4 patients died and 6 patients began dialysis during the 
first year. In the second year, 4 died and another 4 began dialysis. 
There were 22 hospital admissions, which corresponded to a total of 305 inpatient 
days (average 30.50±26.5, range 1-82, median 33). This is about 1% of the patient-days at 
risk for the same period. Data related to hospital admissions and ER usage is presented in 
table 22. One patient had a different health plan and also used another hospital. Therefore, 
data of hospital admissions and ER episodes is not presented. 
 
Table 22 - Hospital Admissions and ER episodes at 24 months (n=42) 
 
 Number of patients Number of Episodes Number of episodes per subject 
 n (%) n avg±sd range median 
Hospital Admissions      
0 31 (73.81)     
> 0 10 (23.81) 22 2.00±1.32 1-5 2 
ER Episodes      
0 17 (40.48)     
> 0 24 (57.14) 96 4.00±6,76 1-35 2 
No Hospital Admissions 
and no ER episodes 
16 (38.10)     
 
 
Some predictive values of baseline variables for study endpoints could be found and 
are presented in table 23: 
- for endpoint “Death within 24 months”, significant risk determinants were: 
higher age, lower income, lower schooling, higher comorbidity index (by both 
scales), and lower eGFR (only for CG scale);  
- for endpoint “Beginning dialysis within 24 months”, significant risk predictors 
were higher comorbidity index (measured by Charlson_2011) and lower eGFR 
(regardless the formula used);  
- for endpoint “Hospital admissions within 24 months”, the only risk predictor with 
significant influence was higher comorbidity index (measured by both scales);  
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- for endpoint “ER episodes within 24 months”, significant risk predictors were 
lower schooling and higher comorbidity index (measured by Charlson_2011); 
- no significant predictive value could be found for Gender and Labour Situation. 
 
Table 23 - Effect of studied variables on the study endpoints 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (Univariate model. units: Hazard ratio: HR, CI95%; p<0.05; ns: non-significant) 
 
Likewise, some predictive value of PROM to study endpoints was found: it is 
presented in table 24. SPPB, WHODAS, KDQoL_PF and KDQoL_RE have shown to significantly 
predict endpoint “death within 24 months”; SPPB, WHODAS and KDQoL_RP could predict 
endpoint “beginning of dialysis within 24 months”; SPPB, KDQoL_PF, KDQoL_VT and 
KDQoL_MH have predictive value to endpoint “hospital admissions within 24 months”; 
KDQoL_MH predicts endpoint “ER episodes within 24 months”.  
 
Mortality 
(HR) 
Dialysis 
(HR) 
Hospital Admissions 
(HR) 
ER Episodes 
(HR) 
Age (years) 
1.139 
[1.025;1.206] 
ns ns ns 
Income (€/year)     
≤7000 
5.071 
[1.210;21.248] 
ns ns ns 
Schooling     
< Primary School 
4.312 
[1.075;17.293] 
ns ns 
2.578 
[1.118;5.942] 
Comorbidities     
Charlson_1987 
1.416 
[1.023;1.961] 
ns 
1.290 
[1.029;1.616] 
ns 
Charlson_2011 
1.236 
[1.027;1.486] 
1.168 
[1.000;1.395] 
1.245 
[1.062;1.460] 
1.153 
[1.017;1.308] 
eGFR     
CG  
0.904 
[0.824;0.991] 
0.789 
[0.687;0.904] 
ns ns 
CKD-EPI ns 
0.849 
[0.767;0.938] 
ns ns 
MDRD4 ns 
0.715 
[0.591;0.867] 
ns ns 
MDRD6 ns 
0.726 
[0.610;0.865] 
ns ns 
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On the contrary, SWLS and KDQoL_SF, KDQoL_Pain and KDQoL_GH didn’t show any 
predictive ability, regarding these endpoints. 
 
Table 24- Predictive value of PROM on the study endpoints 
 
Mortality 
(HR) 
Dialysis 
(HR) 
Hospital Admissions 
(HR) 
ER Episodes 
(HR) 
PROM scores     
SPPB 
0.761 
[0.618;0.937] 
0.824 
[0.686;0.991] 
0.833 
[0.720;0.965] 
ns 
WHODAS 
1.088 
[1.024;1.155] 
1.052 
[1.000;1.108] 
ns ns 
KDQoL_PF 
0.075 
[0.008;0.686] 
ns 
0.172 
[0.037;0.794] 
ns 
KDQoL_RP ns 
0.137 
[0.024;0.786] 
ns ns 
KDQoL_VT ns ns 
0.029 
[0.003;0.273] 
ns 
KDQoL_RE 
0.071 
[0.008;0.605] 
ns ns ns 
KDQoL_MH ns ns 
0.106 
[0.015;0.759] 
0.234 
[0.054;1.000] 
(Univariate model. units: Hazard ratio: HR, CI95%; p<0.05; ns: non-significant) 
 
For Hospital admissions, multivariate analysis revealed a HR of 0.034 (IC95% [0.002; 
0,723], p=0.03) for KDQoL_VT; and for emergency services usage, there was a HR of 2.671 
(IC95% [1.148;6.213], p<0.05) for lower schooling. No multivariable model could be found 
for mortality and dialysis within 24 months. 
 
 
4.8 What are Patients’ Priorities Concerning their Treatment? What Are Their 
Preferences Regarding What Their Physicians First Concerns Should Be? 
 
Table 25 shows the overall preferences of patients to what their physician’s priority 
should be, among the six proposed options. 
Avoidance of death has emerged as the top priority they require from their physician. 
If a general hierarchy was to be defined, data suggested the following: first “avoiding death”; 
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second “avoiding dialysis” and “worsening of laboratory test”s (ex-aequo); then “avoiding 
worsening of general health” and “avoid hospital admissions” (ex-aequo); finally “avoiding 
the need to go to ER”, as illustrated in Figure 11: 
 
Table 25 - Preferences of patients about their physician’s priorities 
 
“My physician’s priority should be…” avg ± sd1 range 1st quartile Median 3rd Quartile 
… that I don’t die 4.0±1.5*** 0-5 3 5 5 
… that I don’t need dialysis 2.9±1.3*** 0-5 2 3 4 
… that my lab tests don’t get worse 2.6±1,2*** 0-5 2 3 3 
… that my general health doesn’t get worse 2.2±1.6*** 0-5 1 2 3.5 
… that I don’t need hospital admissions 1.9±1.0*** 0-4 1 2 3 
… that I don’t need to go to ER 1.2±1.3*** 0-5 0 1 2 
(n=59; one patient refused to answer this question; unit: points, computed as explained in section 4.2.6.; ***p<0.001; 
 1 One-way repeated measures: FH-F (4.59;270.96) = 26.840; p<0.001. 
 
 Interindividual variation coefficients were 36%, 42%, 44%, 72%, 49% and 100%, 
respectively for the alternatives “…that I don’t die”, “…that I don’t need dialysis”, “…that my 
lab tests don’t get worse”, “…that my general health doesn’t get worse”, “…that I don’t need 
hospital admissions” and “… that I don’t need to go to ER”. This shows an increasing 
dispersion of answers from the first to the last option, with the exception of the already 
mentioned more subjective “worsening of general health”. 
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Figure 12 - Hierarchy of patients’ preferences their physicians’ about priorities  
 
Another way of presenting this data is to consider the percentage of patients for 
each alternative preference at each place in the ranking of options (Table 26). Numbers 
highlighted in bold enhance the positions assigned by at least 50% of the patients. It draws 
a approximate diagonal pattern, similar to the bars that can be seen in figure 11.  
 
Table 26  - Patients’ preferences expressed as order of option 
 Avoid 
death 
Avoid 
dialysis 
Avoid worsening 
of lab tests 
Avoid worsening 
of general health 
Avoid hospital 
admissions 
Avoid ER 
episodes 
1st option 61,0% 1,7% 5,1% 6,8% 0,0% 1,7% 
2nd option 11,9% 39,0% 16,9% 18,6% 3,4% 6,8% 
3rd option 11,9% 30,5% 33,9% 18,6% 25,4% 5,1% 
4th option 6,8% 15,3% 30,5% 22,0% 33,9% 20,3% 
5th option 3,4% 6,8% 8,5% 11,9% 33,9% 33,9% 
6th option 5,1% 6,8% 5,1% 22,0% 3,4% 32,2% 
Numbers highlighted in bold represent the ones that together sum more than half of the patients. 
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While the first option was clearly assigned to “avoid death” (61%), the other places 
of the hierarchy are not so evident.  The other options need at least two options to reach 
50% of the answers and there is some overlap between them, meaning that patients are not 
so sure of their answers. 
The order of preferences was not very different from one group another. However, 
small specificities occurred and it is worthy to look closer to the hierarchy assigned by the 
different groups, as shown in table 27 shows the scores of patient’s preferences for each 
studied baseline variable as discriminator. Significant differences are worthy a mention. Men 
gave a higher score to “avoid worsening of lab tests” than women (2.9±1.1 vs. 2.3±1.3). 
Active patients gave more points to “avoid worsening of general health” than retired ones 
(2.8±1.5 vs. 1.9±1.6). Low income patients also gave a high punctuation to “avoid death” 
than high income patients (4.7±0.7 vs. 3.7±1.7).  
 
Table 27 - Hierarchy of patients’ preferences about physicians’ priorities 
 Avoid 
death 
Avoid 
dialysis 
Avoid 
worsening of 
lab tests 
Avoid  
worsening of 
general health 
Avoid  
hospital 
admissions 
Avoid  
ER 
episodes 
 avg±sd avg±sd avg±sd avg±sd avg±sd avg±sd 
Gender       
Male (n=30) 4.0±1.4 3.0±1.3 2.9±1.1* 2.0±1.4 1.9±1.3 1.2±1.3 
Female (n=29) 4.0±1.7 2.8±1.3 2.3±1.3* 2.3±1.8 1.9±1.3 1.2±1.3 
Age       
≤65 (n=24) 4.0±1.8 3.0±1.3 2.8±1.2 2.4±1.6 1.7±0.7 1.1±1.2 
>65 (n=35) 4.0±1.4 2.8±1.3 2.4±1.2 2.0±1.6 2.0±1.1 1.3±1.3 
Labour situation       
Active (n=17) 3.9±1.8 3.0±1.3 2.7±1.4 2.8±1.5* 1.5±0.7 1.0±1.2 
Retired (n=42) 4.0±1.4 2.8±1.3 2.6±1.1 1.9±1.6* 2.0±1.0 1.3±1.3 
Income (€/year)       
≤7000 (n=17) 4.7±0.7* 2.7±1.6 2.7±0.8 2.2±1.6 1.8±1.0 0.9±0.8 
>7000 (n=42) 3.7±1.7* 2.9±1.2 2.6±1.3 2.2±1.6 1.9±1.0 1.4±1.4 
Schooling       
<Primary School (n=12) 4.2±1.5 2.8±1.6 2.5±1.1 1.5±1.5 1.6±1.1 1.2±1.2 
>Primary School (n=47) 3.9±1.6 2.9±1.2 2.6±1.3 2.3±1.6 2.0±0.9 1.2±1.3 
(unit: points, as explained in section 5.2.6.; *p<0.05; n=59: one patient refused to answer) 
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Although every sub-group assigned the first priority to avoidance of death, the 
highest score of all was given by poorer patients (4.7±0.7) and the lowest by richer patients 
(3.7±1.7), immediately followed by more educated (3.9±1.6) and active patients (3.9±1.8).  
Regarding other endpoints and positions in this hierarchy, there is no clear 
preference for the second place between “avoiding dialysis” and “worsening of lab tests”, 
especially in males (3.0±1.3 vs. 2.9±1.1) and poorer patients (2.7±1.6 vs. 2.7±0.8). Also, there 
was some overlapping between “avoiding worsening of lab tests” and “avoiding worsening 
of general health” in females (2.3±1.3 vs. 2.3±1.8), active patients (2.7±1.4 vs. 2.8±1.5) for 
the third place, as well as between “avoiding worsening of general health” and “avoid 
hospital admission” in males (2.0±1.4 vs 1.9±1.3), patients over 65 (2.0±1.6 vs. 2.0±1.1) and 
less educated patients (1.5±1.5 vs. 1.6±1.1) for the fourth place. 
A deeper analysis returned interesting data for sub-groups. They ranked the available 
options roughly the same way, with some exceptions: 
Firstly, men valued “Avoid worsening of lab tests” more than women (2.9±1,1 vs. 
2.3±1.3 points), but not enough to invert their priorities as a whole. Women gave roughly 
the same importance to “Avoid worsening of general health” and “Avoid worsening of lab 
tests” (2.3±1.3 vs. 2.3±1.8). More testing is needed to assess if this is consistent with a 
different importance given by women to laboratory tests. 
 Older patients ranked all options the same way as younger people did, except for 
fourth place, for which they did not separate “Avoid worsening of general health” and “Avoid 
hospital admissions”, meaning probably that they have perceived these alternatives as 
equivalent. 
Active patients gave a higher rate to “Avoid worsening of general health” than retired 
ones (2.8±1.5 vs. 1.9±1.6). Active patients assigned the second place to this objective, 
overtaking “worsening of lab tests” (2.8±1.5 vs. 2.7±1.4). 
Poorer patients had two extreme results: the highest score, given to “Avoid death” 
(4.7±0.7) and the lowest one, “Avoid going to ER” (0.9±0.8). They also gave the second 
preference ex-aequo to “Avoid dialysis” and “Avoid worsening of lab tests”.   
Less educated patients did not differentiate between the alternatives “Avoid 
worsening of general health” and “Avoid hospital admissions” (1.5±1.5 vs. 1.6±1.1) which 
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are in a tie, for the fourth place. They had the highest usage or ER services (a 2.5-fold 
increase in comparison with more educated ones), probably meaning that they did not 
perceive this behaviour as an indicator of a worse health status or a poorer quality of life 
and arguing against its inclusion of a surrogate of a worse quality of life in a model, in 
particular for this sub-group of patients. 
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5 Discussion 
 
The traditional model of medical practice, in which the patient seeks the physician 
for an episodic consultation composed of a medical interview, a physical examination and 
followed by a one-way communication relating to diagnosis, treatment and prognosis, now 
faces increasing challenges.  
Firstly, because people are getting older and prevalence of chronic diseases is 
increasing, contacts between physicians and patients have become long lasting 
relationships, a rather than episodic contacts. Patients and their families generally have 
much easier access to the physicians.  
Secondly, because there is a reasonable probability that these patients with chronic 
diseases do not always see the same physician every time they need health services. 
Technological developments and market conditions are making individual medical practice 
offices less clinically effective. Most medical work is now carried out in larger collective 
medical environments with intervention of several professional groups.  
Thirdly, because careful, exhaustive, medical appointments take time, there is a need 
for more efficient ways of characterizing conditions and guiding patients are needed.  
Fourthly, because the processes of diagnosis and follow-up of chronic patients 
generates data of diverse relevance there is a need for objective indicators of performance 
to distinguish the wheat from the chaff. 
Finally, because patients and families have almost open access to information and 
have access to the resources needed to challenge physicians’ verdicts and confront them 
directly with their opinions 227 228. Therefore, the time for information asymmetry and full 
power of the physician (who orders) and the patient and families (who blindly obey) is no 
longer acceptable, both on ethical and practical grounds 229. Prescription and expert advice 
may now be the object of negotiation 230 and for that, the demand for accountability is at a 
higher level than ever. This emphasises the need for objective reliable information which is 
easily understandable and transmissible to the patient. 
Nevertheless, this new paradigm doesn’t change the essential situation: the 
physician (often a team of physicians, nurses and other health professionals), together with 
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the patient and families or informal caregivers must work as a team to define a strategy with 
clear processes and goals, so that the remaining time of life of the patient can be enjoyed 
as well as possible, together with that of the  family 231 232. Each one has a specific role in this 
setting: the physician gives advice based on the available medical evidence and on his 
professional experience, families provide the context and the patient has the final choice 
regarding the several options that arise from the discussion. Incorrect management of 
expectations is often a cause of stress and unhappiness, and the patient and family must 
learn to deal with the upcoming problems 233. A plan of action should, thus, be developed 
that is clear to all participants. 
This enhances the need for a common, fully adopted language and vocabulary 
between all stakeholders, that will guide everyone through the successes and failures 
without losing hope. This winding road has to be accepted by the patient as fundamental 
and the achievement of each following milestone must be used as an opportunity to 
celebrate or, in failures, and if pertinent, to change plans towards the next goal. It is the 
journey that counts and, whilst there is a goal in life to pursue, everyone will want to 
postpone the final destiny. Each step of this way is to be negotiated as a part of a model of 
relationship between the physicians and the diseased person, that some have called 
“Personalised Medicine” 234. 
Such a strategy calls for a coherent and realistic set of measures of well-being, to 
assess the disease progression through time and allow accountability, as “one can’t improve 
what can’t be measured”. This set of studies is aimed at finding some KPIs of that 
progression, where choice is based on three conditions:  
a) that they are relevant to the patient’s life, improving his experience of being ill; 
b) that they are related to the factors that led to the disease, if possible with a 
proven epidemiological link or a sound pathophysiological explanation; and 
c) that they have impact on the outcomes that are easy to define as disease 
milestones or catastrophic events that should be avoided or postponed. 
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These questions were the components of our conceptual research model, that will 
be discussed in this chapter (section 5.5.). Furthermore, building the conceptual model 
requires the answer to some formulated research questions: 
1. Regarding kidney function measurement; which estimated Glomerular Filtration 
Rate (eGFR) formula is more useful to predict outcomes and correlate with well-
being? (section 5.1.) 
2. How do PROM represent a CKD population? How does a CKD population perform 
as far as PROM are concerned?  (sections 5.2. and 5.3.) 
3. What is the impact of baseline variables on future endpoints? And how PROM 
can predict those endpoints? (section 5.4.) 
4. What are patients’ priorities concerning their treatment? What are their 
preferences regarding what their physicians’ first concerns should be? (section 
5.6.) 
The following sections will present discussion regarding these questions. 
 
 
5.1 Regarding Kidney Function Measurement, Which eGFR Formula is More 
Useful at Predicting of Outcomes and Correlating with Well-Being? 
 
Being the final pathway of a number of different diseases, CKD behaves very 
heterogeneously. However, as a disease that is caused by progressive kidney dysfunction, it 
tends to be analysed through the criterium of residual kidney function, the numerical 
quantification of which is proportional and roughly equivalent to a percentage of the normal 
value of GFR. In spite of all the pitfalls with its measurement, it remains the gold standard, 
and it makes sense: the lower the function, the sicker the patient might be. However, eGFR 
calculation, thoroughly reviewed in a previous chapter, doesn’t guarantee a rigorous 
quantification of the remaining GFR.  Nor does it provide a guide to the complete clinical or 
biochemical situation for the patient, both at present and for the future.  
In this context, our work could demonstrate that: 
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- There was a high correlation between kidney function assessments by the 4 most 
published eGFR formulae (CG, MDRD4, MDRD6 and CKD-EPI) regardless of the 
time points in which they were done (tables 11, 12 and 13).  
- Both MDRD4 and MDRD6 formulae returned eGFR values that classify patients 
in more advanced stages of CKD, as compared to both CG and CKD-EPI formulae. 
(Fig 7) 
- The four eGFR formulae are not good at predicting their own value 24 months 
later. The higher coefficient of correlation (0.507) between determinations at 
baseline and at 24 months is given by CG formula. (table 15) 
- No correlation could be proved between eGFR measured by any of the four 
formulae and a set of eleven PROM. (table 17) 
- CG formula is the only formula that could predict death within 24 months, with 
HR coefficient of 0.904 for each 1 mL/min of increase of eGFR. (table 23) 
- The four formulae can predict beginning of dialysis within 24 months, with HR 
coefficients of 0.715 for MDRD4, 0.726 for MDRD6, 0.789 for CG and 0.849 for 
CKD-EPI formulae for each 1mL/min of increase of eGFR. (table 23) 
 
Our findings reveal that the four formulae are, in fact, measuring the same concept, 
as they show a high correlation between them. 
An interesting point is that more than half the patients who survived 24 months kept 
the same level of kidney function. This is probably due to the heterogeneity of CKD and 
censorship of the more diseased patients. Some aetiologies of CKD have a more indolent 
evolution than others and time imposes a selection that censors the most aggressive. 
Patients surviving 24 months may not present degradation of kidney function. Also, the 
control of complications is not the same in all patients. This requires a deeper analysis of 
other patient’s features, namely aetiology of CKD, medication or presence of other known 
complications, for example albuminuria, to find more useful prognostic clues. In this study, 
the Charlson Comorbidity Indices were evaluated, as representative of a subject’s degree of 
illnesses, but were not useful to address this question because kidney disease is part of the 
index, bringing statistic interference. 
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The fact that the several formulae return different values when used in the same 
population leads to considerations about bias of age, gender or ethnicity as they present 
variations in muscular mass, as well as an overestimation up to more than 60% than it may 
have in advanced kidney disease. This is due to an increased proportion of tubular secretion 
in relation to the total clearance of creatinine 235.  
The lower value returned by MDRD equations had already been reported 88. This 
study reported an underestimation of GFR by MDRD equations by 6% in CKD patients and in 
29% in healthy people, turning healthy into diseased people, namely the elderly ones. This 
increase in CKD prevalence, due to overconfidence on MDRD 78, which resulted from the 
KDOQI guidelines was one of the motivations for this work.   
Notwithstanding the accuracy of GFR determination, as kidney disease is a known 
risk factor for cardiovascular mortality, it would be predictable that there might be a 
relationship between eGFR and cardiac events in these patients. The advantage of CG 
formula in predicting mortality that we found has already been presented: Zamora, in 2012 
236, reported that CG formula, compared with MDRD4 and CKD-EPI, was the most accurate 
for predicting death in ambulatory patients with heart failure. He postulates that the reason 
for this was the influence of weight, which is both present in the formula and also a risk 
factor for death in heart failure.  
Also, in 2016 226, the value of several eGFR formulae were tested in different cohorts 
and concluded that in cohorts with cardiovascular risk, heart failure, and post-myocardial 
infarction the most accurate formula in predicting cardiovascular mortality was the CG, if 
calibrated for body surface area, although that relationship was not present in a general 
population cohort. Four other studies 237-240 reached similar conclusions in post myocardial 
infarction patients: CG formula is a better predictor of death than the other formulae, as 
long as it is corrected to body surface.  
Reinforcing this controversy, authorities, scientific societies and patients’ 
associations still don’t agree on which is the best formula to use: the FDA 241 and the 
American College of Cardiology 242 recommend the use of CG formula at the bedside. The 
National Kidney Foundation recommends the MDRD formula 19. 
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The ability of the 4 studied formulae to predict the results of PROM is worthy of 
comment: only CG formula could predict the scores of a PROM scale: SPPB, KDQoL_PF and 
WHODAS. None of the others returned useful results in this context. 
Irrespective of the formula used to compute eGFR, one of the goals of medical 
intervention is preventing the decline of kidney function. Although most of the cited studies 
agree on the fact that MDRD is more reliable in terms of assessing the true GFR 243, its utility 
could be greater if it correlated with endpoints. And, as it is a fact that the concept of 
“healthy start” of RRT exclusively based on eGFR 244-246 is outdated 247, the question about 
finding an exact number, given by a specific formula, to be used as a KPI of disease 
progression, loses some importance, because of the importance of the classification stages 
of the disease. In addition to this is the importance and the interpretation of symptoms, 
signs and laboratory abnormalities associated with CKD for detection, staging, management 
(including drug administration) and prognosis. This could be an argument for not having to 
choose one, as long as the same formula is used throughout time. Yet, the CG formula is 
simpler and easier to use at the bedside.  
Another question of interest is whether a different proportion of each of the several 
CKD stages in a sample constitutes a potential source of noise in statistical analysis. As there 
is no clear advantage of one to the others, in our opinion no single eGFR formula seems to 
deserve to be considered the gold standard, as each one of them has advantages as 
drawbacks.  
Nevertheless, we agree that the search of a better indicator of kidney function than 
creatinine, with stronger associations with clinical symptoms and adverse outcomes is not 
over yet and should continue 248.  
 
 
5.2  How do PROM Represent a CKD Population? How Does a CKD Population 
Perform as far as PROM are Concerned? 
 
Our CKD population was challenged with some PROM in search for reliable Key 
Performance Indicators (KPI) of living with kidney disease other than the usual biochemical 
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and physiological markers. So far, most literature on PROM is reports data on end-stage 
renal patients, already on dialysis (both peritoneal and haemodialysis) or transplanted, when 
life is only possible with RRT, therefore introducing a significant interference factor on well-
being. This work studied diseased persons without that bias. 
 
5.2.1 Kidney Disease Quality of Life (KDQoL) 
 
 As it can be seen in table 28, our patients scored fairly well, in every domain, as 
compared with other series of CKD patients already on dialysis 249 250 and with the series of 
Mujais 196, which also included patients in several CKD stages. They performed better than 
another study that compared two groups of pre-dialysis CKD patients, divided according to 
the state of nutrition 197. 
 
Table 28 - KDQoL in several series of CKD patients 
 
1 2 3a 3b 4 5 
 
Our Study 
2018 
Mujais 196 
2009 
Campbell 197 
2008 
Moura 249 
2014 
Lessan-Pezeshki 250 
2009 
 
Stages III-V 
(n=60) 
Stages III-V 
(n=1186) 
well nourished 
(n=43) 
mal nourished 
(n=10) 
HD 
(n=322) 
HD 
(n=152) 
KDQoL_PF 0.64±0.32 0.56±0.29 0.43±0.28 0.21±0.23 0.44±0.31 0.41±0.30 
KDQoL_RP 0.78±0.30 0.50±0.43 0.32±0.39 0.13±0.32 0.27±0.33 0.27±0.32 
KDQoL_Pain 0.69±0.35 0.68±0.28 0.67±0.26 0.64±0.33 0.63±0.30 0.49±0.30 
KDQoL_GH 0.47±0.19 0.48±0.21 0.42±0.18 0.34±0.14 0.35±0.22 0.39±0.22 
KDQoL_MH 0.84±0.20 0.75±0.20 0.71±0.21 0.40±0.23 0.61±0.25 0.49±0.23 
KDQoL_RE 0.84±0.27 0.72±0.40 0.63±0.39 0.27±0.41 0.45±0.32 0.35±0.38 
KDQoL_SF 0.65±0.26 0.75±0.27 0.72±0.29 0.46±0.33 0.68±0.34 0.45±0.28 
KDQoL_VT 0.50±0.25 0.48±0.24 0.42±0.23 0.28±0.26 0.48±0.20 0.39±0.24 
 (unit avg±sd; range 0-1, in our study there was a small percentage of Stage II patients, according to CG and CKD-EPI) 
 
Figure 12 shows a graphic representation of the averages and standard deviations of 
the eight domain results presented in table 28. It is interesting to note that our patients 
performed better in KDQoL_PF, KDQoL_RP, KDQoL_MH and KDQoL_RE, but not so well in 
KDQoL_Pain, KDQoL_GH, KDQoL_SF, KDQoL_VT, whose scores seem to have been 
overtaken by both non-dialysis and dialysis patients of other series. This suggests that the 
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several domains of the KDQoL test evolve separately and argue in favour of an independent 
analysis of each domain as an autonomous KPI. This supports the theory and aim of this 
work. 
Also, worthy of reference is that fact that in our sample, the median was 100% for 
two variables (KQQoL_RP and KDQoL_SF) and the 3rd quartile was 100% for three 
(KQQoL_RP, KDQoL_PF and KDQoL_Pain). These results suggest a “ceiling effect” that may 
be a drawback to the use of the test in this population, as the variables may not be 
“selective” enough to untangle subjects with mild disease, not being useful for prognosis at 
this level of illness. More detailed testing, namely in patients with a “worse” status, is 
needed to assess the utility of each one of the variables separately, namely the performance 
of a longitudinal study to access the evolution and, in case of worsening, the steepness of 
that deterioration.  
Considering KDQoL scores for each CKD stage, our patients seem to have better 
results than Cruz’s 251 , who used CG formula to define CKD stages, and have performed 
similarly in Mujais 196 patients, where there is no mention to the used formula. 
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Figure 13 - Mean and standard deviation of the studies mentioned in table 28 
(Study numbers are presented in table 28; our study (1) is in darker grey) 
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5.2.2 World Health Organization Disability Assessment Scale (WHODAS) 
 
When challenged with the WHODAS 2.0, 12-items, our patients scored an average 
20±9.8 points, with a range of 12 to 47 in a scale that ranges from 12 (the less disabled 
patient) to 60 (the most disabled patient). In a 0-100 scale, the average would correspond 
to a 17% level of disability. However, most patients presented little disability, as the first 
quartile was 13 points (2% disability), the median 15.5 points (7% disability) and the third 
quartile 23.25 points (23% disability). We are not aware of published reports of series of 
non-dialysis CKD to compare with and other series are not directly comparable because of 
co-variables that may exist. However, some literature can be found regarding other chronic 
diseases.  
Some studies present these results in a range from 0-48 (the punctuation of each 
question ranges from 0 to 4 points, instead of 1 to 5), which carries some difficulty with 
directly comparing data. However, if conversion is made to percentages then comparison is 
easier and results are not very different from other reported work. For example, in a 
Portuguese population of elderly people in a nursing room  an average score of 11.45±11.21 
(24% of disability) was presented 252. Another paper described a chronic population with 
musculoskeletal pain that had an average score of 25% of disability (no raw scores were 
published) 253. Additionally, a survey, carried out in a  surgical context 254, reported WHODAS 
2.0 results, just before surgery, of 6.6±0.06 (14%), in General Surgery, 9.5±0.08 (20%), in 
Maxillo-Facial Surgery, 18.8±0.17 (39%), in Plastic Surgery, 20.0±0.12 (42%), in Gynaecologic 
Surgery and 24.3±0.23 (51%) in Orthopaedic Surgery. In this survey, the results showed 
significant improvements on these scores after surgery. A fourth paper reported a 
population in a community rehabilitation clinic with several kinds of deficiencies, in Uganda 
255, whose WHODAS 2.0 12-item average score was 12.68±8.3 (27% of disability). There was 
no information about comorbidities in this work, therefore a more detailed comparison was 
not possible to carry out. 
 Another large epidemiologic study made in Taiwan 256, involving more than 100,000 
people, ranked several diseases according to their WHODAS 2.0, as follows (all data are 
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presented as mean percentage points with standard deviations): Dementia (61.42±23.32), 
Stroke (60.20±23.82), Spinal Cord Injury (55.14±22.61), Depression (43.40±18.60), Bipolar 
Affective Disorder (40.38±19.87), Schizophrenia (36.4±18.90), Visual Impairment 
(34.73±20.75), Mental Retardation (34.57±20.32), Autism (33.10±20.15) and Hearing 
Impairment (25.35±18.44), as compared with “normal”/healthy people who presented an 
average score of 6.4±8.6. The patients in the work presented here scored better than all 
groups, except the “normal”/healthy ones. Impairment can be sensory, mental and physical 
and each one of these vectors is differently affected in each disease context. 
 
5.2.3 Short Physical Performance Battery (SPPB) 
 
The average SPPB score in our sample of patients was 7.4±3.4 (median 8), which 
corresponds to a 62% of the maximum possible score. A slightly higher result (8.3±2.4; 
median 9) was reported by Reese 257 in a population of CKD patients with frailty. Another 
study 258 compared SPPB in two samples of patients, one in Brazil (8.59±2.5) and another in 
Canada (9.60±2.44), the reported results were similar to this reported in this study. Finally, 
in another series of elderly patients in the USA 259 the SPPB score was 8.3±2.7. All of them 
appear to have performed slightly better. Surprisingly, Lattanzio’s patients 213  presented, 
on average, the lowest results (5.2±3.6), in a sample with better average renal function (57 
mL/min, using CKD-EPI formula). Although a direct comparison cannot be freely done, the 
patients in this study performed similarly to those published series, except for the last one. 
 
5.2.4 Satisfaction with Life Scale (SWLS) 
 
To our knowledge, SWLS was also never used in CKD patients before. Our patients 
scored an average of 25.6±7.5 points and a median of 27, in the range of “high score”, well 
above the neutral 20-point score referred in the instrument. According to the scoring 
instructions 260, it means that these are “Individuals who like their lives and feel that things 
are going well. Of course, their lives are not perfect, but they feel that things are mostly good. 
Furthermore, just because the person is satisfied does not mean he or she is complacent. In 
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fact, growth and challenge might be part of the reason the respondent is satisfied. For most 
people in this high-scoring range, life is enjoyable, and the major domains of life are going 
well – work or school, family, friends, leisure, and personal development. The person may 
draw motivation from the areas of dissatisfaction.”  This was a surprise for us in a sense that 
it doesn’t fit the general idea that a nephrologist understands from his patients after some 
years of experience, as many patients complain a great deal during medical appointments, 
mostly due to subjects not related to health matters.  
On the other hand, this general impression of the patient’s mood, can be influenced 
by anticipation of dependence on a machine to live in the near future. This fits from an 
emotional point of view that is not the focus of this test, as explained earlier 215. The test 
doesn’t cover this aspect. 
Curiously, the patients in this study returned a better result than 33 of the 36 
samples of people reported, in many different contexts, some of them referred as healthy 
in a revision of the instrument, published in 2009 261. Moreover, our patients performed 
better than two published series: one from Spain with Multiple Sclerosis (17.8±7.0) 262 and 
another from Poland with Breast Cancer (20.67±4.63) 263. The results were similar to another 
two series: one also from Spain, representative of the “general” population (24.16±5.73) 264, 
and another from Sweden with Parkinson Disease (24.2±7.7) 265. Although the comparison 
of different diseases at different stages of those diseases is of limited value, it is interesting 
to verify that a population of CKD is not an outlier both among chronic patients and in 
“normal” healthy people. Resilience, resistance and coping well are possible weapons to be 
used to face adversity.  
However, deeper psychological evaluation is required before any definite conclusion 
can be drawn. The SWLS scale claims to be a good predictor of future behaviours such as 
suicide attempts and to have a high correlation with a life satisfaction component of 
subjective well-being. We didn’t look for depression in this study, so there might perhaps be 
a bias of selection, as some elderly people with depression refused to participate in the 
study. Therefore, without a context of depression, these results are not encouraging for the 
usage of this test for the evaluating CKD patients as a general screening or follow-up test. 
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5.2.5 Correlation Between Several PROM  
 
As far as we know, many of these testes were never used together. Consequently, 
there is no record of relationships between them. However, it is interesting to observe 
significant correlations between the several PROM tests (table 19). 
- The strongest correlations occur between physical related scales: SPPB, 
WHODAS and KDQoL_PF. 
- The most transversal domain was KDQoL_VT. This domain has shown significant 
correlation with all but two tests: the KDQoL_SF and KDQoL_GH. The first, as 
already discussed, is the most problematic as representative of the claimed 
construct. 
- On the other side, KDQoL_GH has no correlation with any of the others. In fact, 
this domain is probably so non-specific that no other factor correlates 
significantly with it. Also, it also has shown a borderline internal consistency and 
many not be representing the construct it was meant to. 
- It is also noteworthy that the domains that have a bigger contribution to the 
Physical Component Summary (KDQoL_PF, KDQoL_RP, KDQoL_Pain and 
KDQoL_GH) have few (only two in six possible) and weak correlations. Also 
Walker 266 has found a correlation between CKD and physical disability. 
- The major components of the Mental Component Summary of KDQoL return 
more significant correlations, both in number (3 out of 5) and in strength. 
KDQoL_SF was not considered. 
- There are also some significant correlations between domains across summary 
components. The highest is between KDQoL_PF and KDQoL_VT, but some others 
(6 out of 12 possible) can be noted. 
- SWLS has shown only two significant correlations: KDQoL “Mental Health” and 
“Energy/Fatigue”, both belonging to the Mental Component Summary of KDQoL. 
- SPPB correlates with all but two tests: SWLS and KDQoL_GH. A Portuguese study 
designed to validate KDQoL domains and ESRD-specific variables, failed to 
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correlate the construct “Satisfaction of the Patient” with any of the 8 KDQoL 
domains, which did not happen with other variables 221. 
- WHODAS correlates with 2 scales of the Physical Component Summary 
(KDQoL_PF and KDQoL_RP) and another 2 of the Mental Component Summary 
(KDQoL_VT and KDQoL_MH) 
 
These findings suggest a clustering of the tests according to the summary measures 
of KDQoL which, to be confirmed, seem to have a higher association for mental domains. 
Though, this division between physical and mental components is interesting but our data 
cannot confirm this hypothesis. 
 
 
5.3 What Are the Most Important Predictors of PROM in a CKD population?  
  
5.3.1 Kidney Disease Quality of Life (KDQoL)  
 
Several predictive relationships were found between baseline variables and KDQoL 
domains scores (table 20): 
- KDQoL_PF is positively influenced by male gender, labour situation active, higher 
education, and negatively influenced by older age, higher comorbidity index 
(both scales) and decreasing eGFR (only CG formula).  
- The only influence that could be found on KDQoL_RP was negative, by higher 
comorbidity index (with 1987 scale).  
- The only influence that could be found on KDQoL_VT was negative, by higher 
comorbidity index (with 1987 scale).  
- KDQoL_RE is positively influenced by male gender, labour situation active, and 
negatively influenced by older age. 
- None of the studied variables demonstrated any influence on KDQoL_Pain, 
KDQoL_GH, KDQoL_MH and KDQoL_SF.  
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In his paper involving 1186 patients, Mujais 196 demonstrated that the level of kidney 
function had a similar effect on scores of KDQoL_PF and KDQoL_MH, as ours, but also on 
KDQoL_PF, KDQoL_GH, and KDQoL_RE and KDQoL_SF, which our study didn’t show. Neither 
study could demonstrate a relationship between kidney function and domains KDQoL_Pain 
and KDQoL_VT. No mention is made regarding the formula that was used to estimate GFR. 
The differences between results may also be due to different sizes of series. Campbell 197 
demonstrated the effect of nutritional state on the scores of all domains, except pain, in a 
CKD population. Also Miskulin 267 has compared Autosomal Dominant Polycystic Kidney 
Disease with CKD patients with their counterparts with the same level of kidney function 
from the general population. They found that KDQoL scores of patients with lower renal 
function (GFR 20-44 mL/min) were lower for several domains: KDQoL_PF, KDQoL_RP, and 
KDQoL_GH, and KDQoL_VT. They also found that those scores in patients with GFR above 
45 mL/min were at least the same as their age matched general population in all but 
KDQoL_GH domain. This reinforces the statement that QoL in earlier stages of CKD is not 
worse than that in healthy people. 
In summary, there seems to be no question as to whether worsening of kidney 
function is an important determinant of KDQoL scores, although there isn’t a consensus on 
the real impact on each of the domains, as it varies from sample to sample. This is 
compatible with the heterogenicity of CKD itself.  
 
5.3.2 World Health Organization Disability Assessment Scale (WHODAS) 
 
In our patients, the WHODAS is negatively influenced by female gender, retired 
labour situation, by higher comorbidity index (only demonstrated with 1987 scale), by older 
age and by decreasing eGFR (only when computed by CG).  
This is in accordance with a Taiwanese study 256, which also reached similar 
conclusions: women, elderly and poorer  populations are affected disproportionally by 
disability. Another paper 268 analysed disability in diabetic patients and found that 
depression, especially severe, frequency of exercise, number of diabetic complications, 
severity of diabetes, and extent of chronic comorbidities were the factors with a significant 
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influence on higher WHODAS 2.0 scores, expressing more disability. It is also in accordance 
with our findings, as CKD is also an important complication of diabetes. 
 
5.3.3 Short Physical Performance Battery (SPPB) 
 
SPPB in our population was positively influenced by higher education, by labour 
(employment) situation “active” and negatively influenced by older age, higher comorbidity 
index (both scales) and decreasing eGFR (only when computed by the CG formula). 
Our search in literature found some interesting data: Reese 257 reported the negative 
influence of frailty and decreased GFR on physical performance, as expressed by SPPB 
results. Also, Lattanzio 213, in her paper about physical performance and hospitalization, 
reported that SPPB is dependent on GFR, on age, albumin level, mental state, comorbidities, 
level of autonomy, and antecedents of stroke. The overall direction of these findings is the 
same as ours. 
 
5.3.4 Satisfaction with Life Scale (SWLS) 
 
None of the studied variables demonstrated any influence on the SWLS scale. In fact, 
this test was developed to represent individual assessment of one’s global judgement of life. 
It is an intellectual procedure, dependant on both affective and cognitive mechanisms that 
affect subjective well-being and it may be influenced by factors other than disease, mainly 
related to life expectations, positive/negative affect, self-esteem, optimism or pessimism, 
perceived stress, or suicide ideation 269. We didn’t cover depression within the scope of this 
work, so this test probably is not useful as an exploratory work or follow-up test without that 
context. Therefore, no utility of this scale for this context cold be proven in this study. 
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5.4  What is the Impact of Baseline Variables on Future Endpoints and How 
PROM can Predict Those Endpoints?  
 
Although a relatively small sample size was used in this study our data can confirm 
that some PROM predict “hard” outcomes (Table 24): 
- Lower scores of SPPB predict risk of death, beginning of dialysis and hospital 
admissions within 24 months. 
- Higher scores of WHODAS (the more disabled patients) predict risk of death and 
beginning of dialysis within 24 months. 
- Lower scores of KDQoL_PF predict risk of death and hospital admissions. 
- Lower scores of KDQoL_RP predict risk of beginning of dialysis within 24 months. 
- Lower scores of KDQoL_VT predict risk of hospital admissions within 24 months. 
- Lower scores of KDQoL_RE predict risk of hospital admissions within 24 months. 
- Lower scores of KDQoL_MH predict risk of hospital admissions and usage of 
emergency services. 
- No predictive value could be found for SWLS, KDQoL_Pain, KDQoL_GH and 
KDQoL_SF. 
 
These results are comparable to published series. Volpato 270 reported that the SPPB 
score at discharge from hospitalization due to congestive heart failure, pneumonia, chronic 
obstructive pulmonary disease, or minor stroke correlated negatively with rate of decline in 
activity of daily living performance over the follow-up and that early decline in SPPB had a 
steeper increase in activity of daily living difficulty and higher risk of rehospitalization or 
death over the next year. Guralnik found that SPPB can predict future disability 271 and 
mortality 172. Pennix 272 found a correlation between low score SPPB and hospitalization in 
non-disabled old people.  
Lee 273 has shown that WHODAS is a good predictor to return to work for patients 
with head and neck cancer. 
Dialysis Outcomes Practice Patterns Study (DOPPS), a very large study involving 
17,236 patients in 7 countries, found a correlation between all the 8 domains of KDQoL and 
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both mortality and hospitalization 274.  Hall 191 correlated KDQoL scores with mortality and 
hospitalizations. 
Moreover, the confirmation of these relationships between some PROM and certain 
endpoints, supports new approaches, assuming different strategies and aiming directly at 
improving PROM scores as surrogates of future outcomes. For example, one important 
determinant of QoL, already known, is anaemia, which has a significant impact on 
hospitalizations 275 276. Hansen 277 proved that it is possible, not only to improve outcomes, 
decreasing hospitalizations, but also to improve scores of KDQoL, when anaemia is treated. 
This same rationale can be applied to other situations in which there is a slow response to 
medical decisions: the result of the decision could be guided by the PROM; provided that it 
is proven that it has impact on the desired endpoint. 
 
 
5.5 What Are Patients’ Priorities Concerning Their Treatment? What Are Their 
Preferences Regarding What Their Physicians First Concerns Should Be? 
 
The general hierarchy for the preferences of our patients of his/her physician’s 
priority was: 
- Avoiding death 
- Avoiding dialysis = Avoiding worsening of laboratory results 
- Avoiding worsening of general health = Avoiding hospitalisations  
- Avoiding ER usage. 
 
Overall, 61% of the patients, have chosen “Avoid death” as first option.  The option, 
“Avoid Dialysis” was also chosen as second option by 39% and as third option by 30.5% of 
the patients.  The alternative “Avoid worsening of lab tests” was chosen by 33.9% as third 
option and by 30.5% as fourth option. “Avoid worsening of general health”, was the option 
in which there was greater dispersion of results: 22.0% as fourth and sixth preference, 18.5% 
as second and third option. It is possible that this dispersion is due to the difficulty of defining 
it, as it is the least measurable alternative. “Avoid hospital admissions” was placed in fourth 
Discussion 
 
 117 
place, as well as fifth places by 33.9% of patients each. Finally, “Avoid ER episodes” was the 
lowest ranked alternative; being classified in fifth place by 33.9% and in sixth place by 32.2% 
of the patients. 
The increasing variation coefficient from the first to last choice is in line with the 
difficulty in answering this question with a Likert scale that the patients have shown at the 
beginning. This method of defining the hierarchy of patients’ preferences uncovers that 
people are sure of their first preferences, but not so sure about the following ones. The 
method we used has the advantage of avoiding neutrality, because it demands an answer 
to the question, rather than a defensive “middle option”. It returns an ordinal variable which 
as a result can then be analysed the same way as the result of the Likert scale. It may have 
the inconvenience of being one sided, because it only gives the order of options from the 
most wanted to the least wanted, rather than the result variable of the Likert scale, which 
can have two directions (either from the neutral position to positive – “most wanted”, and 
to the negative position – “most hated”), but this was not relevant for this particular study. 
The endpoint “death” is still the most valued by patients, it was the only one that 
more than half of the preferences assigned a defined rank. This confirms that it is the most 
valued endpoint to follow. This is true in spite of the drawbacks already mentioned, which 
were the motivation for this work. It further reinforces the need that any future surrogate 
endpoints to be adopted must be able to anticipate this one, to be of value in the clinical or 
research context.  
The case of “Avoiding worsening of general health”, being the one with most 
disparity of results confirms that the lack of an objective definition makes it vague and 
reinforces the need of validated tangible indicators when it comes to defining surrogate 
outcomes to guide medical practice or clinical research.  On the other hand, options that got 
a higher rank seem to be the ones that patients really appreciate: “avoid death”, “avoid 
dialysis” and “avoid worsening of lab tests”.  
Moreover, there seems to be a tie between “Avoiding worsening of general health” 
and “Avoid hospital admissions”, in more educated, retired, over 65 and men. This may be 
interpreted in two ways: either they don’t separate both situations, or they consider that 
the physicians cannot avoid it.  
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An interesting finding was the relative low importance that patients gave to the 
usage of medical services, both hospitalization and emergency services. These endpoints 
were included in the model as surrogates of bad health. At this point, it is our belief that 
many of them did not understand the question the same way. This is particularly true for 
poorer and less educated patients. This last group used emergency services 2.578-fold more 
than their more educated counterparts. Opposite to the intention of the study, it may be 
possible that for some patients the utilization of medical services was not perceived as a 
surrogate of bad quality of life. Probably they face those choices as solutions, rather than 
proxies of their health problems and understand that therefore it is not their physician’s 
obligation to avoid the utilization of medical services. 
As expected, all groups gave higher scores to “Avoid Hospitalizations” than “Avoid 
ER Services”. This last option is consistently the one with fewer points, meaning that they 
want to avoid a hospitalization if they can solve their problem in ambulatory. 
The apparent tie between “Avoiding dialysis” and “Avoiding worsening of lab tests” 
also deserves a commentary. Men and poorer patients gave them a tie. All the other groups 
appreciated not beginning dialysis over not worsening laboratory tests. Moreover, one 
problem of CKD is that it is an asymptomatic condition until the later stages, with too much    
importance being given to laboratory tests. Some patients can understand that this is a 
limitation and is the only data that physicians have to follow-up with them, but it may be 
possible that some think that laboratory tests are the key to their recovery. 
This is a field that requires more research. The concepts of preferences and patient’s 
needs and their preferences must be dealt together because they are related. There is a 
large  clinical trial ongoing to understand  the expectations and priorities of elderly patients 
for a first medical treatment for cancer (PRIORITY Study) 278. Recruitment is ongoing until 
2020. It will evaluate the opinion of patients regarding these issues not only at the beginning 
of treatment, but also over time, giving a longitudinal picture of patients’ performance. 
Patients with CKD would benefit from a similar study.  
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5.6 Qualitative Appraisal of the Proposed Conceptual Model of Relationships 
Between Predictors, PROM and Endpoints 
 
Gathering all data, it becomes clear that some relationships between studied 
predictors and chosen endpoints are in accordance with the proposed conceptual model. 
According to this model, a given PROM would be influenced by one or more predictors and 
transmit that significance to a particular endpoint and serve as a surrogate for it. Eleven 
PROM were studied and challenged with 11 variables as justification. Four endpoints were 
considered. 
Tables 29 through 32 show the significant relationships that could be found between 
predictors, PROM and endpoints. On the top line of each table, predictor variables are 
presented: gender, age, yearly income, labour situation, schooling, comorbidities (by both 
scales, 1987 and 2011) and estimated GFR (computed by four formulae). On the left column, 
endpoints (in bold) and significant PROM are presented. Numbers enhanced in orange are 
the significant univariate linear regression coefficients between predictors and PROM. 
Numbers highlighted in blue are the hazards ratios of predictive value of PROM to endpoints. 
Finally, the numbers in green represent the hazards ratio of predictive value of predictors to 
endpoints. Empty cells represent non-significant statistic relationships. For the sake of 
simplicity, for each endpoint, when a given PROM had significant value to show, that line 
was erased. Sub-titles under the tables mention PROM whose lines were erased. 
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Table 29 - Conceptual Model for Endpoint “Death within 24 months” 
  Predictive value 
of PROM to 
Endpoint 
Gender 
Male 
Age Income  
<7000€/y 
Labour 
Situation 
Retired 
Schooling 
<Primary 
Charlson 
1987 
Charlson 
2011 
eGFR 
CG  
eGFR  
CKD-EPI 
eGFR 
MDRD4 
eGFR 
MDRD6 
Mortality   HR: 1.139 HR: 5.071   HR: 4.312 HR: 1.416 HR: 1.236 HR: 0.904       
SPPB HR: 0.761   -0.154   -3.828 -2.812 -0.826 -0.342 0.083       
WHODAS HR: 1.088 -6.039 0.361   7.774   1.980   -0.224       
KDQoL_PF HR: 0.075 0.213 -0.015   -0.302 -0.300 -0.081 -0.032 0.008       
KDQoL_VT             -0.034           
KDQoL_RE HR: 0.071       -0.157               
KDQoL_RP             -0.032           
(SWLS, KDQoL_Pain, KDQoL_GH, KDQoL_SF, and KDQoL_HM have shown no utility for this concept model regarding this endpoint) 
 
 
Table 30 - Conceptual Model for Endpoint “Dialysis within 24 months” 
  Predictive value 
of PROM to 
Endpoint 
Gender 
Male 
Age Income  
<7000€/y 
Labour 
Situation 
Retired 
Schooling 
<Primary 
Charlson 
1987 
Charlson 
2011 
eGFR 
CG  
eGFR  
CKD-EPI 
eGFR 
MDRD4 
eGFR 
MDRD6 
Dialysis             HR: 1.168 HR: 0.789 HR: 0.849 HR: 0.715 HR: 0.726 
SPPB HR: 0.824   -0.154   -3.828 -2.812 -0.826 -0.342 0.083       
WHODAS HR: 1.052 -6.039 0.361   7.774   1.980   -0.224       
KDQoL_PF   0.213 -0.015   -0.302 -0.300 -0.081 -0.032 0.008       
KDQoL_VT             -0.034           
KDQoL_RE         -0.157               
KDQoL_RP HR: 0.137           -0.032           
KDQoL_MH                         
(SWLS, KDQoL_Pain, KDQoL_GH, KDQoL_SF, and KDQoL_HM have shown no utility for this concept model regarding this endpoint) 
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Table 31 - Conceptual Model for Endpoint “Hospital Admissions within 24 months” 
  Predictive value 
of PROM to 
Endpoint 
Gender 
Male 
Age Income  
<7000€/y 
Labour 
Situation 
Retired 
Schooling 
<Primary 
Charlson 
1987 
Charlson 
2011 
eGFR 
CG  
eGFR  
CKD-EPI 
eGFR 
MDRD4 
eGFR 
MDRD6 
Hospital Admissions           HR: 1.290 
HR: 
1.245         
SPPB HR: 0.833   -0.154   -3.828 -2.812 -0.826 -0.342 0.083       
WHODAS   -6.039 0.361   7.774   1.980   -0.224       
KDQoL_PF HR: 0.172 0.213 -0.015   -0.302 -0.300 -0.081 -0.032 0.008       
KDQoL_VT HR: 0.029           -0.034           
KDQoL_RE         -0.157               
KDQoL_RP             -0.032           
KDQoL_MH HR: 0.106                       
(SWLS, KDQoL_Pain, KDQoL_GH and KDQoL_SF, have shown no utility for this concept model regarding this endpoint) 
 
 
Table 32 - Conceptual Model for Endpoint “ER utilization within 24 months” 
  Predictive value 
of PROM to 
Endpoint 
Gender 
Male 
Age Income  
<7000€/y 
Labour 
Situation 
Retired 
Schooling 
<Primary 
Charlson 
1987 
Charlson 
2011 
eGFR 
CG  
eGFR  
CKD-EPI 
eGFR 
MDRD4 
eGFR 
MDRD6 
ER episodes         HR: 2.578   HR: 1.153         
SPPB     -0.154   -3.828 -2.812 -0.826 -0.342 0.083       
WHODAS   -6.039 0.361   7.774   1.980   -0.224       
KDQoL_PF   0.213 -0.015   -0.302 -0.300 -0.081 -0.032 0.008       
KDQoL_VT             -0.034           
KDQoL_RE         -0.157               
KDQoL_RP             -0.032           
KDQoL_MH HR: 0.234                       
(SWLS, KDQoL_Pain, KDQoL_GH and KDQoL_SF, have shown no utility for this concept model regarding this endpoint) 
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Figure 14: presents the schematic representation of all possible relationships 
between Predictors, PROM and Endpoints, according to the proposed conceptual model. It 
is divided into 8 schemes, designated alphabetically from A to H, each representing different 
meaning and utility of the PROM in a given situation. 
 
 
Figure 14 - Map of all possible relationships of the proposed conceptual model 
(Arrows represent significant relationships between predictors, PROM and endpoints) 
 
Scheme A is the one that fulfils the whole model: for these cases, it was possible to 
prove that a given predictor had influence on both a PROM and on an Endpoint, and, at the 
same time, that PROM could predict the same Endpoint. It means that the PROM carries the 
influence that the predictor has on that endpoint. This qualifies these PROM to become 
useful for daily use in clinical context because there is a known justification for the predictive 
capacity of the PROM. Examples of these situations are shown in table 33:  
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Table 33 - Predictors, PROM and Endpoint fulfilling the proposed conceptual model 
 
Predictors PROM Endpoints 
Age, Schooling, Comorbidities (both scales), eGFR (only GC 
formula) 
KDQoL_PF Mortality 
Comorbidities (both scales) KDQoL_PF Hospital Admissions 
Age KDQoL_RE Mortality 
Comorbidities (only 1987 scale) KDQoL_VT Hospital Admissions 
Age, Schooling, Comorbidities (both scales), eGFR (only GC 
formula) 
SPPB Mortality 
Comorbidities (only 2011 scale), eGFR (only CG formula) SPPB Dialysis 
Comorbidities (both scales) SPPB Hospital Admissions 
Age, Comorbidities (only 1987 scale), eGFR (only CG formula) WHODAS Mortality 
eGFR (only CG formula) WHODAS Dialysis 
 
In a number of cases, represented in scheme B, predictors have influence on PROM 
and PROM can predict endpoints, but there is no relationship between predictors and 
endpoints. In these cases, these PROM can be used as surrogate of endpoints, but they 
cannot claim to be representative of those predictors and other causes of that capacity must 
be sought. These are listed in table 34. 
 
Table 34 - Predictors predict PROM, PROM predict Endpoints, Predictors do not predict Endpoints 
Predictor PROM Endpoint 
Comorbidities (only 1987 scale) KDQoL_RP Dialysis 
Age, Labour Situation, Schooling, Comorbidities (only 1987 scale) SPPB Dialysis 
Gender, Age, Labour Situation, Comorbidities (only 1987 scale) WHODAS Dialysis 
Gender, Age, Labour Situation, Schooling, eGFR(CG)  KDQoL_PF Hospital Admissions 
Age, Labour Situation, Schooling, eGFR (CG) SPPB Hospital Admissions 
Gender, Labour Situation KDQoL_PF Mortality 
Gender, Labour Situation KDQoL_RE Mortality 
Labour Situation SPPB Mortality 
Gender, Labour Situation WHODAS Mortality 
 
In a third group, depicted in scheme C, there is no relationship between predictors 
and PROM, but there is a predictive relation between PROM and endpoints, as well as 
between predictors and endpoints. In these situations, PROM can be used as surrogate of 
endpoints, but they do not express the relationship of those predictors on endpoints. These 
are shown in table 35. 
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Table 35 - Predictors and PROM predict Endpoints, but Predictors do not predict PROM 
Predictors PROM Endpoints 
Income SPPB Mortality 
Schooling, Income, Comorbidity (only 2011 scale) WHODAS Mortality  
Income KDQOL_PF Mortality 
Schooling, Income, Comorbidity (both scales), eGFR (CG) KDQOL_RE Mortality 
eGFR (MDRD4, MDRD6 and CKD-EPI) SPPB Dialysis 
eGFR (MDRD4, MDRD6 and CKD-EPI) WHODAS Dialysis 
eGFR (all formulae) KDQOL_RP Dialysis 
Comorbidity (only 2011 scale) KDQOL_VT Hospital admissions 
Comorbidity (only 2011 scale) KDQOL_MH Hospital admissions 
  
A fourth group, charted in scheme D, includes PROM that can predict endpoints, but 
do not reflect the influence of the studied variables as predictors. In these cases, PROM are 
expressing some other background other than the variables of the proposed conceptual 
model. This is shown in table 36. 
 
Table 36 - PROM predict Endpoints, but Predictors do not predict neither PROM nor Endpoints 
PROM Endpoint Predictors not represented 
SPPB Mortality Gender, eGFR (MDRD4, MDRD6 and CKD-EPI formulae) 
WHODAS Mortality eGFR (MDRD4, MDRD6 and CKD-EPI formulae) 
KDQoL_PF Mortality eGFR (MDRD4, MDRD6 and CKD-EPI formulae) 
KDQoL_RE Mortality eGFR (MDRD4, MDRD6 and CKD-EPI formulae) 
SPPB Dialysis Gender, Income 
WHODAS Dialysis Schooling, Income, Comorbidity (only 2011 scale) 
KDQoL_RP Dialysis Age, Gender, Schooling, Labour Situation, Income, Comorbidity 
(only 2011 scale) 
SPPB Hospital Admissions Gender, Income, eGFR (MDRD4, MDRD6 and CKD-EPI formulae) 
KDQoL_PF Hospital Admissions Income, eGFR (MDRD4, MDRD6 and CKD-EPI formulae) 
KDQoL_VT Hospital Admissions Age, Gender, Schooling, Labour Situation, Income, eGFR (all 
formulae) 
KDQoL_MH Hospital Admissions Age, Gender, Schooling, Labour Situation, Income, Comorbidities 
(only 1987 scale), eGFR (all formulae) 
 
 
After the upper row, which confirms PROM as useful, according to the proposed 
conceptual model, the lower row also shows some relationships between predictors, PROM 
and endpoints which do not fit the model but, nevertheless, they are worthy be looked at. 
Scheme E applies to situations in where there is no relationship involving PROM, 
while keeping relationships between predictors and endpoints. Although this relationship 
exists, no PROM of our conceptual model has proven to be useful to express it.  
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In another group, outlined in scheme F, there is a significant relationship between 
predictors and PROM, also between predictors and endpoints, but no relation between 
PROM and endpoints. In these situations, PROM are not useful as surrogates of endpoints, 
although they bring the influence of those predictors.   
In some of other cases, predictors can predict PROM, but have no other relationship 
in the model. In these cases, the utility of PROM is limited to representing the predictors 
with no prognostic value, as far as these endpoints are related. In these cases, PROM are 
representative of predictors, but no conclusion to the future can be proposed. They are 
represented by scheme G. 
Finally, scheme H is representative of those hypotheses of relationships of the 
proposed model that could not be confirmed at all. PROM involved in these hypothetic 
relationships may not be helpful. In other words, although their intrinsic value remains 
intact, they are not useful as KPI in the context of the patients studied in this work, with 
those predictors and endpoints. Four scales and domains presented no relationship either 
with studied PROM and with endpoints: SWLS, KDQoL_Pain, KDQoL_GH and KDQoL_SF.  
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6 Conclusions and Future Work 
 
A common flaw in the management of a chronic disease, namely Chronic Kidney 
Disease (CKD) is the lack of consistency between clinical data, including laboratory tests, and 
the patient’s experience of being ill. Since this disease is asymptomatic until late stages, the 
physician is usually guided by available data derived from laboratory tests and physical 
examination, which supports his prescriptions and advice. However, often, these numbers 
fail to show a close connection with the patient’s real status, especially as far as prognosis is 
concerned. 
The goal of this work was to search for Key Performance Indicators (KPI) which might 
be indicators of disease other than the usual clinical data and laboratory tests in CKD. Those 
indicators should express the experience of living with the disease. They would have to have 
a significant link to both a set of pre-existing variables and to endpoints that are relevant to 
the patients. They could then be targeted for intervention, as their improvement would lead 
to a better management of living with the disease. In addition, we aimed to compare both 
comorbidities indices and eGFR formulae in a well-being perspective, finding out which of 
these available indices would be more useful in predicting the endpoints that are most 
relevant to patients. 
In chapter 2, a contextualization of the disease is made, presenting key definitions, 
mechanisms of disease, epidemiology, causes, pathophysiology, natural history and 
diagnosis, with a special emphasis on the difficulties of measuring kidney function. Also, we 
present an extensive list of the standard indicators that reflect the mechanistic perspective 
that often drives physicians’ decisions. 
Broadening the scope of the problem, a general approach to chronic diseases is 
presented in chapter 3, highlighting models of interventions, both at the individual and 
organizational levels. Some existing indicators are also covered, together with the contexts 
in which they are commonly used. 
For that exploration, we conducted an observational study and recruited 60 patients 
with Chronic Kidney Disease to whom questionnaires of Performance (Short Physical 
Performance Battery), Disability (World Health Organization Disability Assessment 
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Schedule), Satisfaction with Life and Health Related Quality of Life (Kidney Disease Quality 
of Life) were administered. These tests are generally called Patient Reported Outcome 
Measures (PROM). The description of the experimental work and its results is presented in 
chapter 4. 
Our hypothesis was based on a conceptual model which postulated that a given 
PROM would be suitable for daily use in clinical context provided that it met 3 conditions: a) 
that it had significant predictive capacity of a given endpoint; b) that any baseline variable 
that was predictive of that PROM also had prognostic ability of the same endpoint of which 
the PROM proved to be predictor; c) that its determination is simple enough to be used in 
clinical context, as part of a medical appointment. That specific PROM would have the ability 
to link Predictors with PROM and Endpoints with statistically significant relationships. We 
tested 11 PROM against 11 baseline variables and 4 endpoints. 
As predictors, we have selected Demographic Data (gender, age, education, income 
and labour situation), Comorbidity indices (using the original Charlson’s 1987 scale and a 
newer, published in 2011), estimations of Glomerular Filtration Rate (GFR), comparing the 4 
most published formulae: Cockcroft-Gault, MDRD with 4 and 6 variables and CKD-EPI) and 
untoward health events of the previous year. As relevant endpoints, we have chosen death, 
time to chronic dialysis, hospital admissions and emergency services utilization. The follow-
up period was 24 months. 
Two years later, patients were checked to see if they were either still alive; if had 
undergone renal replacement therapy in the form of haemodialysis or peritoneal dialysis 
and if they had been hospitalized or used emergency services. In addition, their kidney 
function was checked at two time points: 12 and 24 months following their use of the 
questionnaires. 
Lastly, we wanted to order the relevancy of the endpoints to the patients. For that, 
they were asked to rank six endpoints according to what they think should be their 
physician’s priority (avoid death, avoid dialysis, avoid worsening of laboratory tests, prevent 
further deterioration of medical condition, avoid hospital admissions and avoid emergency 
episodes). 
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Notwithstanding the small sample size, this study provides useful insights into a 
number of important questions: 
A. Concerning usefulness of PROM: 
1. Short Physical Performance Battery (SPPB) can predict death, dialysis and 
hospital admissions within 24 months. Related to its capability of predicting 
death, it is influenced by age, education, comorbidities (by both scales tested) 
and eGFR (only according to CG formula). Concerning prediction of dialysis, it 
carries the influence of comorbidities (only by 1987 index) and eGFR (only 
according to CG formula). Regarding prediction of hospital admissions, it 
represents both scales of comorbidities. 
2. Disability, as quantified by the World Health Organization Disability Assessment 
Schedule (WHODAS) 2.0 12-items test, can predict death and dialysis within 24 
months. Connected to prediction of death, it carries the influence of age, 
comorbidities (only by 1987 index) and eGFR (only according to CG formula). The 
ability to forecast dialysis is influenced by eGFR (only according to CG formula). 
3. Physical Functioning domain of Kidney Disease Quality of Life (KDQoL_PF) can 
predict death and hospital admissions within 24 months. In relation to death, the 
involved predictors are age, education, comorbidities (both scales) and eGFR 
(only according to CG formula). Connected to hospital admissions, we have found 
both scales of comorbidities. 
4. Role Emotional domain of Kidney Disease Quality of Life (KDQoL_RE) can predict 
death within 24 months. It reflects the influence of age. 
5. Energy/Vitality domain of Kidney Disease Quality of Life (KDQoL_VT) can predict 
hospital admissions within 24 months, expressing the influence of comorbidities 
(by both scales) 
6. Role Physical domain of Kidney Disease Quality of Life (KDQoL_RP) can predict 
dialysis within 24 months, but none of the variables of our model could explain 
this relationship. 
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7. Mental Health domain of Kidney Disease Quality of Life (KDQoL_MH) can predict 
hospital admissions and ER utilization within 24 months, but none of the 
variables of our model could explain this relationship. 
8. Pain, Social Function and General Health domains of Kidney Disease Quality of 
Life (KDQoL_Pain, KDQoL_SF and KDQoL_GH), as well as the Satisfaction With 
Life Scale (SWLS) were not found to be useful in predicting any of the proposed 
endpoints, in the context or our patients. The particular case of domain 
KDQoL_SF has shown little internal consistency, in line with other Portuguese 
language papers. This suggests that it may be the weakest scale of the test and, 
as this doesn’t happen in the original language there may be a problem with 
translation. 
 
B. Concerning the measurement of kidney function: 
9. The Cockcroft-Gault formula to compute estimated GFR is the only that can 
predict mortality within 24 months.  
10. All eGFR formulae could predict beginning of dialysis. 
11. Only the Cockcroft-Gault formula could predict the scores of PROM scales: Short 
Physical Performance Battery, Physical Function domain of Kidney Disease 
Quality of Life short form and World Health Organization Disability Assessment 
Schedule 2.0. 
 
C. Concerning comorbidity assessment: 
12. Both the Charlson comorbidity scales (1987 and 2011) are useful for the 
prediction of studied endpoints. The 1987 formula predicts death and hospital 
admissions, while the 2011 formula is more comprehensive, with the ability to 
predict mortality, dialysis, hospital admissions and emergency episodes.  
 
D. Concerning preferences of patients 
13. The highest priority of patients is that their physician’s main concern should be 
to “Avoid death”. The options “Avoid dialysis” and “Avoid worsening of lab tests” 
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come next, in a tie. This was roughly reproduced in every sub-group. Thus, these 
are the distal endpoints that, in the absence of closer ones, should continue to 
guide medical practice, clinical research and accountability in health 
management. 
14. Patients seem to consider health services a benefit, rather than surrogates of bad 
health, as they ranked “Avoid hospitalization” and “Avoid emergency episodes” 
in the last places, after all the others, including “Avoid worsening of general 
health”. 
 
E. Concerning the proposed conceptual model 
15. Eight possible schemes were drawn from the analysis. The first four have shown 
to have clinical utility.  
- The most significant and useful is scheme A, in which a given predictor had 
influence on both a PROM and on an Endpoint, and, at the same time, that that 
PROM could predict the same Endpoint. It means that the PROM carries the 
influence that the predictor has on that endpoint. 
- In scheme B, predictors have influence on PROM and PROM can predict 
endpoints, but there is no relationship between predictors and endpoints. n 
these cases, these PROM can be used as surrogate of endpoints, but they cannot 
claim to be representative of those predictors and other causes of that capacity 
must be sought. 
- In scheme C, there is no relationship between predictors and PROM, but there is 
a predictive relation between PROM and endpoints, as well as between 
predictors and endpoints. In these situations, PROM can be used as surrogate of 
endpoints, but they do not express the relationship of those predictors on 
endpoints. 
- In scheme D, PROM can predict endpoints, but do not reflect the influence of the 
studied variables as predictors. In these cases, PROM are expressing some other 
background other than the variables of the proposed conceptual model. 
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- In schemes E through H it was not possible to find predictive capacity of PROM 
and thus they cannot be considered useful for usage in this clinical context. Four 
scales and domains presented no relationship either with studied PROM and with 
endpoints: SWLS, KDQoL_Pain, KDQoL_GH and KDQoL_SF.  
 
There is a new paradigm of health care. Volume of services is being replaced by 
delivery of value to the patient and the society. In this context, value is the relationship 
between the outcomes and the costs. So far, they have been analysed separately, mostly 
due to lack of standardization. The pressure to reduce costs demands that outcomes 
become tangible. Death is the most used outcome, both in clinical and in research contexts 
and everyone’s mindset is tuned to it, as our study of patients’ preferences has shown, 
understandably so. However, as everyone will eventually die, death can only be postponed 
and thrown out of the observational period. Focusing on death as the main outcome will not 
change patients’ experience of being ill. Giving priority to this experience is the difference 
between excellent and good care. However, existing outcomes have been developed by 
medical specialities within hospital and physician-centred models of care. It is time to 
reinforce work related to on patient-centred frameworks of outcomes that give priority to 
patients’ needs, rather than focusing on postponing death or other catastrophic events. The 
development of strong measures of outcomes reported by patients is a good path to follow. 
The ambition of this exploratory work is to have added something to the construction of 
that model. 
One limitation of this study is the reduced sample size. However, the recruitment 
difficulties, which had already been reported 251, and the time it takes to gather data 
reinforces the need to look for simple questionnaires that can serve as easy-to-use PROM in 
the office and at the bedside. Otherwise, gathering data to build evidence or to have 
information about each patient will always be very difficult.  
For future work it would be important to strengthen the power of these tests to 
evaluate the patients’ well-being, namely through research with a bigger sample and a 
longitudinal, rather than a cross sectional study, for which multicentric studies may be 
needed. That would give insight about the evolution of scores and the factors that can 
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influence it on a dynamic perspective. So far, most of the analysis was made after univariate 
models and the multivariate approach is the next step. 
Another angle for which there may be some interest is disclosing the relationship 
that these PROM have with the current medical indicators that generally are followed when 
physicians are treating CKD patients. 
Also, the study of the impact of medical interventions on PROM scores would give 
information on the effectiveness of this strategy of targeting surrogate endpoints rather that 
the distal ones. All these instruments would have practical utility if they consistently proved 
to be predictors of outcomes, carrying the influence of the patients’ circumstances. 
Moreover, little is still known about the issue of patients’ preferences. Every patient 
is different from the next and it is not certain that a treatment goal serves the two equally. 
From the moment a patient is defined as being sick and what should be measured, there 
must be a search for personalized outcomes when managing a patient with chronic disease, 
possibly negotiated with the patients and their families. Personalized Medicine is also arising 
as a new paradigm. To make that possible, solid clinical outcome measures are needed to 
assess success and failures. That is why physicians should lead this process 279. 
In the origin of this project there was the idea of building a Clinical Balanced 
Scorecard for better management of Chronic Kidney Disease. The conclusions drawn from 
this work begin to fill in the tables of the “client’s perspective”. Some of these endpoints 
that have proven to be predictors of important outcomes and, at the same time, 
representatives of the patient’s characteristics can now be targets for intervention. 
The continuing development and endorsement of valid surrogate endpoints will 
facilitate medical decision, guide clinical research and establish an agenda for accountability 
in clinical governance, shortening the time for reaction, as it will not be necessary to wait 
for the more distal endpoints to assess, reinforce or correct decisions. 
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	 1	
Consentimento	Informado	para	estudo	observacional	
“O	 Balanced	 Scorecard	 clínico:	 uma	 grelha	 de	 avaliação	 do	 acompanhamento	
clínica	de	doentes.	O	exemplo	da	Doença	Renal	Crónica.”		Eu,	 abaixo	 assinado	 _________________________________________________________	 [nome	completo],	declaro	que		Fui	 convidado(a)	 a	 participar	 no	 estudo	 de	 investigação	 clínica	 acima	identificado,	o	qual	tem	por	objectivo	a	análise	de	factores	de	risco	para	evolução	de	doença	renal	crónica,	bem	como	a	sua	expressão	a	nível	clínico	e	analítico.		Foi-me	dito	que	o	referido	estudo	é	do	tipo	observacional,	ou	seja,	em	nenhuma	fase	 	do	estudo	vai	ser	alterada	a	maneira	como	o	meu	médico	tem	realizado	o	seu	acompanhamento	e	medicação	clínica	da	minha	situação.		Sei	 que	 neste	 estudo	 também	 está	 prevista	 a	 realização	 de	 um	 inquérito	 aos	quais	devo	responder	nos	dias	em	que	vier	ao	Centro	Hospitalar	de	Vila	Nova	de	Gaia,	para	consultas	ou	realização	de	exames	complementares.		Também	 sei	 que	 os	 resultados	 das	 minhas	 análises	 e	 outros	 exames	complementares	 vão	 também	 ser	 utilizados	 para	 análise	 neste	 estudo.	 Neste	particular,	 foi	 me	 garantido	 que	 todos	 os	 dados	 relativos	 à	 identificação	 dos	participantes	neste	estudo	são	confidenciais	e	que	será	mantido	o	anonimato.	Os	resultados	 do	 estudo	 serão	 divulgados	 no	meio	 científico,	mas	 os	meus	 dados	pessoais	nunca	serão	apresentados.	
	 2	
	Sei	 que	 posso	 recusar-me	 a	 participar	 ou	 interromper	 o	 estudo	 a	 qualquer	momento,	sem	nenhum	tipo	de	penalização	ou	ressentimento	pelo	meu	médico	assistente.	Também	sei	que	posso,	em	qualquer	altura,	requerer	ao	médico	que	retire	os	meus	dados	da	base	de	dados,	ou	os	corrija,	bastando	para	tal	enviar-lhe	um	 email	 (serafim.guimaraes@chvng.min-saude.pt),	 telefonar-lhe	 (telef	927810781)	ou	falar	com	ele	pessoalmente,	no	serviço	de	Nefrologia	do	Centro	Hospitalar	de	Vila	Nova	de	Gaia.		Compreendi	a	informação	que	me	foi	dada,	tive	oportunidade	de	fazer	perguntas	e	as	minhas	dúvidas	foram	esclarecidas.		Aceito	participar	de	livre	vontade	no	estudo	acima	mencionado.	Nome	do	Participante	no	estudo	_______________________________________________________	Data	__________/___________/______________	Assinatura	________________________________________		Código	de	Identificação	______________________		Declaro	ter	explicado	ao	Participante	os	objectivos	e	métodos	do	estudo	Nome	do	médico	investigador	responsável.	Data	__________/___________/______________	Assinatura	________________________________________	
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Código de identificação: 
____________________ 
 
Questionário de caracterização do participante 
Este questionário tem como objetivos recolher os seus dados sociodemográficos. Selecione com 
um círculo a opção que considera mais adequada ou indique a informação pedida.  
 
Data: ___/___/_______ 
 
1. Sexo  
(1) Feminino (2) Masculino  
 
 
2. Data de nascimento  
___/___/_______ (dia/mês/ano) 
 
3. Nível de escolaridade 
(1) Não tem o 1º ciclo do ensino básico (< 4ª ano, antigo ensino primário) 
(2) 1º Ciclo do Ensino Básico (ensino primário, 1ª, 2ª, 3ª e 4ª classe) 
(3) 2º Ciclo do Ensino Básico (5º e 6º ano, antigo ciclo preparatório, antigo 1º e 2º ano do liceu) 
(4) 3º Ciclo do Ensino Básico (7º, 8º e 9º ano, 9º ano unificado, antigo 3º, 4º e 5º ano do liceu) 
(5) Ensino secundário (10º, 11ºe 12º, antigo 2º ciclo do ensino secundário, antigo 6º e 7º ano 
do liceu/comercial) 
(6) Ensino universitário (bacharelato e licenciatura) 
(7) Ensino universitário (mestrado, doutoramento, etc.) 
 
4. Situação laboral 
(1) Ativo  
(2) Reformado 
 
5. Profissão (se reformado, indicar a profissão anterior):________________________________ 
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Código de identificação: 
____________________ 
6. Rendimento familiar 
  Por mês 
(14 meses) 
 Por mês 
(12 meses) 
(1) Rendimento anual até 7000 euros  Até 500 €  Até 583 € 
(2) Rendimento anual superior a 7000 euros e inferior a 
20 000 euros 
 Até 1429 €  Até 1667 € 
(3) Rendimento anual superior a 20 000 euros e inferior 
a 40 000 euros 
 Até 2857 €  Até 3333 € 
(4) Rendimento anual superior a 40 000 e inferior a  
80 000 euros 
 Até 5714 €  Até 6667 € 
(5) Rendimento anual superior a 80 000 euros  Mais de 5714 €  Mais de 6667 € 
 
7. Neste momento a prioridade do meu médico deve ser evitar que… 
7.1 □ as análises piorem OU □ entre em diálise 
7.2 □ tenha que ir ao serviço de urgência OU □ que fique internado 
7.3 □ piore e deixe de estar ativo OU □ que eu morra 
7.4 □ as análises piorem OU □ tenha que ir ao serviço de urgência 
7.5 □ fique internado OU □ que eu morra 
7.6 □ as análises piorem OU □ que fique internado 
7.7 □ entre em diálise OU □ piore e deixe de estar ativo 
7.8 □ tenha que ir ao serviço de urgência OU □ que eu morra 
7.9 □ piore e deixe de estar ativo OU □ que as análises piorem 
7.10 □ entre em diálise OU □ que fique internado 
7.11 □ eu morra OU □ que as análises piorem 
7.12 □ entre em diálise OU □ tenha que ir ao serviço de urgência 
7.13 □ tenha que ir ao serviço de urgência OU □ piore e deixe de estar ativo 
7.14 □ eu morra OU □ que entre em diálise 
7.15 □ fique internado OU □ piore e deixe de estar ativo 
 
Authorization of the Hospital’s Administration Board
Authorization of the Local Ethics Commission of the Hospital
Authorization of the National Data Protection Commission
Informed Consent Form
Questionnaire for initial participants characterization 
Questionnaire about patients’ priorities
Short Physical Performance Battery (SPPB) form
World Health Organization Disability Assessment Schedule (WHODAS) 2.0, 12-itens
Satisfaction With Life Scale (SWLS) form
Kidney Disease Quality of Life (KDQoL), version 1.3 form

 
Código de identificação: 
_____________________ 
 
SPPB – Folha de registo 
1. Levantar e sentar de uma cadeira (5 vezes) 
Completou o teste (seg):_______ 
Não completou: _______ 
 
Pontuação ordinal do teste de levantar e sentar: _______ 
0 = não realiza 
1 = > 16,7 
2 = 16,6 – 13,7 seg 
3 = 13,6 - 11,2 seg 
4 = < 11,1 seg 
 
2. Teste do equilíbrio (10 seg) 
a. Pés juntos: _______ 
b. O calcanhar de um pé colocado ao lado do dedo grande do outro pé: _______ 
c. Um pé à frente do outro: _______ 
 
Pontuação ordinal do teste do equilíbrio: _______ 
0 = lado a lado 0-9 seg ou não realiza  
1 = lado a lado 10, <10 seg com a parte lateral de um calcanhar a tocar nos dedo grande do outro pé. 
2 = parte lateral de um calcanhar a tocar nos dedo grande do outro pé 10 seg, um pé à frente do outro 0-2 seg  
3 = parte lateral de um calcanhar a tocar nos dedo grande do outro 10 seg, um pé à frente do outro 3-9 seg  
4 = um pé à frente do outro 10 seg 
 
3. Marcha (2,44 metros) 
a. Completou o teste (seg): _______ 
b. Não completou: _______ 
c. Ajuda técnica:   □  Não usou  □  Usou. Indique qual _______________________        
 
Pontuação ordinal para a marcha: _______ 
0 = não faz  
1 = >5.7 seg (<0.43 m/seg)  
2 = 4.1-5.6 seg (0.44-0.60 m/seg)  
3 = 3.2-4.0 (0.61-0.77 m/seg)  
4 = <3.1 seg (>0.78 m/seg)  
 
Pontuação ordinal final: _______ 
Amplitude: 0 (pior performance) a 12 (melhor performance).  
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Código de identificação: 
 
____________________ 
Versão Portuguesa da WHODAS 2.0 12 itens 
 
 
As questões seguintes são acercadas dificuldades que sentiu devido à sua condição de saúde.  
Condições de saúde incluem doenças, problemas de saúde de curta ou longa duração, lesões, problemas 
mentais ou emocionais, ou problemas relacionados com álcool ou drogas. 
 
As suas respostas só devem refletir os últimos 30 dias e responda às questões pensando em quanta 
dificuldade teve em realizar as seguintes atividades. 
 
 
Nos últimos 30 dias, quanta dificuldade 
teve em: 
Nenhuma Ligeira Moderada Grave Completa 
/ Não faz 
 
S1 
 
 
Ficar de pé por longos 
períodos, como 30 minutos? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S2 
 
 
Tratar das suas 
responsabilidades domésticas? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S3 
 
 
Aprender uma nova tarefa, por 
exemplo, aprender o caminho 
para um novo lugar? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S4 
 
 
Quanta dificuldade que teve 
em participar em atividades na 
comunidade (como por 
exemplo, festivais, religiosas 
ou outras) da mesma forma 
que qualquer outra pessoa? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S5 
 
 
Quanto se sentiu 
emocionalmente afetado pela 
sua condição de saúde? * 
 
 
1 
 
2 
 
3 
 
4 
 
5 
* Codificação: Nada | Ligeiramente | Moderadamente | Gravemente |Completamente 
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Código de identificação: 
 
____________________ 
 
Nos últimos 30 dias, quanta dificuldade 
teve em: 
Nenhuma Ligeira Moderada Grave Completa 
/ Não faz 
 
S6 
 
 
Concentrar-se a fazer algo 
durante dez minutos? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S7 
 
 
Andar uma distância longa 
como um quilómetro [ou 
equivalente]? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S8 
 
 
Lavar todo o corpo? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S9 
 
 
Vestir-se? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S10 
 
 
Lidar com pessoas que não 
conhece? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S11 
 
Manter uma amizade? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
S12 
 
No seu trabalho/escola do dia-
a-dia? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
H1 Globalmente, nos últimos 30 dias, quantos dias estiveram 
presentes estas dificuldades? 
Registe o número de dias __ 
H2 Nos últimos 30 dias, em quantos dias esteve totalmente 
impossibilitado de realizar as suas atividades habituais ou 
de trabalhar devido à sua condição de saúde? 
Registe o número de dias __ 
H3 Nos últimos 30 dias, sem contar os dias em que esteve 
totalmente impossibilitado, em quantos dias diminuiu ou 
reduziu as suas atividades habituais ou de trabalho devido 
à sua condição de saúde? 
Registe o número de dias __ 
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Código de identificação: 
 
____________________ 
 
SWLS – SATISFACTION WITH LIFE SCALE 
 
Encontra-se a seguir cinco afirmações com as quais pode concordar ou discordar. Utilizando a escala de 1 
a 7 refira o seu grau de acordo com cada item colocando um círculo no número que corresponde à sua 
resposta. Procure ser sincero nas suas respostas. 
 
 1 – discordo totalmente 
 2 – discordo 
 3 – discordo ligeiramente 
 4 – nem concordo, nem discordo 
 5 – concordo ligeiramente 
 6 – concordo 
 7 – concordo totalmente  
 
 
1. Em muitos aspetos, a minha vida aproxima-se dos meus ideais. 1   2   3   4   5   6   7 
 
2. As minhas condições de vida são excelentes.   1   2   3   4   5   6   7 
 
3. Estou satisfeito com a minha vida.     1   2   3   4   5   6   7 
 
4. Até agora, consegui obter aquilo que era importante na vida. 1   2   3   4   5   6   7 
 
5. Se pudesse viver a minha vida de novo, não alteraria pratica- 1   2   3   4   5   6   7 
             mente nada. 
 
 
 
Total: ___________ 
 
Score: 
30-35  Totalmente satisfeito 
25-29 Satisfeito 
20-24  Mais ou menos satisfeito 
15-19  Um pouco insatisfeito 
10-14  Insatisfeito 
5-9  Totalmente insatisfeito 
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A sua saúde 
– e – 
o seu bem-estar 
 
 
Doença Renal e Qualidade de Vida (KDQOL-SF™ 1.3) 
 
 
O presente estudo pretende saber como olha para a sua 
saúde. Estas informações dar-nos-ão a conhecer a forma 
como se sente e qual a sua capacidade para desempenhar 
as actividades do seu dia-a-dia. 
 
 
 
 
 
 
 
Obrigado por responder a estas perguntas! 
 
 
 
Kidney Disease and Quality of Life™ Short Form (KDQOL-SF™) Version 1.3 
Copyright © 1993, 1994, 1995 by RAND and the University of Arizona 
Copyright © 2003 Versão Portuguesa, Centro de Estudos e Investigação em Saúde da Universidade de Coimbra (CEISUC) 
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ESTUDO DA QUALIDADE DE VIDA 
PARA DOENTES EM DIÁLISE 
 
 
 
Qual é o objectivo do estudo? 
Este estudo tem contado com a colaboração de médicos e doentes. O 
objectivo é avaliar a qualidade de vida dos doentes com doença renal. 
 
 
 
O que terei de fazer? 
Para este estudo, queríamos que respondesse hoje a um inquérito sobre a 
sua saúde, como se sente e os seus dados pessoais. 
 
 
 
Confidencialidade das informações? 
Não lhe pedimos o nome. As suas respostas serão misturadas com as de 
outros participantes nas conclusões do estudo. Qualquer informação que 
permita a sua identificação será encarada como estritamente confidencial. 
Além disso, todas as informações recolhidas serão apenas usadas para a 
finalidade deste estudo e não serão reveladas ou disponibilizadas para 
qualquer outra finalidade sem a sua autorização prévia.   
 
 
 
De que modo é que a minha participação me poderá beneficiar? 
As informações que prestar dir-nos-ão o que pensa dos cuidados e dar-nos-
-ão uma compreensão adicional sobre os efeitos dos cuidados médicos na 
saúde dos doentes. Estas informações ajudarão a avaliar os cuidados 
prestados.   
 
 
Tenho que participar? 
Não é obrigado/a a preencher o inquérito e pode recusar-se a responder a 
qualquer pergunta. A sua decisão de participar não vai afectar os cuidados 
médicos que irá receber. 
 3 
A sua saúde 
 
 
Este questionário inclui uma ampla variedade de perguntas 
sobre a sua saúde e a sua vida. Estamos interessados em saber 
como se sente em relação a cada um destes assuntos. 
 
 
 1. Em geral, diria que a sua saúde é:  [Marque um  no 
quadrado que melhor descreve a sua saúde.] 
Excelente Muito Boa Boa Razoável Fraca 
∇ ∇ ∇ ∇ ∇ 
   1    2    3    4    5 
 
 
 2. Comparando com o que acontecia há um ano, como 
descreve o seu estado geral actual? 
Muito 
melhor 
agora do 
que há um 
ano atrás  
Um pouco 
melhor 
agora do 
que há um 
ano atrás 
Aproxima-
damente 
igual há 
um ano 
atrás 
Um pouco 
pior 
agora do 
que há um 
ano atrás 
Muito 
pior 
agora do 
que há um 
ano atrás 
∇ ∇ ∇ ∇ ∇ 
   1    2    3    4    5 
 4 
 3. As perguntas que se seguem são sobre actividades que 
executa no seu dia-a-dia. Será que a sua saúde o/a limita 
nestas actividades? Se sim, quanto? [Marque um  em 
cada linha.] 
 Sim, 
muito 
limitado/a 
Sim, 
um pouco 
limitado/a 
Não, 
nada 
limitado/a 
 a Actividades violentas, tais como 
correr, levantar pesos, participar 
em desportos extenuantes ........  
 ∇ ∇ ∇ 
 
  1 ...........  2..........  3 
 b Actividades moderadas, tais como 
deslocar uma mesa ou aspirar a 
casa ...................................  
 
 
  1 ...........  2..........  3 
 C Levantar ou pegar nas compras de 
mercearia ............................  
 
  1 ...........  2..........  3 
 d Subir vários lanços de escada .....    1 ...........  2..........  3 
 e Subir um lanço de escadas .........    1 ...........  2..........  3 
 f Inclinar-se, ajoelhar-se ou baixar-
-se......................................  
 
  1 ...........  2..........  3 
 g Andar mais de 1 Km .................    1 ...........  2..........  3 
 h Andar várias centenas de metros .    1 ...........  2..........  3 
 i Andar uma centena de metros ...    1 ...........  2..........  3 
 j Tomar banho ou vestir-se 
sozinho/a .............................  
  
  1 ...........  2..........  3 
 5 
 4. Durante as últimas 4 semanas teve, no seu trabalho ou 
actividades diárias, algum dos problemas apresentados a 
seguir como consequência do seu estado de saúde físico?  
Quanto tempo, 
nas últimas quatro semanas Sempre 
A maior 
parte do 
tempo 
Algum 
tempo 
Pouco 
tempo Nunca 
 ∇ ∇ ∇ ∇ ∇ 
 a Diminuiu o tempo gasto a 
trabalhar ou noutras activi-
dades? ..........................  
 
 
  1.......  2 .....  3 ....  4 ....  5 
 b Fez menos do que queria? ....   1.......  2 .....  3 ....  4 ....  5 
 c Sentiu-se limitado/a no tipo 
de trabalho ou outras activi-
dades? ..........................  
 
 
  1.......  2 .....  3 ....  4 ....  5 
 d Teve dificuldade em execu-
tar o seu trabalho ou outras 
actividades (por exemplo,  
foi preciso mais esforço? ......
 
 
  1.......  2 .....  3 ....  4 ....  5 
 
 5.  Durante as últimas 4 semanas, teve com o seu trabalho 
ou com as suas actividades diárias, algum dos problemas 
apresentados a seguir devido a quaisquer problemas 
emocionais (tal como sentir-se deprimido/a ou ansioso/a)?  
Quanto tempo, 
nas últimas quatro semanas Sempre 
A maior 
parte do 
tempo 
Algum 
tempo 
Pouco 
tempo Nunca 
 ∇ ∇ ∇ ∇ ∇ 
 a Diminuiu o tempo gasto a 
trabalhar ou noutras activi-
dades? ..........................  
 
 
  1.......  2 .....  3 ....  4 ....  5 
 b Fez menos do que queria? ....   1.......  2 .....  3 ....  4 ....  5 
 c Executou o seu trabalho ou 
outras actividades menos 
cuidadosamente do que era 
costume ........................  
 
 
  1.......  2 .....  3 ....  4 ....  5 
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 6. Durante as últimas 4 semanas, em que medida é que a sua 
saúde física ou problemas emocionais interferiram no seu 
relacionamento social normal com a família, amigos, 
vizinhos ou outras pessoas? 
Nada Um pouco Moderadamente Bastante Imenso 
∇ ∇ ∇ ∇ ∇ 
   1    2    3    4    5 
 
 
 
 
 7. Durante as últimas 4 semanas teve dores? 
Nenhumas Muito   fracas Ligeiras Moderadas Fortes 
Muito 
fortes 
∇ ∇ ∇ ∇ ∇ ∇ 
   1    2    3    4    5    6 
 
 
 
 
 8. Durante as últimas 4 semanas, de que forma é que a dor 
interferiu com o seu trabalho normal (tanto o trabalho 
fora de casa como o trabalho doméstico)? 
Nada Um pouco Moderadamente Bastante Imenso 
∇ ∇ ∇ ∇ ∇ 
   1    2    3    4    5 
 7 
 9. As perguntas que se seguem pretendem avaliar a forma como se 
sentiu e como lhe correram as coisas nas últimas quatro semanas. 
  Para cada pergunta, coloque por favor um círculo à volta do 
número que melhor descreve a forma como se sentiu. 
  Certifique-se que coloca um círculo em cada linha. 
 
Quanto tempo, 
nas últimas quatro semanas Sempre 
A maior 
parte do 
tempo 
Algum 
tempo 
Pouco 
tempo Nunca 
 ∇ ∇ ∇ ∇ ∇ 
 a Se sentiu cheio/a de 
vitalidade? .......................
 
  1.......  2 .....  3 ....  4 ....  5 
 b Se sentiu muito nervoso/a? ...   1.......  2 .....  3 ....  4 ....  5 
 c Se sentiu tão deprimido/a 
que nada o/a animava? ........
 
  1.......  2 .....  3 ....  4 ....  5 
 d Se sentiu calmo/a e 
tranquilo/a? .....................
  1.......  2 .....  3 ....  4 ....  5 
 e Se sentiu com muita 
energia? ..........................
  1.......  2 .....  3 ....  4 ....  5 
 f Se sentiu deprimido/a? ........   1.......  2 .....  3 ....  4 ....  5 
 g Se sentiu estafado/a? ..........   1.......  2 .....  3 ....  4 ....  5 
 h Se sentiu feliz? ..................   1.......  2 .....  3 ....  4 ....  5 
 i Se sentiu cansado/a?...........   1.......  2 .....  3 ....  4 ....  5 
 
 8 
10. Durante as últimas quatro semanas, até que ponto é que a 
sua saúde física ou problemas emocionais limitaram a sua 
actividade social (tal como visitar amigos ou familiares 
próximos)? 
Sempre 
A maior 
parte do 
tempo 
Algum 
tempo 
Pouco 
tempo Nunca 
∇ ∇ ∇ ∇ ∇ 
   1    2    3    4    5 
 
 
11.  Por favor, diga em que medida são verdadeiras ou falsas 
as seguintes afirmações. 
 Absolutamente 
verdade Verdade 
Não
sei Falso 
Absolutamente 
falso 
 a  Parece que 
adoeço mais 
facilmente do 
que os outros ....
   ∇ ∇ ∇ ∇ ∇ 
 
 
  1 ...........  2 .....  3 ...  4........  5 
 b Sou tão 
saudável como 
qualquer outra 
pessoa ............
 
 
  1 ...........  2 ....  3 ...  4 ........  5 
 c Estou 
convencido/a 
que a minha 
saúde vai 
piorar .............
 
 
 
  1 ...........  2 ....  3 ...  4 ........  5 
 d A minha saúde 
é óptima..........
 
  1 ...........  2 ....  3 ...  4 ........  5 
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A sua doença renal 
 
 
12. Até que ponto é que cada uma das seguintes afirmações é 
verdadeira ou falsa para si? 
 Completa-
mente 
verdadeira 
Quase 
toda 
verdadeira 
Não 
sei 
Quase 
toda 
falsa 
Completa-
mente 
falsa 
 a  A minha doença renal 
interfere demasiado 
na minha vida .........
 ∇ ∇   ∇   ∇   ∇ 
 
  1 .........  2 ......  3 ...  4......  5 
 b Passo demasiado 
tempo a tratar da 
minha doença renal .
 
 
  1 .........  2 ......  3 ..  4 ......  5 
 c Sinto-me 
desanimado/a com a 
minha doença renal ...
 
  1 .........  2 ......  3 ..  4 ......  5 
 d Sinto-me um peso 
para a minha família .
 
  1 .........  2 ......  3 ..  4 ......  5 
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13. Estas perguntas são sobre como se sente e como têm 
corrido as últimas 4 semanas. Para cada pergunta, dê a 
resposta que mais se aproxima da forma como se tem 
sentido.  
  Quantas vezes nas últimas 4 semanas … 
 Nunca Poucas vezes 
Algumas 
vezes 
Bastantes 
vezes 
Quase 
sempre Sempre 
 a se isolou das 
outras pessoas à 
sua volta? ..........
 ∇ ∇ ∇ ∇ ∇ ∇ 
 
  1 ....  2 ......  3.........  4 .......  5 .....  6 
 b demorou a reagir 
a coisas que 
foram ditas ou 
feitas? ..............
 
 
  1 ....  2 ......  3.........  4 .......  5 .....  6 
 c se mostrou 
irritável com os 
que o/a 
rodeiavam?.........
 
 
  1 ....  2 ......  3.........  4 .......  5 .....  6 
 d teve dificuldades 
em se concentrar 
ou pensar? .........
 
 
  1 ....  2 ......  3.........  4 .......  5 .....  6 
 e se deu bem com 
as outras 
pessoas?. ...........
 
  1 ....  2 ......  3.........  4 .......  5 .....  6 
 f se sentiu 
confuso/a? .........
 
  1 ....  2 ......  3.........  4 .......  5 .....  6 
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14. Nas últimas 4 semanas, até que ponto se sentiu 
incomodado/a por cada uma das seguintes situações? 
 
 Nada 
incomodado 
Um pouco 
incomodado 
Moderada-
mente 
incomodado 
Muito 
incomodado 
Extrema-
mente 
incomodado 
 ∇ ∇ ∇ ∇ ∇ 
A Dores 
musculares? .......
 
  1 ........  2 .........  3 ........  4 ........  5 
b Dor no peito?......   1 ........  2 .........  3 ........  4 ........  5 
c Cãibras?............   1 ........  2 .........  3 ........  4 ........  5 
d Comichão? .........   1 ........  2 .........  3 ........  4 ........  5 
e Pele sêca? .........   1 ........  2 .........  3 ........  4 ........  5 
f Falta de ar? .......   1 ........  2 .........  3 ........  4 ........  5 
g Sensação de 
desmaio e 
tonturas?...........
 
 
  1 ........  2 .........  3 ........  4 ........  5 
h Falta de apetite? .   1 ........  2 .........  3 ........  4 ........  5 
i Esgotado/a ou 
sem forças?........
  
  1 ........  2 .........  3 ........  4 ........  5 
j Mãos ou pés 
dormentes?........
 
  1 ........  2 .........  3 ........  4 ........  5 
k Náusea ou 
indisposição .......
 
  1 ........  2 .........  3 ........  4 ........  5 
l (Apenas para doentes em hemodiálise) 
 Problemas com a 
fístula? .............
 
  1 ........  2 .........  3 ........  4 ........  5 
m (Apenas para doentes em diálise peritoneal) 
 Problemas com 
seu catéter? .......
 
  1 ........  2 .........  3 ........  4 ........  5 
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Efeitos da doença renal no seu dia-a-dia 
 
15. Algumas pessoas sentem-se incomodadas com os efeitos 
da doença renal no seu dia-a-dia, enquanto outras não. 
Até que ponto é que a doença renal o/a incomoda em 
cada uma das seguintes áreas? 
 Nada 
incomodado 
Um pouco 
incomodado 
Moderada-
mente 
incomodado 
Muito 
incomodado 
Extrema-
mente 
incomodado 
 ∇ ∇ ∇ ∇ ∇ 
 a Restrição de 
líquidos? ..........
 
  1.........  2.........  3.........  4 .......  5 
 b Restrição 
dietética? ........
 
  1.........  2.........  3.........  4 .......  5 
 c Capacidade 
para fazer os 
trabalhos 
domésticos?......
 
 
 
  1.........  2.........  3.........  4 .......  5 
 d Capacidade 
para viajar? ......
 
  1.........  2.........  3.........  4 .......  5 
 e Dependência de 
médicos e outro 
pessoal clínico?..
 
 
  1.........  2.........  3.........  4 .......  5 
 f Stresse ou 
preocupações 
causadas pela 
doença renal? ...
 
 
        1 ........  2.........  3.........  4 .......  5 
 g Vida sexual? .....  1.........  2.........  3.........  4 .......  5 
 h Aparência 
física? .............
 
  1.........  2.........  3.........  4 .......  5 
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As três perguntas que se seguem são pessoais e dizem 
respeito à sua actividade sexual, mas as suas respostas são 
importantes para compreendermos de que forma é que a 
doença renal interfere na vida das pessoas. 
 
16. Teve actividade sexual nas últimas 4 semanas? 
     (Faça um círculo à volta de um número) 
 
Não .............................. 1 →   
Sim .............................. 2 
 
 
  Até que ponto cada uma das seguintes situações 
constituiu um problema nas últimas 4 semanas 
 Sem problema 
Um 
pequeno 
problema 
Algum 
problema 
Um grande 
problema 
Um 
problema 
grave 
 ∇ ∇ ∇ ∇ ∇ 
 a Ter prazer 
sexual?.............
 
  1 .........  2 ........  3........  4 .......  5 
 b Ficar excitado/a 
sexualmente?.....
 
  1 .........  2 ........  3........  4 .......  5 
 
 
 
Se respondeu não, por favor 
salte para a Pergunta 17
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17. Para a pergunta seguinte, classifique o seu sono usando 
uma escala de 0 a 10 em que 0 representa “muito mau” e 
10 “muito bom”. 
 
Se acha que o seu sono fica entre o “muito mau” e o 
“muito bom”, faça uma cruz no quadrado por baixo do 
número 5. Se acha que o seu sono é um nível melhor do 
que 5, faça uma cruz no quadrado por baixo de 6. Se acha 
que o seu sono é um nível pior do que 5, faça uma cruz 
no quadrado por baixo do 4 (e assim por diante).  
 
  Numa escala de 0 a 10, como classificaria o seu sono em 
geral? [Faça uma cruz no quadrado.] 
 
Muito mau    Muito bom 
∇    ∇ 
 0 1 2 3 4 5 6 7 8 9 10  
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18. Com que frequência é que nas últimas 4 semanas... 
 Nunca Poucas vezes 
Algumas 
vezes 
Bastantes 
vezes 
Quase 
sempre Sempre 
 a acordou durante 
a noite e teve 
dificuldades em 
voltar a 
adormecer? ........
 ∇ ∇ ∇ ∇ ∇ ∇ 
 
 
 
  1 .....  2 .....  3 ........  4 ......  5 ......  6 
 b dormiu o tempo 
suficiente? ........
 
  1 .....  2 .....  3 ........  4 ......  5 ......  6 
 c teve dificuldade 
em se manter 
acordado/a 
durante o dia? .....
 
 
 
  1 .....  2 .....  3 ........  4 ......  5 ......  6 
 
 
 
19. Relativamente à sua família e aos seus amigos, qual o seu 
grau de satisfação com... 
 Muito 
insatisfeito 
Um pouco 
insatisfeito 
Um pouco 
satisfeito 
Muito 
satisfeito 
 a a quantidade de 
tempo que consegue 
passar com a família 
e com os amigos? .....
 ∇ ∇ ∇ ∇ 
 
 
  1...........  2 ..........  3 ..........  4 
 b o apoio que recebe 
da família e dos 
amigos? .................
 
 
  1...........  2 ..........  3 ..........  4 
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20. Nas últimas 4 semanas, teve um trabalho remunerado? 
Sim            Não 
 ∇ ∇ 
   1            2 
 
 
 
21. A sua saúde impossibilita-o/a de ter um trabalho 
remunerado?  
Sim              Não 
 ∇ ∇ 
   1                                   2 
 
 
 
 
 
22. Em geral, como classificaria a sua saúde? 
 A pior possível 
(tão má ou pior 
do que estar 
morto/a)  
  
Nem muito boa 
nem muito má 
  
A melhor 
possível 
∇  ∇  ∇ 
 0 1 2 3 4 5 6 7 8 9 10  
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Satisfação com os cuidados prestados 
 
 
23. Pense nos cuidados que recebe na diálise renal. Em 
termos da sua satisfação, como classificaria a amabilidade 
e o interesse que tiveram consigo como pessoa? 
Muito 
mau Mau Suficiente Bom 
Muito 
bom Excelente 
O melhor 
possível 
∇ ∇ ∇ ∇ ∇ ∇ ∇ 
   1    2    3    4    5    6    7 
 
 
 
24. Até que ponto é que cada uma das seguintes afirmações é 
verdadeira ou falsa? 
 
Completa-
mente 
verdadeira 
Quase 
toda 
verdadeira 
Não 
sei 
Quase 
toda 
falsa 
Completa-
mente 
falsa 
 a  O pessoal da 
diálise incita-
me a ser tão 
independente 
quanto possível .
 ∇ ∇ ∇ ∇ ∇ 
 
 
 
  1 ........  2........  3........  4 ........  5 
 b O pessoal da 
diálise ajuda-
me a lidar com 
a minha doença 
renal ..............
 
 
  1 ........  2........  3........  4 ........  5 
 
Obrigado por responder a estas perguntas! 
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